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INTRO
Aims of thesis
Chemokines and their receptors (G protein-coupled 
receptors; figure 1) play important roles in cellular 
immunity by controlling activation and differentiation of 
leukocytes and directing migration of immune cells to 
sites of inflammation or infection. In essence, this system 
is tightly controlled by spatial and temporal expression 
of chemokines and their receptors, facilitating adequate 
immune responses. About 19 human chemokine receptors 
exist, with a total of around 50 chemokines. Some 
chemokines bind to multiple receptors, while others bind 
a single receptor, and therefore the chemokine system is 
highly complex (figure 2). Moreover, different cell types 
express distinct combinations of chemokine receptors 
conferring sensitivity towards specific sets of chemokine 
concentration gradients. Improper expression of 
chemokine and/or chemokine receptors results in a variety 
of immune-related diseases, like chronic inflammation, or 
autoimmune disease. Examples include chronic obstructive 
pulmonary disease (COPD), inflammatory bowel disease 
(IBD), rheumatoid arthritis, multiple sclerosis, allograft 
rejection, psoriasis, and atherosclerosis. Furthermore, the HIV-1 virus utilizes CCR5 or CXCR4 
as a co-receptor to infect immune cells. In addition, a subset of chemokine receptors appears 
to contribute to tumorigenesis and cancer metastasis. Taken together, chemokine receptors 
and their ligands can be considered as interesting therapeutic targets. As such, a lot of effort 
has been focused on the discovery and development of small-molecule chemokine receptor 
antagonists. This has been rewarded by the market approval of two novel chemokine receptor 
inhibitors, maraviroc (CCR5) and AMD3100 (CXCR4) for treatment of HIV-1 infection and stem 
cell mobilization, respectively. 
CXCR3 is a chemokine receptor that, together with its three major ligands, CXCL9 (MIG), 
CXCL10 (IP-10) or CXCL11 (I-TAC) is involved in inflammatory responses, mediated mainly 
by T-cells. In all the above-mentioned immune-related diseases, CXCR3 and/or its ligands 
are found to be overexpressed, implying a role for this receptor in these diseases. Several 
Figure 1: Schematic representation of 
a 7-transmembrane spanning chemo-
kine receptor (GPCR) and a chemokine 
ligand binding to it.
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animal models have confirmed the therapeutic potential of targeting CXCR3 in the treatment 
of such diseases. The role of CXCR3 in cancer seems somehow contradictory, as reports have 
appeared that show either positive or negative correlation of CXCR3 and/or ligand expression 
on tumor growth. 
The chemokine receptor CXCR7 is a relatively new member of the chemokine receptor family, 
as it was deorphanized in 2005. Interestingly, CXCR7 shares one chemokine ligand with CXCR3, 
namely CXCL11, and one with CXCR4, which is CXCL12 (SDF-1). CXCR7 is an interesting 
receptor, as it is devoid of G protein-mediated signaling. Its actual signaling characteristics 
are still under debate, although there is accumulating evidence, with a contribution of this 
thesis, pointing to alternative signaling pathways for CXCR7. This receptor is preferentially 
expressed during embryonic development, but is also present on a variety of transformed 
cells. In the past years, it has become increasingly clear that CXCR7 plays an important role in 
tumorigenesis and metastasis of e.g. breast, prostate, or lung cancer, either by direct receptor 
signaling, or transactivation of other receptors. Alternatively, a chemokine scavenger role was 
also suggested for CXCR7, where it acts as a ‘chemokine sink’, modulating the availability of 
CXCL11 and CXCL12 to CXCR3 and CXCR4, and thus signaling via these receptors. In addition, 
this potentially provides a directional cue, not only for cellular movement in embryonal 
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Figure 2: Chemokine receptors and their respective chemokine ligands, according to IUPHAR database (http://www.
iuphar-db.org/DATABASE/GPCRListForward). Chemokines binding specific to only one receptor are displayed in gray 
text. Chemokine receptors binding only one chemokine are indicated as "specific", while chemokine receptors binding 
multiple chemokines are indicated as "shared".
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development, but also for metastasizing tumor cells.
Altogether, both CXCR3 and CXCR7 chemokine receptors are interesting from a therapeutic 
point of view. In case of CXCR3, a lot of efforts by academic groups and industry have focused 
on the discovery of CXCR3 antagonists, to counteract the generally observed increased 
infiltration of CXCR3-expressing immune cells in diseased tissue, likely due to aberrant ligand 
and/or receptor expression. The emerging evidence pointing to an involvement of CXCR3 and 
its ligands in processes like wound healing, suggests a role for CXCR3 agonism as therapeutic 
approach in some cases. Figure 3 shows a selection of small-molecule compounds binding to 
CXCR3 subject of our studies presented in this thesis.
Aims
1. As little was known on how small molecules (figure 3) interact with CXCR3, one of the 
aims of this thesis was to understand the molecular mechanism by which small-molecule 
antagonists and agonists bind to CXCR3 compared to the relatively large chemokines (±10-
20 fold size difference), and to elucidate whether these molecules mediate their effects via 
orthosteric or allosteric mechanisms.
2. CXCR7 is a relatively new receptor and not much is known about its signaling properties. 
As such, we aimed to characterize the function of this receptor, comparing it to CXCR3, and to 
unravel the molecular determinants that are key players in its regulation.
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Figure 3: Chemical structures of small CXCR3 molecules used in this thesis
Outline
Chapter 1 provides a general introduction to chemokine receptors, including chemokine 
binding and receptor activation and characteristics of small molecule binding to this class 
of receptors. A snapshot of novel disclosures concerning small molecules in clinical trials for 
treatment of chemokine-related disease, is given in chapter 2. Chapter 3 describes the detailed 
functional and binding analysis of small-molecule CXCR3 antagonists, and how they behave 
on different species variants of the receptor. A small-molecule CXCR3 agonist was subjected 
to detailed pharmacological characterization and compared to the CXCR3 chemokines in 
chapter 4. In chapter 5 the binding sites of a selection of CXCR3 ligands are mapped using 
site-directed mutagenesis complemented with computational modeling studies. In chapter 
6, a label-free method to measure receptor activity was employed to further characterize the 
functional behavior of this small-molecule agonist and CXCR3 chemokines. A subtle switch 
between antagonism and agonism was found for a non-peptidomimetic class of CXCR3 
ligands. This phenomenon was addressed by using a multitude of pharmacological, synthetic 
and computational methods, described in chapter 7. Finally, in chapter 8, the function and 
regulation of chemokine receptor CXCR7 is portrayed in comparison to CXCR3.
 
To be able to effectively develop therapeutic molecules targeting these receptors, it is crucial 
to obtain insight how these ligands interact with the receptor on a molecular level and affect 
subsequent intracellular signaling events. This facilitates the rational design and optimization 
of such molecules, and aids the fundamental understanding of the molecular pharmacology 
of these receptors. Altogether, knowledge acquired by this kind of studies advances drug 
discovery and optimization of CXCR3 and CXCR7, in an effort to treat immune-related 
diseases. In this thesis, a multi-disciplinary approach is taken, including pharmacology, 
biochemistry, synthesis, and computational modeling, in an effort to characterize ligand 
and receptor properties, hence the title “Chemokine Receptors CXCR3 and CXCR7: Allosteric 
Ligand Binding, Biased Signaling, and Receptor Regulation”. 
CHAPTER 1
Pharmacological modulation of chemokine 
receptor function
Adapted from
DJ Scholten et al., Br. J. Pharmacol. 2012. 165(6):1617-43
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1.1 Chemokines and their receptors 
Chemokines and their receptors are key players in the immune defence by directing and 
controlling the migration, activation, differentiation and survival of the billion of leukocytes 
in our body (2). Some chemokine peptides are constitutively secreted in lymphoid tissues and 
involved in leukocyte homing during immune surveillance. The vast majority of chemokines, 
however, are secreted in response to inflammatory mediators or trauma, and function as 
paracrine chemoattractants to recruit leukocytes to sites of inflammation. To date, at least 45 
chemokine subtypes have been identified in human, which are categorised into four classes 
(i.e. C, CC, CXC, CX
3
C) on the basis of the number and spacing of conserved cysteine residues 
in their N-termini (Figure 1) (188). All chemokines share a similar tertiary protein fold that 
is stabilised by disulfide bonds between the four conserved cysteine residues (or two in the 
case of C-chemokines).  The flexible N-terminus is followed by the C, CC, CXC, or CX3C motif, 
and connected via an exposed N-loop to a highly structured core domain, which consists of a 
single-turn 3
10
 helix, three antiparallel β-strands and a C-terminal α-helix (Figure 2).  Soluble 
chemokines bind via their C-terminal α-helix to glycosaminoglycans (GAGs) on the surface of 
endothelial cells to form an immobilised chemotactic gradient, which guides passing immune 
cells towards the source of chemokine secretion (4, 5). On the other hand, CXCL16 and CX3CL1 
are initially expressed as membrane-bound chemokines to serve as adhesion molecules for 
cells that express CXCR16 or CX
3
CR1, respectively, but can be cleaved by ADAM enzymes to 
become soluble chemokines (6). Chemokines can form dimers as well as oligomers, which is 
essential for their in vivo but not their in vitro activity (5, 7, 8). 
Chemokine receptors are seven-transmembrane (7TM) receptors belonging to the superfamily 
of G protein-coupled receptors (GPCRs) (see below). The majority of chemokine receptors 
can bind a panel of chemokines, whereas some are highly specific (Figure 1). Chemokine 
receptors have been classified according to which chemokine subclass they bind, with one 
C, ten CC, seven CXC, and one CX
3
C chemokine-binding receptors (Figure 1) (nomenclature 
follows (188)). With the exception of CXCR7, which is exclusively biased towards β-arrestin-
mediated signalling (9), all C, CC, CXC, and CX
3
C chemokine receptors signal at least through 
heterotrimeric G proteins (10). Three non-G protein-signalling (so-called decoy) chemokine 
receptors (i.e. D6, DARC, and CCX CKR) are thought to be primarily involved in scavenging a 
(wide) variety of inflammatory chemokines from the extracellular microenvironment, thereby 
limiting the recruitment of leukocytes (11). Differential expression of chemokine receptors 
on selective leukocyte (sub)populations allows these cells to sense and respond to local 
gradients of corresponding chemokines. 
Inappropriate or prolonged expression of chemokines and/or chemokine receptors results 
in an excessive infiltration of (certain) leukocytes into (inflamed) source tissue or confers 
chemokine sensitivity to cells that are normally not responsive to chemokines, respectively, 
resulting in chronic inflammation, autoimmune diseases, tumour growth, survival, and 
metastasis (Figure 3) (10, 12, 13). In addition, the CCR5 and CXCR4 function as co-receptors 
for HIV entry into CD4+ cells (14-16). 
Many humans are latently infected by one or more herpesvirus species. Many of these 
herpesviruses encode GPCRs that are constitutively active but also responsive to human 
chemokines. These virally-encoded chemokine receptors are thought to contribute to immune 
evasion and viral dissemination, but some of them are also involved in the development and/
or progression of herpesvirus-associated inflammatory diseases and cancer (Figure 1 and 
Figure 3) (17-19).
Considering the key role of (viral) chemokine receptors in the pathogenesis of autoimmune 
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and inflammatory diseases, cancer, and HIV infection it is not surprising that these receptors 
gained increasing attention the last decade by both academia and pharmaceutical industry in 
their quest to develop drugs to treat such diseases.
1.2: Redundancy or (functional) selectivity? 
The chemokine system is often “accused” of showing significant redundancy, due to the 
fact that a single receptor binds multiple ligands, and conversely, a single ligand can bind 
several chemokine receptors (Figure 1) (20). However, differential spatio-temporal expression 
patterns for different chemokines and receptors in our body, indicate that they probably 
have distinct roles in vivo (21) (Figure 3). Furthermore, heteromerisation of chemokine 
receptors may enable selective fine-tuning of chemokine receptor signalling (see section on 
‘cross-modulation within chemokine receptor oligomers’). Moreover, activation of a single 
receptor by different agonists might lead to differential signalling or functional selectivity, 
as observed now for different chemokine receptors, including CCR1, CCR2, CCR5, CCR7 and 
CXCR3 (22-27). For example, both CCR7 chemokines CCL19 and CCL21 promote [35S]-GTPγ…S 
binding and calcium signalling with similar potencies. However, only CCL19 induced efficient 
phosphorylation, β-arrestin recruitment and receptor internalisation (24). A more recent study 
showed that CCR7 engages different G protein-coupled receptor kinases (GRKs) in response 
to CCL19 or CCL21, explaining the observed differences in receptor regulation (28). As a 
Figure 1: Overview of chemokine receptors (vertical) and their ligands (horizontal). An open circle indicates the spe-
cific ligand binds to the receptor connected to it by a black line. From top to bottom: human chemokine receptors (XCR1 
to CX
3
CR1), chemokine decoy receptors (D6 to CCX CKR), and viral chemokine receptors (US28 to U51). For reasons 
of clarity, this figure does not show differences in affinity or activity between ligands for the same receptor. For more 
detailed information on ligand properties, visit the website of The International Union of Basic and Clinical Pharmacol-
ogy (IUPHAR) (183).
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consequence, the signalling outcome does not depend on the receptor and ligand alone, but 
also on the expression levels of different signalling proteins in a specific cell, giving texture to 
the responses mediated by ligands. Along these lines, growing evidence supports differential 
binding of chemokines to a single receptor, and a single chemokine to diafferent receptors, 
suggesting that these ligands have distinct roles (29-34). Overall, the evidence seems to 
refute the notion of redundancy in the chemokine receptor system. It rather indicates that the 
interplay between the timing and location of expression of ligands/receptors in the body, in 
combination with functional selectivity is a mechanism for selectivity within the chemokine 
receptor family.
1.3: The two-step model of chemokine-receptor activation
The binding interactions of endogenous ligands in some class A GPCRs, such as the aminergic 
receptors, are relatively well known, especially with the recent successful crystallisation of 
the β
1
- and β2 adrenoceptor, adenosine A2A, and the dopamine D3 receptor (35-38). In contrast, 
binding modes of peptide ligands, such as chemokines, are less well characterised, due to their 
relatively large size and associated challenges in obtaining structural information. However, 
several studies have highlighted important regions in both chemokines and receptors that 
are involved in binding and function. The interaction of chemokines with their receptors is 
generally considered to be a two-step process (20). First, the chemokine binds with its core 
region, including the N-loop (binding domain), to the N-terminus and extracellular loops 
(ELs) of the receptor (Figure 4b). We propose to use the term chemokine recognition site 1 
(CRS1), instead of site I often used in the literature, to avoid confusion with binding sites in the 
transmembrane (TM) pockets for small molecules. The binding to CRS1 is dominated by ionic 
interactions between positively charged residues in the chemokine and negatively charged 
amino acids at the N-terminus and extracellular surface of the receptor, including sulfonated 
tyrosines (20, 39-41). In the second step, the flexible N-terminus (triggering domain) of the 
chemokine is positioned in such a way that it interacts with a second site (CRS2), formed 
by parts of the ELs and/or TM domains, resulting in receptor activation (Figure 4c) (30, 42-
48). This is supported by truncations or mutations in the N-termini of chemokines, generally 
leading to a loss in agonist activity, while often retaining high receptor binding affinity (49-
52). In the case of CCR5, several reports indicate that a TXP motif in TM2 and surrounding 
Figure 2: Overall tertiary structure of chemokines. A. Structure of a CC-chemokine (CCL5). B. Structure of a CXC-family 
chemokine (CXCL12). The disulfide bonds are indicated in ball and stickall and stick. The N-loop is shown as a grey tube 
(right bottom of each image). See text for more details.
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aromatic residues in TM2 and 3 are involved in chemokine-mediated activation of CCR5, but 
not in high-affinity binding, suggesting that in step two the N-terminus interacts with residues 
in this TM region (30, 53, 54). Since this motif is conserved among chemokine receptors it is 
hypothesised that the TM2-TM3 interface in these receptors takes part in a common mechanism 
of ligand-induced conformational rearrangements leading to movements of helices, notably 
TM2 and TM3, and thereby chemokine receptor activation. For CXCR4, different studies have 
demonstrated that the core region of its ligand CXCL12 binds to the extracellular regions of 
CXCR4, while the N-terminus has additional interactions with TM residues, including D972.63 
and E2887.39 in TM2 and TM7, respectively (55). Ballesteros-Weinstein numbering is used 
in superscript throughout the text to enable the comparison of residue positions between 
receptors (1) (Appendix 1: table A1). Another recently described numbering scheme is used 
for residues in EL2 (3).
TM2 has also been suggested to regulate functional selectivity through an extended allosteric 
interface by an hydrogen bonding network (56, 57), as the mutation of a conserved proline 
in TM2 in the angiotensin II receptor (P2.60 in chemokine receptors) led to a loss in G
q
 
coupling for the agonist angiotensin II, while functional selectivity for the biased agonist 
[Sar1-Ile4-Ile8]angiotensin II was lost at this same mutation (56, 58). The triggering domain 
of chemokines is thought to interact with residues in this region as well (CRS2) (Appendix 1: 
table A1). Together with the finding that (modified) chemokines show functional selectivity 
at a single receptor, including CCR5 (59), it can be hypothesised that this region is involved in 
functional selectivity of chemokines. 
Despite the increasing evidence supporting the two-step model for chemokine receptor 
binding and activation, the exact regions of CRS1 and CRS2 used for these interactions seem 
to be different not only between receptors, but also for different ligands binding to the same 
receptor (30-33).
1.4: Allosteric interactions in chemokine receptors and their consequences
Chemokines bind with high affinity to their receptors involving numerous interactions with 
the receptor extracellular surface (20). Interestingly, low-molecular weight ligands (500-
600 Da) are often able to disrupt binding or function of the roughly 10 to 100-fold larger 
chemokine ligands (or HIV gp120 envelope glycoprotein) with nanomolar potencies. From the 
size differences, it seems evident that these small ligands probably do not act via simple steric 
hindrance or competition, but rather operate in an allosteric manner. In general, allosteric 
ligands bind to sites that are topographically distinct from the orthosteric endogenous 
ligand-binding site. Only since the past decade we have begun to appreciate the different 
mode-of-action between allosteric and orthosteric ligands. The ability of allosteric ligands to 
change receptor conformations via distant, yet conformationally-linked sites can positively or 
negatively impact the affinity as well as the efficacy of endogenous (orthosteric) ligands (60).
Modulation by allosteric ligands is saturable, meaning that its maximum is attained with full 
occupancy of the allosteric sites on the receptor. In addition, this maximum effect further 
depends on the level of cooperativity between the two ligands. Furthermore, allosteric ligands 
exert effects that are generally probe-dependent, meaning that these effects are not the same 
towards all orthosteric agonists. This may be exemplifed by allosteric CCR1 agonists, which 
enhance the binding of CCL3, while they inhibit the binding of CCL5 at the same receptor (33). 
In addition, an allosteric modulator can differentially affect receptor signalling mediated by 
orthosteric agonists, by selective potentiation of one signalling pathway while inhibiting a 
second, and leaving a third unaltered, reflecting the permissive nature of allosterism. Next 
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to orthosteric ligand modulation, allosteric ligands can also exhibit agonistic activity in the 
absence of an orthosteric agonist, which is also referred to as allosteric agonism (61, 62). 
This may include selective or biased activation of signalling pathways, also referred to as 
functional selectivity, or biased agonism (63, 64). Altogether, allosterism adds another layer 
of complexity to GPCR pharmacology, which has forced us to reconsider the approaches to 
identify and optimise ligands in drug discovery and development programmes.
Allosteric ligands have been identified for different chemokine receptors, including CC and 
CXC chemokine receptors (33, 65-69). These ligands include not only small molecules, but 
also metal chelators and peptides. In the next sections we will discuss some of the evidence 
supporting allosteric modulation and functional selectivity of chemokine receptors and 
the implications of receptor dimerisation. In addition, development of biologicals for the 
treatment of chemokine-associated disease is discussed.
1.4.1 Allosteric small-molecule chemokine receptor antagonists
The growing evidence implicating chemokine receptors and their ligands in disease has 
boosted the discovery and development of related therapeutics in the past decade. About 10 
years ago, Berlex Biosciences entered clinical trials with the first antagonist for a chemokine 
receptor, BX-471, a selective, potent and orally available CCR1 antagonist. However, the 
compound failed in a phase II trial with MS patients due to lack of efficacy. Nevertheless, it 
had set the stage for the clinical development of other chemokine receptor antagonists. Since 
Figure 3: Chemokine receptors, their cellular expression profile and association with disease. The cellular expression 
profiles of the chemokine receptors are shown by open circles on the left-hand side. The cells are divided in haema-
topoietic cells and miscellaneous cells. Meaning of abbreviations: VSMC, vascular smooth muscle cells; VE, vascular 
endothelial cells; LE, lymphatic endothelial cells; BSMC, bronchial smooth muscle cells. The association of a particular 
receptor with disease is shown on the right-hand side of the figure. The diseases are categorised into inflammatory 
diseases and cancer. Abbreviations: IBD, inflammatory bowel disease; COPD, chronic obstructive pulmonary disease.
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then, several chemokine receptor antagonists have been developed but failed in clinical trials 
due to failure of reaching clinical endpoints (70). However, the recent approval of maraviroc 
(CCR5 antagonist) and AMD3100 (CXCR4 antagonist), together with numerous clinical trials 
currently being conducted with small molecules and biologicals, reflects the faith in the 
chemokine system as a tractable therapeutic target (70) ("Appendix 1: table A1" and table 1). 
Small molecules generally interact with residues in the TM helices of the receptor. Two binding 
pockets in these helices can be distinguished: the minor and the major binding pocket, formed 
by residues from TM1, 2, 3, 7, or TM3, 4, 5, 6, respectively (Figure 4e, f) (71). To avoid confusion 
with the chemokine recognition sites, we refer to these sites as transmembrane site 1 (TMS1), 
and TMS2, respectively. Many ligands bind in both TMS1 and TMS2, but some seem to bind 
exclusively to TMS1 or TMS2 (Appendix 1: table A1). The mechanisms by which small-molecule 
ligands modulate chemokine affinity and/or efficacy are largely unknown. Although some 
ligands have been demonstrated to act in an allosteric manner, there are also studies that 
show overlap in binding sites of chemokines and small molecules, supporting a competitive 
component in the mechanism of action. However, ligands with partially overlapping binding 
sites, such as the CXCR3 chemokines CXCL10 and CXCL11, also show non-competitive 
‘allosteric’ behaviour (32, 47). Blanpain and co-workers showed that mutations in TM2 and 
3 of CCR5 affect the function but not the binding of CCL3, while CCL5 binding and function 
remains unchanged (30). Since many small-molecule ligands for CCR5 have also shown to 
bind in this region (e.g. Y371.39, W862.60, Y1083.32, and E2837.39) including maraviroc, aplaviroc, 
vicriviroc, SCH-C and TAK-779 (72-74), it can be hypothesised that these compounds compete 
with the CCL3 N-terminus to bind in the TM region and, thereby block its ability to activate 
CCR5 (Figure 4b, e). However, a simple competition hypothesis is not sufficient to explain the 
fact that these CCR5 antagonists are able to inhibit the binding of both CCL3 and CCL5 in 
an insurmountable allosteric manner (67). In addition, aplaviroc showed behaviour deviating 
from the other CCR5 antagonists, in that it only displaced 20% of CCL5 even at 10 μM (K
i
 ± 3 
nM), while the calcium response mediated by the chemokine was completely blocked by only 
10 nM of the ligand. The latter suggests an allosteric mode of action for aplaviroc, illustrated 
by the saturability and probe-dependence of the effects observed for this CCR5 antagonist 
(67).
A study of the CCR1-specific compound BX-471, showed that mutation of residues in both 
TMS1 and TMS2 affect ligand binding, including residues Y411.39, Y1133.32, Y1143.33, I2596.55, 
and Y2917.43, which are not important for CCL3 binding and function (66). Nevertheless, the 
compound was still able to displace [125I]-CCL3 from the receptor, indicating an allosteric 
mechanism of inhibition. In contrast, the chemokine did not affect the binding of a radiolabelled 
analogue of BX-471. UCB-35625 is another small-molecule CCR1 antagonist, for which 
residues Y411.39, Y1133.32, and E2877.39 (TMS1), were shown to be involved in ligand binding, 
sharing residues Y411.39 and Y1133.32 with BX-471, indicating that these two small molecules 
bind to different, yet overlapping sites (75). UCB-35625 has a potency in the picomolar range 
to block CCL3-induced eosinophil shape change, while it has a ~1000-fold lower potency 
in displacing the chemokine from the receptor (76). Moreover, the displacement of CCL3 
is incomplete, even at saturating concentrations of the compound. The latter suggests an 
allosteric inhibition of efficacy but not affinity. In contrast to CCL3, CCL5-induced activation of 
CCR1 is dependent on E2877.39 (33), and although not investigated, it might be speculated that 
the observed effects of UCB-35625 on CCL3 binding and activity would have been different 
when CCL5 was used as a probe. Also CCR2 and CCR3 ligands, like RS-504393, TAK-779, and 
UCB-35625, interact with TM residues shown to be involved in chemokine-induced receptor 
activation (75, 77-79).
Evidence for the mode of action of antagonists is not only found for CC, but also for CXC 
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chemokine receptors, including CXCR4. As for many other chemokine receptors, CXCL12 
binding to CXCR4 follows the two-step activation model (55). CXCR4 CRS2 contains residues 
from EL2 and TM domains, such as D18745.51 (EL2), D972.63, and E2887.39 that are involved in 
both chemokine binding and activation (80). In the recent crystal structures of CXCR4, the 
small-molecule antagonist IT1t is shown to bind to these same residues, and it was suggested 
that it competitively blocks the interactions of the CXCL12 N-terminus with CXCR4 (81). 
Similarly, the binding site of the well-studied bicyclam antagonist AMD3100 is mainly lined 
by three acidic TM residues, D1714.60, D2626.58 and E2887.39 (82-85). Although the binding site 
of AMD3100 and IT1t do not seem to overlap completely, AMD3100 might bind partly to CRS2 
where the N-terminus of CXCL12 interacts with the receptor (55). Altogether these findings 
might, at least in part, suggest a competitive mechanism of action for these compounds, 
by preventing the binding of the CXCL12 to CRS2 on the receptor, leading to the observed 
antagonism of functional responses. Along with the data presented above for CC chemokine 
receptors, competition of small molecules with this triggering domain of the chemokine might 
pose a general mechanism of action for chemokine receptor antagonists that have effects on 
Figure 4: Schematic overview of G protein-coupled chemokine receptors, their activation and ligand binding sites. 
A. The overall topology of a GPCR structure, with annotated TM helices, and N- and C-terminus. B and C. Schematic 
representation of the two-step model of chemokine receptor activation. B. The first step: chemokine binding to the 
extracellular surface of the chemokine receptor, including the N-terminus (CRS1). C. The second step: the flexible N-
terminus of the chemokine is positioned to interact with ECLs and TM residues (CRS2), mediating receptor activation. 
D. Intracellular allosteric binding pocket (ICS) used by CXCR2 and CCR4 ligands. Also the G protein binds in this region. 
E. Binding pocket for small-molecule ligands in the chemokine receptor between TM1, 2, 3, and 7 (TMS1). F. Binding 
pocket for small-molecule ligands in chemokine receptors between TM3, 4, 5, 6 and 7 (TMS2). Table A1 (Appendix 1) 
and Figure 5 give an overview of the interaction residues of small ligands binding to chemokine receptors.
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efficacy rather than affinity. Table A1 (Appendix 1) shows an overview of evidence for binding 
mechanisms of small ligands targeting chemokine receptors.
1.4.2: The success story of chemokine receptor antagonists: CCR5 and CXCR4 
The quest for therapeutics targeting chemokine receptors has been catalysed by their 
significant involvement in various human diseases. In the 1990s, it was shown that chemokine 
receptors were promising targets for treatment in HIV-1 infection (14, 16). Genetic evidence 
was provided by the impact of the naturally occurring mutation CCR5-∆32 that encodes a 
truncated, non-functional form of CCR5 with no apparent deleterious consequences. It was 
found that CCR5-∆32 is significantly underrepresented in the HIV-1 infected groups, and 
individuals homozygous for the mutation are only rarely infected with HIV-1 (86) supporting 
the role of CCR5 in HIV-1 entry. In addition, CXCR4 was found as a second co-receptor for HIV-
1. Namely, CCR5 and CXCR4 facilitate HIV-1 entry to macrophages and T-cells, respectively 
(87). In the first stages of infection the virus mainly uses CCR5 as a co-receptor (CCR5-tropic). 
These findings paved the way for discovery and development of small-molecule antagonists 
for CCR5. TAK-779 was the first to be discovered, showing inhibition of HIV-1 infection in vitro 
and in vivo (88). Since then, several CCR5 antagonists have entered clinical trials, including 
aplaviroc, maraviroc, and vicriviroc. Maraviroc (Celsentri…, developed by Pfizer) is the first 
CCR5 antagonist approved by the European Medicines Agency (EMA) for use in treatment-
experienced patients harbouring only CCR5-tropic viruses. It represents a novel class of anti-
retroviral drugs, as it is the first therapeutic targeting a cellular rather than a viral protein. 
Maraviroc is a potent inhibitor of CCL4 binding to the CCR5 receptor (IC
50 
= 2 nM) and a potent 
antiviral agent (EC
90 
= 1 nM) (89). In addition, Maraviroc has been demonstrated to behave as 
an allosteric antagonist. It binds to a site in the receptor that is topographically distinct to the 
site where the viral gp120 envelope protein binds (67, 90) and that involves key interactions 
with the TM domains of CCR5 (73) (Appendix 1: table A1). More recently, a second-generation 
maraviroc analogue has been described, PF-232798, which retains the attractive antiviral 
effect combined with improved absorption profiles in rat and dog (91) and is currently in 
phase II clinical trials. In addition, vicriviroc also showed long-term potent antiviral activity 
and is currently in phase III clinical trials (92). 
During the course of disease, HIV-1 shifts its tropism from CCR5 to CXCR4, a hallmark 
of the symptomatic stage when the disease progresses to acquired immuno-deficiency 
syndrome (AIDS) (93). Consequently, there has been an increased interest in the discovery 
and development of CXCR4 antagonists able to block the interaction of HIV-1 with CXCR4, 
preventing subsequent infection of cells. One of the early compounds showing anti-HIV activity 
was AMD3100 (94). However, despite its efficacy in clinical trials, AMD3100 treatments in 
HIV-1 patients were discontinued due to several events of cardiac toxicity. A serendipitous 
finding during these trials was that AMD3100 promoted mobilisation of hematopoietic stem 
cells from the bone marrow to the periphery. Subsequently, AMD3100 (plerixafor, Mozobil…) 
has been successfully developed by Genzyme as an effective therapeutic for autologous bone 
marrow transplantations in patients suffering from non-Hodgkin’s lymphoma and multiple 
myeloma (95). As can be seen from the blocking of CXCR4 with AMD3100, the CXCL12/CXCR4 
axis is involved in multiple homeostatic processes. These include T cell trafficking and homing, 
stem cell localisation and organ development (96). Since CXCR4 or CXCL12/SDF-1 knockout 
mice are not viable because of significant defects in B-cell lymphopoiesis and bone-marrow 
myelopoiesis (97), long-term CXCR4 antagonism might lead to severe adverse effects. Future 
in vivo studies are required to answer the question whether CXCR4 can actually be targeted 
safely for the (long-term) treatment of CXCR4-tropic HIV-1 infection. 
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1.4.3: Allosteric agonists for chemokine receptors and functional selectivity 
Despite the therapeutic focus on chemokine antagonists, the process of screening for and 
optimisation of chemokine receptor antagonists, has led to the discovery of several small-
molecule agonists for different chemokine receptors, such as CCR1, CCR3, CCR5, CCR8, 
CXCR3 and CXCR4 (62, 65, 69, 79, 98, 99). Despite their relatively small size, these ligands are 
generally able to fully activate receptor signalling. Similarly to small-molecule antagonists, 
residues involved in receptor binding have been shown to reside in TMS1 and TMS2 of the 
receptors (Appendix 1: table A1). For example, CH0076989, a small-molecule agonist for CCR3, 
activates multiple signalling pathways including chemotaxis and receptor internalisation by 
interacting with residues in TMS1 (i.e. Y411.39, Y1133.32, and E2877.39) (79). Since these residues 
are also important for CCL11-induced receptor activation, this suggests that CH0076989 
activates the receptor in a similar manner as the chemokine, probably by interacting with 
the TM2-TM3 interface (30, 54). As pointed out earlier, this receptor region might be involved 
in ligand-biased signalling (56). Indeed, CCR3 agonist CH0076989 seems to bind in that 
region (TMS1) (Appendix 1: table A1). Interestingly, while equal receptor internalisation was 
observed when stimulating CCR3 with either CH0076989 or CCL11, the efficacy of the small 
agonist to induce chemotaxis was significantly lower than for the chemokine, suggesting 
functional selectivity. YM-370749, a small-molecule agonist for the CCR5 receptor, also 
exhibited functional selectivity, while it binds to TMS2 and not TMS1. This compound promoted 
calcium mobilisation and receptor internalisation, but was unable to induce chemotaxis 
(62). Importantly, YM-370749 inhibited HIV-1 replication. The use of functionally selective 
agonists that down-regulate the receptor without concomitant undesired side effects, such 
as chemotaxis, might pose a novel therapeutic avenue for the treatment of diseases like HIV-1 
infection. Since chemokine receptors can initiate more signalling pathways than described 
here, including Janus kinase/signal transducers and activators of transcription (JAK/STAT) 
Figure 5: Alignment of important amino acid residues of TM domains and EL2. The TM residues are shown using the 
Ballesteros-Weinstein (B&W) numbering scheme (1). An adapted version is also used for the EL2 residues (45.50 and 
45.51; indicating residues in the loop between TM4 and TM5, using the conserved cysteine as reference: 45.50 (3). 
Mutation of residues highlighted in gray significantly affected ligand binding. Also the TXP motif is shown (2.56-2.58), 
which is conserved among chemokine receptors (see text for details). TMS1 (minor pocket) residues are indicated in 
blue, TMS2 residues (major pocket) in orange, interface residues between TMS1 and TMS2 in yellow, and intracellular 
residues in green. For CXCR4, contacts from the crystal structures of the receptor with ligands are indicated with a 
thick black border. Bold pink indicates specific contacts for the small-molecule IT1t, bold green for the peptide CVX15, 
and bold orange for both ligands. For more detailed information on the residues, ligands, and associated literature 
references, see table A1 (Appendix 1).
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(100), it would be interesting to see whether chemokine receptor agonists, e.g. CCR8 agonist 
LMD-009 (binds in TMS1), show selectivity in activation of these other signalling pathways. 
Moreover, there is accumulating evidence for GPCRs suggesting that selective activation of 
specific signalling routes, i.e. G proteins versus β-arrestins, might be beneficial over non-
biased agonists (101), again highlighting the therapeutic potential of such functionally 
selective ligands.
1.4.4: Intracellular binding sites in chemokine receptors
GPCR signalling is allosteric by nature, in which extracellular endogenous agonists act as 
positive allosteric modulators on the coupling of intracellular G proteins, and vice versa 
(102). Indeed, high affinity chemokine binding to a number of tested receptors is G protein 
dependent as revealed by experiments in which G
i/o
 proteins are uncoupled using e.g. GTPγS, 
Gpp(NH)p, or pertussis toxin (32, 103-106). Agonist-induced or constitutive coupling of 
a GPCR to G proteins can limit the availability of a shared G protein pool to interact with 
other receptors, which may subsequently hamper high affinity agonist binding to the latter 
receptors (103).
In addition, GPCRs can interact with multiple other interacting partners, such as receptor 
activity-modifying proteins (RAMPs), β-arrestins, GRKs, and other GPCRs (101), via regions 
that do not overlap with the binding site of endogenous ligands. Experimental evidence 
for such binding sites was presented for CCR4 and CXCR2 where some small-molecule 
antagonists appeared to bind along the intracellular surface of the GPCRs instead of the TM 
domains (68, 107, 108). Nicholls et al. studied two classes of CXCR2 antagonists that had 
a 1000-fold higher affinity for CXCR2 compared to CXCR1 (108). By constructing different 
chimeras between CXCR1 and CXCR2, they found a reversal of antagonism when switching 
the intracellular C-terminal tails. Using a similar approach, evidence was presented for an 
intracellular binding site in CCR4 (107). In the case of CXCR2, the point mutant K320N7.59 
in Hx8 of CXCR2 led to a 10-fold decrease in affinity for the compounds, while mutation 
of N311K7.59 at the same position in CXCR1 led to a 100-fold increase in affinity, providing 
additional evidence for an intracellular binding mode (108). Moreover, other groups, including 
our own, have presented pharmacological evidence for an allosteric binding mode for these 
and other classes of CXCR2 ligands (104, 109, 110). These include the inability of chemokines 
to displace a small-molecule antagonist with similar chemical structure, and insurmountable 
inhibition of CXCL8-promoted β-arrestin recruitment and [125I]-CXCL8 binding. Site-directed 
mutagenesis of different intracellular residues was performed to further delineate the binding 
pocket for these CXCR2 ligands (68). Salchow and co-workers identified several key CXCR2 
residues involved in interaction of CXCR2 antagonist SCH-527123, a ligand already suggested 
to bind in an allosteric manner (110), and compounds similar to those used in the previous 
study (108). The binding pocket seems to be lined by T832.39, D842.40, D1433.49 (E/DRY motif), 
Y3147.53, and K3207.59 along the intracellular surface of the TM helices (see Appendix 1: table 
A1 and Figure 4d). Since studied mutations are in close proximity to the site of G protein 
coupling, or to a region that is involved in receptor signal transduction, this might in fact 
govern a mechanism of allosteric inhibition (Figure 4d).
Recently, pharmacological modulation through interactions with intracellular parts of CXCR4 
has also been described by Tchernychev and colleagues who identified the pepducin ATI-
2341 as a potent agonist of this receptor (111). Pepducins are synthetic molecules that are 
composed of a peptide derived from the amino acid sequence of an intracellular loop of the 
target GPCR coupled to a lipid tether. The peptide component of the pepducin confers receptor-
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modulating activity whilst the lipid counterpart facilitates cell penetration and access to the 
intracellular face of the target GPCR. The ATI-2341 is derived from IL1 of CXCR4 and activates 
CXCR4-mediated signalling pathways, induces receptor internalisation, and promotes both, 
in vitro and in vivo chemotaxis. Interestingly, ATI-2341 acts as functional antagonist in vivo, 
leading to a similar mobilisation of hematopoietic stem cells from the bone marrow as is 
observed for the CXCR4 antagonist AMD3100 (111). The mechanism responsible for these 
seemingly contradictory effects requires further investigation. Although more evidence is 
needed regarding the molecular determinants of these ligand-receptor interactions, these 
studies indicate that targeting of allosteric regions other than the classical major and minor 
TM binding pockets is feasible within the class of chemokine receptors.
Receptor/
mAbs
Epi-
tope
Iso 
type Pathological condition(s) Phase
Trial
(PMID)
sta-
tus
CCR2
MLN1202 N.a. IgG1
Metastatic cancer II NCT01015560 S
Atherosclerotic cardiovascular disease II NCT00715169 C
Multiple sclerosis II NCT01199640 C
CCR4
KW-0761 Nt IgG1
Adult T-Cell Leukemia-Lymphoma and 
Peripheral T-cell lymphoma
I + II
NCT00920790
NCT00355472
NCT00888927
O
O
O
KW-0761 +
multidrug che-
motherapy
Peripheral and Cutaneous T-Cell Lym-
phoma
II NCT01226472 R
Peripheral T/NK-cell Lymphoma II NCT01192984 R
Adult T-Cell Leukemia-Lymphoma II NCT01173887 R
CCR5
HGS004/
CCR5mAb004
EL2 IgG4 HIV infection I NCT00114699 C
PRO140
Nt
&EL2
IgG1 HIV infection I + II
NCT00110591
NCT00613379
NCT00642707
C
C
C
PRO140 + oral 
antiretroviral
therapy
HIV infection II NCT01272258 R
CXCR4
MDX-1338 N.a. N.a. Acute Myeloid Leukemia I NCT01120457 R
Table 1: Clinical trials with mAbs targeting chemokine receptors. Info obtained in January 2011 on www.clinicaltrials.
gov. Epitope indicates the receptor region involved in mAb recognition: Nt, N-terminus; N.a., information not available. 
Status of clinical trials:  C, completed; O, ongoing; R, recruiting; S, suspended.
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1.5: Biological therapeutics targeting chemokine receptors
Monoclonal antibody (mAb)-derived therapeutics have been proven to be an excellent 
paradigm as high-affinity biopharmaceuticals in the diagnosis and treatment of cancer and 
inflammatory diseases, as exemplified by the acquisition of monoclonal antibody (mAb) 
technology companies by major drug companies (112). During the last 2-3 decades, 42 
engineered mAbs that target growth factors and receptor tyrosine kinases have gained US Food 
and Drug Administration (FDA) approval (113). Hitherto, no mAb-derived therapeutic against 
GPCRs has been approved for clinical use. The difficulty to develop such therapeutics may 
have been due to the intrinsic nature of GPCRs. Their limited availability as purified proteins 
as well as their low immunogenicity as membrane-embedded proteins render GPCRs difficult 
antigens for the generation of antibodies that recognise their targets with high specificity 
and affinity (114, 115). However, several attempts have been successful and clinical trials 
are currently evaluating the therapeutical potential of mAbs targeting chemokine receptors 
(table 1).
Therapeutic antibodies can act via two different mechanisms. First, mAbs can bind and block the 
target protein, directly interfering with its function (i.e. direct targeted therapy). Alternatively, 
the mAb triggers an indirect biological activity upon recognition of its antigen by recruiting 
cytotoxic monocytes/macrophages (i.e. antibody-dependent cell-mediated cytotoxicity) or by 
binding complement factors (i.e. complement-dependent toxicity). In addition, other proteins 
or drugs that are conjugated to such targeting mAbs can induce cellular responses (116, 117). 
MLN1202 is a genetically engineered human IgG1 mAb targeting CCR2 that has been 
developed by Millenium Pharmaceuticals, and optimised to reduce antibody- and complement-
dependent cytotoxicity. MLN1202 inhibits chemokine-induced CCR2 signalling in transfected 
cells (118). This mAb has been in clinical trials for the treatment of various inflammatory 
diseases involving CCR2-expressing monocytes/macrophages (Figure 2 and Table2). Treatment 
of patients at risk for atherosclerotic diseases with MLN1202 significantly reduced median 
serum levels of C-reactive protein (119), which is considered to be a predictive biomarker of 
inflammation associated with cardiovascular diseases (120). In contrast, MLN1202 failed to 
block CCR2-mediated infiltration of macrophages into the inflamed synovium of rheumatoid 
arthritis patients or reduce the expression of synovial pro-inflammatory cytokines (118). This 
failure may have been due to the incomplete receptor occupancy (86-94%) by MLN1202 or 
the fact that CCR2 is not the correct/only therapeutical target for this pathological condition 
(118, 121). Finally, clinical trials in multiple sclerosis patients have also been conducted with 
MLN1202 but no results are publicly available. Also, a phase 2 clinical trial for the treatment 
of bone metastasis by MLN1202 had been initiated but was recently suspended.
Two mAbs targeting CCR5 have been developed by Human Genome Science (HGS004) and 
Progenics Pharmaceuticals (PRO 140) and have been investigated in the context of CCR5-
mediated HIV-1 infection (122). HGS004 binds to EL2 of CCR5 and inhibits chemokine-induced 
signalling as well as HIV co-receptor activity (123). Phase 1 clinical studies demonstrated that 
HGS004 reduces plasma HIV-1 RNA levels ³ 10-fold in 54% of treated patients (123). However, 
the lack of a clear dose-response relationship indicated that the anti-HIV potency of HGS004 
as a single agent might be suboptimal. Also, some patients treated with high doses of HGS004 
showed a shift from CCR5- to CXCR4-tropic viruses or dual strains. 
PRO 140 binds to the N-terminal region (residue D2) and extracellular loop 2 (R16845.40, 
24  Pharmacological modulation of chemokine receptor function
C1
Y17645.48) of CCR5. Interestingly, PRO 140 is more potent in inhibiting HIV-1 co-receptor 
activity than antagonising chemokine-induced signalling, giving the possibility to inhibit HIV-
1 infection without affecting CCR5-mediated signalling, an example of permissive antagonism 
(124). Phase 1 and 2 clinical studies demonstated that a single intravenous injection of PRO 
140 could reduce HIV-1 viral loads in 100% of treated patients (125, 126). Importantly, some 
patients displayed a more than 100-fold decrease in viral load and patients treated with high 
doses of PRO 140 displayed no change in co-receptor tropism and no emergence of PRO 
140-resistant viral strains (125). Such strong antiviral effects supported the development of 
subcutaneous formulations of PRO 140. Three weekly subcutaneous injections of PRO 140 led 
to an anti-viral activity similar to that observed with one single intravenous injection (127). 
This phase 2 study provided proof-of-concept for the subcutaneous use of PRO 140 and the 
subcutaneous PRO 140 was selected for further development on the basis of its potential to 
be self-administered by patients (125, 127).
Monoclonal Abs against CCR4 have been optimised by Kyowa Hakko Kirin Ltd to block the 
receptor, but also induce antibody-dependent cellular cytotoxicity (ADCC) (116, 128). To this 
end, these mAbs (i.e. KW-0761 and KM2760) have been modified to remove fucose groups from 
the Fc region of their heavy chains, thereby increasing their affinity for leukocyte receptors 
FcgRIIIa. Upon binding to CCR4-expressing cells, these mAbs recruit FcgRIIIa-expressing 
natural killer cells leading to the lysis of CCR4+ tumor cells (116, 128). Preclinical studies have 
shown that the antitumor activity of KW-0761 and KM2760 in adult T-cells leukemia-lymphoma 
(ATLL) mouse models is mediated via ADCC (128, 129). Furthermore, the clinical application 
of KW-0761 was demonstrated by its ability to induce ADCC-mediated cytotoxicity of primary 
ATLL cells ex vivo (128). Phase 1 and 2 clinical trials are currently ongoing to evaluate the 
therapeutic effect of KW-0761, alone or in combination with multidrug chemotherapy, in 
patients with T-cell and NK-cell lymphomas (table 1).
A new class of antibody-based therapeutics has recently joined the family of GPCR-
targeting biologicals. VHH antibody fragments, also defined as nanobodies by Ablynx, are 
immunoglobulin single variable domains of heavy-chain antibodies that occur naturally 
in the Camelidae family. Due to their small size of approximately 15 kDa, nanobodies can 
be easily expressed and produced in organisms such as yeasts or bacteria, and are also 
highly stable and soluble. Furthermore, complementarity-determining regions (CDRs) of 
nanobodies can penetrate into grooves and cavities of proteins, accessing a new range of 
non-planar epitopes, such as enzymatic clefts (130). We recently described the first GPCR-
specific antagonistic nanobodies against the chemokine receptor CXCR4 (131). 238D2 and 
238D4, were generated and their epitopes were localised mainly in EL2 but also EL3 loop of 
CXCR4, with one amino acid common to both different epitopes. Both nanobodies showed 
high affinity towards CXCR4, with inhibition constants in [125I]-CXCL12 displacement assays, 
signalling and chemotaxis assays in the nanomolar range. In addition, both nanobodies proved 
to behave as competitive antagonists. Interestingly, when both 238D2 and 238D4 monovalent 
nanobodies were linked together, the affinity of the resulting biparatopic nanobody increased 
almost 30 times compared to its monovalent counterparts, reaching a Ki value of 0.35 nM. 
The affinity of this biparatopic single domain antibody was 100-fold higher than the CXCR4 
benchmark compound AMD3100. Pre-clinical characterisation of the CXCR4 nanobodies also 
demonstrated their ability to fully inhibit entry of CXCR4-tropic HIV-1 strains in vitro. Finally, 
a single intravenous injection of biparatopic nanobody resulted in stem cell mobilisation in 
cynomolgus monkeys, to a similar extent as AMD3100 (131). Currently, CXCR4 nanobodies are 
in advanced stage of pre-clinical development and will enter clinical trials this year (http://
www.ablynx.com/wp-content/uploads/2010/11/7_ALX-06511.pdf). It will be interesting 
to see the potential of these molecules and their therapeutical benefit compared to the 
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AMD3100/Pleraxifor drug currently used in the clinic. 
A VHH antibody fragment against the atypical chemokine receptor Duffy antigen receptor 
for chemokines (DARC) has also been reported. Unlike the CXCR4 nanobody, the DARC VHH 
fragment has been generated solely against the N-terminal domain of the receptor (132). The 
CA52 nanobody binds to DARC with a very high affinity of 0.2 nM. It displaces the endogenous 
DARC ligand CXCL8 and was able to prevent the infection of red blood cells by Plasmodium 
vivax. As such, this nanobody may serve as a basis for the development of therapeutics against 
malaria (132, 133).
1.6: Crystal structures of CXCR4 and their impact on chemokine receptor-targeted 
drug design
The determination of the first GPCR crystal structure of bovine rhodopsin (bRho) in 2000 was 
a milestone in GPCR research (134). The bRho structure served as template for in silico GPCR 
homology modelling, including chemokine receptors and structure-based drug design (135). 
About three years ago the first structures of liganded GPCRs (i.e. b2- and b1-adrenoceptor 
(ADRB1/2), and adenosine A2A receptor (AA2AR)) were reported (36-38), which were 
subsequently used as new GPCR modelling templates. While the recently solved dopamine 
receptor D
3
 (DRD3) crystal structure (35) gives insights into bioaminergic receptor subtype 
specificity (by comparison with ADRB1/2), the recently solved CXCR4 chemokine receptor 
crystal structures (81) open up new possibilities for structure-based drug design on the 
chemokine receptor family. One crystal structure has been elucidated with a large cyclic 
peptide CVX15 and several crystal structures have been elucidated with the small-molecule 
antagonist IT1t (81). 
The GPCR structure features seven TM helices and one intracellular helix (Hx8). Traditionally, 
the GPCR TM bundle is categorised in two subpockets in which ligands can reside. These are a 
minor pocket comprised of TMs 1, 2, 3 and 7 (TMS1) (Figure 4e), and a major pocket comprised 
of TMs 3, 4, 5, 6 and 7 (TMS2) (71) (Figure 4f). While the ligands in the bRho, ADRB1, ADRB2, 
AA2AR, and DRD3 co-crystal structures all occupy TMS2, the CXCR4 crystal structures show 
for the first time ligand binding to not only TMS2 (CVX15) but also TMS1 (IT1t) (Figure 6a).
The cyclic peptide CVX15 resides in TMS2 and, due to its size, points out of the TM domain 
towards the extracellular side of the protein (Figure 6b). The peptide makes ionic interactions 
with D1714.60 and D2626.58 similar to other CXCR4 ligands that bind to TMS2 (Appendix 1: table 
A1, and Figure 4f), and makes additional interactions with D18745.51, D19345.57 and E2777.28 in 
the extracellular region (Figure 6b). The CXCR4 crystal structures with the antagonist IT1t are 
unique in the sense that they are the first to portray a ligand binding to TMS1 (Figure 4e, Figure 
6d). It forms ionic interactions with D972.63 and E2887.39, the latter being a highly conserved 
binding partner in other chemokine receptors (Figure 5). The CXCR4 crystal structures as 
well as site-directed mutagenesis data of other chemokine receptors and their ligands (i.e. 
TAK-779 and AMD11070, Appendix 1: table A1) show that both pockets (TMS1 and TMS2) 
are interconnected. The existence of different ligand binding sites makes the structure-based 
design of small-molecule ligands for chemokine receptors challenging.
Next to the novel ligand binding modes, the CXCR4 crystal structures portray several other 
differences to those of previously resolved GPCRs. First, TM2 of the chemokine receptor 
family possesses a unique S/TXP motif (Figure 5: residues 2.56-2.58) which induces a unique 
helical kink to position the two ligand-binding residues W942.60 (Q in CCR8) and D972.63 (S or 
Y in other chemokine receptors) into TMS1 instead of towards the membrane layer as in the 
bRho, ADRB2, DRD3, and AA2AR crystal structures (35, 36, 38, 134). This alternative kink of 
TM2 is supported by site-directed mutagenesis data probing the TM2-TM3 interface (53) and 
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receptor-ligand interactions (Appendix 1: table A1) and is in line with earlier predictions of TM 
flexibility (136).
Secondly, the crystal structures of ligand IT1t show a disordered Hx8 (81). The impact of this 
distortion on future modelling attempts based on the CXCR4 crystal structures is that models 
for ligands that bind to a putative intracellular pocket (Figure 4d) will be difficult to construct 
Figure 6: Crystal structures of CXCR4 receptors complexed with ligands. A. Comparison of the ligand binding modes 
of the small molecule antagonist IT1t (magenta, 3odu) and the peptide-like ligand CVX15 (green, 3oe0) in the (IT1t 
bound) CXCR4 crystal structure. While IT1t binds in the TMS1 (minor pocket) between TM helices 1, 2, 3, and 7, CVX15 
binds primarily in TMS2 (major pocket) between TMs 3, 4, 5, 6, and 7. TMs 2, 4, and 7 are coloured cyan, yellow, and 
orange, respectively, and Calpha atoms of residues D2.63 (TMS1), D4.60 (TMS2), and E7.39 (interface between TMS1 
and TMS2) are indicated with black spheres (like in panels B, D, and E). Furthermore the beta sheet of extracellular 
loop 2 (EL2) and the disordered helix 8 are labeled; B. Interactions between the residues 1-4 and 13-14 of CVX15 (green 
sidechain in ball-and-stick, backbone as ribbon) and CXCR4 (3oe0). Important residues are displayed as ball-and-stick 
(grey carbon atoms), while CVX15-1T1t H-bond and ionic interactions are indicated with black and grey dashed lines, 
respectively. Nitrogen, oxygen, and sulfur atoms are coloured blue, red, and yellow, respectively. For reasons of clarity 
the top of TM3 is not shown, while only the first beta strand of EL2 is displayed; C. Chemical structures of IT1t and 
CVX15 (part of molecule displayed in panel B is coloured green); D-E. Comparison of the interactions between IT1t 
(magenta carbon atoms) and CXCR4 in the experimentally determined X-ray crystal structure (3odu, panel D) and the 
best in silico CXCR4 model in the world-wide GPCR DOCK 2010 competition (panel E) correctly predicting the highest 
number of IT1t-CXCR4 contacts (prior to release of the CXCR4-IT1t crystal structure). Important residues are displayed 
as ball-and-stick (grey carbon atoms), while IT1t-CXCR4 H-bonds are indicated with black dashed lines. Colour coding 
of helices and heteroatoms are the same as defined in panels A-B. For reasons of clarity the top of TM3 is not shown.
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since they contact TM7 (e.g. SCH-527123, SB265610 in CXCR2, see section on intracellular 
binding sites and table A1 (Appendix 1)).
Thirdly, EL2 of CXCR4 contains the same β-strand in the crystal structure as observed in 
rhodopsin, but is oriented outward (Figure 6a), to accommodate the large peptide ligand or 
Hx8 of the CXCR4 monomer, demonstrating the plasticity of this loop to fold in an open or 
closed conformation.
Before the release of CXCR4-CVX15 and CXCR4-IT1t structures (81), the scientific community 
was invited to submit a structural model of CXCR4 in complex with either CVX15 or IT1t in 
the open challenge GPCRDOCK2010 (137). Given the differences with previously released 
GPCR crystal structures and the lack of conclusive experimental data to guide the modelling 
procedure, correct prediction of the CXCR4 fold and CXCR4-ligand interactions was shown 
to be highly challenging. Our model of the CXCR4-IT1t complex (Figure 6e) was in fact the 
only model out of 103 models (from 25 different groups) which correctly captured both ionic 
interactions with D972.63 and E2887.39, placing the dicyclohexylthiorea between TM2 (W942.60, 
ionic interaction with D972.63), TM3 (V1123.28), and EL2 (I19045.54) and the imidazothiazole ring 
between TM2 (W942.60) and TM3 (cation-π interaction with Y1163.32), and TM7 (ionic interaction 
with E2887.39). Although the overall position of the ligand was more shifted towards TM2 and 
TM3, the model was the only model that identified more than 20% of the ligand-receptor 
atomic contacts in the crystal structure (Figure 6d, e) (137). The TM bundle of our CXCR4 
model was constructed based on the ADRB2 crystal structure (36) (next to ADRB1, the 
structural template with the highest resolution to CXCR4) and TM2 was modelled in an 
alternative kink, stabilised by the chemokine receptor specific TXP motif (53, 138, 139) and 
orienting W942.60 and D972.63 towards the ligand binding pocket. This modelling procedure 
was guided by site-directed mutagenesis data probing the TM2-TM3 interface (53) and 
receptor-ligand interactions (Appendix 1: table A1), including the experimentally determined 
involvement of D972.63 in the binding of other CXCR4 ligands (85). We docked IT1t into the 
CXCR4 TM bundle in line with ligand binding mode hypotheses (135) matching the essential 
positively ionisable thiorea and imidathiazole groups of IT1t (140) with the negatively charged 
carboxylate groups of D972.63, D1714.60, D2626.58 and E2887.39 (85). Furthermore, the steep 
structure-activity relationship around the dimethyl-imidathiazole group (140) supported 
the tight cation-π stacking interaction with Y1163.32 at the bottom of TMS1 (Figure 6d, e). It 
should be noted that none of the CXCR4-CVX15 models predicted the important interactions 
in the crystal structure, indicating that accurate prediction of flexible peptide ligands in large 
receptor binding pockets (without the availability of experimentally supported receptor-ligand 
interaction anchors) is currently beyond the reach of molecular modelling approaches. The 
low accuracy of the loop predictions in the GPCRdock challenge compared to the reasonable 
accuracy of the predicted fold of the TM helices (137), is furthermore in line with a previous 
evaluation of the implication of EL2 modelling on structure-based virtual screening (3).
The binding modes of ligands in earlier ADRB1/2 homology models generally resemble the 
binding orientations of ligands in the respective crystal structures (36, 135, 141) and the 
recently solved DRD3-ligand co-crystal structure could be correctly predicted based on the 
closely related ADRB1/2 crystal structures (137). The use of experimental anchors to guide 
the construction of a AA2AR-ligand crystal structure complex were, however, somewhat 
misleading (135), while the spatial distribution of experimentally determined interaction 
partners in CXCR4 (negatively ionisable residues D972.63, D1714.60, D2626.58 and E2887.39 (85) 
and its ligand (two positively ionisable groups) allows the definition of several alternative 
binding modes. The success of our customised CXCR4 modelling approach demonstrates that 
a careful consideration of experimental data (site-directed mutagenesis data in combination 
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with structure-activity relationships) is essential in predicting protein structure and protein-
ligand interactions (135). Finally it should be noted that customised chemokine receptor 
models based on bRho and ADRB2 crystal structures have already been successfully used to 
identify new ligands for CCR2 (142), CCR3 (143), CCR4 (144, 145), CCR5 (138, 146), CXCR4 
(147), and CXCR7 (148) in the past. Therefore, it is expected that the novel crystallographic 
data on CXCR4 will improve the resolution of in silico models and aid the structure-based 
development of future drugs for targets belonging to the chemokine receptor family.
1.7: Cross-modulation within chemokine receptor oligomers
Although GPCRs can function as monomeric signalling units by coupling of intracellular 
heterotrimeric G proteins or β-arrestins upon agonist binding to their extracellular surface in 
a 1:1:1 stoichiometry (149-152), accumulating evidence suggest that GPCRs are assembled 
in homo- and/or heteromeric complexes for at least part of their lifetime (153-155). Several 
examples of homo- and heteromeric interactions between chemokine receptors, but also 
between chemokine receptors and other GPCR subtypes have been reported in the last decade 
(Figure 7). 
Initial crosslinking experiments suggested that chemokines induce homo- and/
or heteromerisation of CCR2, CCR5 and CXCR4 (156-161). However, more recent co-
immunoprecipitation, resonance-energy transfer (RET), and protein complementation 
assay (PCA)-based studies revealed that all tested chemokine receptors oligomerise in a 
ligand-independent manner (162-166). The latter fits well with the current dogma that 
GPCR oligomers are formed during protein biosynthesis and maturation in the endoplasmic 
reticulum (ER) to facilitate appropriate protein folding and cell surface targeting (167). On 
the other hand, fusion of an ER-retention motif to the C-tail of CXCR2 not only impaired its 
own trafficking to the cell surface, but also of co-expressed wildtype CXCR1 and CXCR2 
through the formation of heteromeric complexes (166). Similar entrapment of wild type CCR5 
by the dominant negative CCR5…32 truncation mutant was proposed to explain the delayed 
progression of HIV-1 infection in heterozygous individuals (168), although others raised 
skepticism on the dominant negative nature of this observation (169). 
Recent studies using fluorescence recovery after photobleaching (FRAP) and total internal 
reflection fluorescence (TIRF) microscopy revealed that some GPCR subtypes are engaged in 
short-living transient homodimers that are formed and fall apart within seconds in a ligand-
independent manner, whereas others are assembled in stable higher order oligomers at the 
cell surface (170-172). Similar FRAP or TIRF microscopy evaluation of chemokine receptor 
oligomer stability remains to be performed. However, CXCR4 and d-opioid receptors were 
Figure 7: GPCR dimerisation partners of chemokine receptors. The open 
circles connect the chemokine receptors with their suggested dimerisa-
tion partners.
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proposed to exist in a ligand-dependent dynamic equilibrium between homo- and heteromers 
(173). Stimulation with either CXCL12 or [D-Pen2, D-Pen5]-enkephalin shifted this equilibrium 
towards signalling homomers, whereas simultaneous addition of both agonists induced the 
formation of signalling-deficient heteromers. 
Heteromerisation of the non-G protein-signalling chemokine receptors CXCR7 and DARC with 
CXCR4 and CCR5, respectively, blunted chemokine-induced G protein signalling by the latter 
two receptors (174, 175). On the other hand, heteromerisation of CCR5 with CCR2 or CXCR4 
shifted G protein coupling from G
i
- towards G
q
-mediated signalling pathways resulting in cell 
adhesion rather than chemotaxis  (157, 176, 177). Recruitment of CCR5/CXCR4 heteromers to 
the immunological synapse stabilises the interaction of T cell with antigen-presenting cells in 
response to chemokine secretion by the latter (157, 176, 177).
Chemokines can induce changes in basal RET and/or PCA signals, which are generally 
interpreted as conformational rearrangements within existing chemokine receptor oligomers, 
rather than de novo formation or dissociation of oligomers (174, 175, 178-182). These 
conformational rearrangements result in allosterism between individual chemokine receptors 
within oligomers. Negative chemokine binding cooperativity has been observed within 
CCR2, CCR5, and CXCR4 heteromers in equilibrium (competition) binding and “infinite” 
radioligand dilution experiments (105, 163, 165, 181). Assuming that chemokine affinities 
for their cognate receptors are within the same order of magnitude (183), these heteromeric 
chemokine receptor configurations allow cells to respond to the highest chemokine (gradient) 
concentration at the expense of other chemokine subtypes by allosterically inhibiting their 
interaction to partnering receptors. Moreover, low-molecular weight (allosteric) antagonists 
acting at one receptor can cross-inhibit in vitro and in vivo chemokine-induced immune cell 
recruitment mediated through the other chemokine receptor within the heteromer (165, 181). 
In contrast, however, the CXCR2 antagonist SB225002 increased signalling of CXCR2/δOR 
heteromers in response to opioid agonists (184). Hence, this allosteric cross-modulation 
should be kept in mind when screening for ligands against a particular chemokine receptor to 
avoid side effects through heteromerised receptor partners. On the other hand, one can also 
take advantage of allosteric modulation by targeting a widely abundant receptor in a more 
cell type-specific manner through its less widely expressed heteromeric partner. Moreover, 
future development of chemokine receptor heteromer-selective (bivalent) ligands may also 
contribute to the specific targeting of a smaller subset of cells (131, 185-187).
1.8: Summary 
In summary, the family of chemokines receptors is a perfect showcase for the GPCR family 
to illustrate the effectiveness of GPCR targeting with small molecule allosteric modulators 
and/or biologicals. This is underscored by the recent FDA approval of 2 small molecules 
targeting CXCR4 and CCR5. Whereas most biologicals are considered to target extracellular 
parts of the receptor, the present data on binding modes of the small-molecule antagonists 
and chemokines suggests that competing with or blocking the entrance of the N-terminus 
of a chemokine to TM residues poses a mechanism of allosteric (or partially competitive) 
inhibition of chemokine-mediated receptor activation for many of the chemokine receptor 
antagonists binding to the classical TMS1 and TMS2 binding pockets (Appendix 1: table A1, 
and figure 4). Since this region is generally not important for chemokine binding, using the 
term allosterism is, in our opinion, justified. Whether these interactions are purely allosteric 
or partially competitive largely depends on the used chemokine probe and its specific receptor 
interactions. There is no discussion needed on the allosteric nature of chemokine receptor 
antagonists suggested to bind to intracellular binding sites of CXCR2 or CCR4. It remains 
to be established whether other chemokine receptors or other members of the large GPCR 
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family can be modulated in a similar manner, but the two examples are intruiging. Similarly 
intruiging is the possibility to specifically target chemokine receptor heterodimers. We would 
like to stress though, that the evidence for such a mechanism of action of small molecule 
modulator still remains to be established.
Targeting chemokine receptors in a functionally selective manner, as suggested to be 
feasible for CCR5 and CXCR4 (62, 67, 69), is a further promise for future drug discovery. The 
association of specific signalling pathways with disease or adverse drug effects is starting 
to emerge, and the overall challenge remains to identify what signalling pathway to target 
in a particular disease. On the other hand, insights in the structure activity relationships 
governing functional selectivity is needed, and in vivo studies will have to shed more light on 
the potential of functional selective ligands in treatment of chemokine-related disease.
Finally, the recent breakthrough of the CXCR4 crystal structure will give a strong impetus 
to additional receptor crystallisation, mutagenesis, modelling and pharmacological studies, 
which will be essential to delineate the mechanism of action of a the various small molecule 
allosteric modulator and/or biologicals.
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2: Abstract
Targeting of chemokine receptors by small molecules has been widely pursued. This review 
highlights recent illustrative disclosures of clinical relevance that could further shape our 
appreciation, and add to our understanding, of the therapeutic value of chemokine receptor 
targeting. Disclosures include new structures, announcements of new trials, or results of 
conducted trials (including setbacks). This review shows how most of the discussed disclosures 
seem to be concentrated on selected receptors, e.g. CCR1, CCR2, CCR5, CCR9, CXCR2 and 
CXCR4, with a wide variety of associated ligand chemotypes and diseases. With two approved 
antagonist drugs and several in Phase III trials, as well as new antagonist chemotypes entering 
the pipeline, the chemokine receptor field proves dynamic and upcoming results will further 
fuel the field.
2.1: Introduction
Chemokine receptors play key roles in a myriad of physiological processes. In many immune-
related diseases, such as auto-immune disorders, allergic diseases as well as allograft 
rejection, but also in several types of cancer, aberrant expression of chemokine receptors 
and/or ligands is commonly observed (1). It will therefore not come as a surprise that a high 
number of small-molecule drug discovery efforts on these receptors have been undertaken. 
‘Drugging’ chemokine receptors has made substantial progress, but many efforts are still 
underway and the diverse nature of small-molecule binding to chemokine receptors remains a 
recurring theme. In general, small-molecule chemokine receptor antagonists bind to sites that 
are distinct from or partly overlapping with regions important for interaction of chemokines 
with the receptor. As such, via allosteric mechanisms, these small ligands are able to block 
chemokine binding and/or responses. A recent in-depth review by our laboratory addresses 
the versatility of these binding events at the molecular level (2). Complementarily, the aim 
of the current review is to show the reader whether and how this small-molecule binding to 
chemokine receptors can be capitalized upon clinically, most notably through antagonism.
Such a review should start with an important positive message from the frontline: Maraviroc 
(compound 1), the first marketed chemokine receptor ligand (CCR5), and the recently 
approved AMD3100 (2, CXCR4) have made pioneering journeys to the market. As such, both 
molecules have been widely described already (3-6). Excellent reviews have portrayed general 
drug discovery efforts on chemokine receptors (7, 8), including the notion of other ‘classics’ 
in chemokine receptor drug discovery (e.g. BX471, MK0812, AMD070, AMG487 and Aplaviroc) 
as well as current advanced candidates (e.g. CCX282-B and Vicriviroc). Notably, a recent 
opinion delivers an expert speculation on the hurdles to be overcome in chemokine receptor 
antagonist development (9). The current review will focus on recent clinically relevant 
articles/disclosures, for example those involving disclosures of clinical results or of structures 
of clinical antagonist candidates. Thus, rather than providing an exhaustive overview of all 
ongoing discovery efforts, the overall aim is to provide the reader with a bird-eye’s view on the 
status quo which can help in shaping a picture of the general potential of chemokine receptor 
drug discovery. The paragraph distinction illustrates which are currently the most intensely 
described receptors.
2.2: CXCR2
CXCR2 and its ligands are involved in neutrophil-dominant diseases such as inflammatory 
bowel disease, atherosclerosis and pulmonary diseases such as COPD (chronic obstructive 
pulmonary disease), lung fibrosis and severe allergic asthma (10, 11). CXCR2 seems to play a 
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central role in the migration of neutrophils (12). Increased expression of CXCR2 and its ligands 
(e.g. CXCL1-3, CXCL8) is correlated with increased neutrophil infiltration (neutrophilia) in the 
lungs of patients suffering from pulmonary diseases like COPD and asthma (10). In addition, 
CXCR2 activation is also linked to goblet cell hyperplasia, leading to mucus overproduction, 
which is associated with asthma (13). As a consequence, antagonism of CXCR2 has been the 
focus of considerable drug discovery efforts over the past decade. In 2010, CXCR2 binders 
like reparixin, SCH-527123 (compound 3) (14) and SB-265610 (compound 4) (15) were 
all reported as being in clinical trials (8). Recent articles have disclosed advancements in 
understanding CXCR2 blockage, both at the molecular as at the clinical level. Several groups 
have now reported detailed studies on compounds like 3, 4 and SB-656933 (compound 5) 
(10), suggesting that they bind at an allosteric intracellular site of CXCR2, instead of in 
the ‘classical’ TM (transmembrane) binding pockets known to be involved in binding of the 
majority of small GPCR ligands (2, 16, 17). Interestingly, preliminary evidence points at a 
similar intracellular binding site for a pyrazinyl sulfonamide-class of compounds binding to 
the chemokine receptor CCR4 (18). Since this novel CXCR2 binding site is in the same region 
as involved in receptor signal transduction, targeting this region might offer a novel means to 
inhibit receptor function in an allosteric fashion. Altogether, this could provide a blueprint for 
future development of potent CXCR2 antagonists. 
As mentioned, more results also emerge on the use of CXCR2 antagonists in humans, most 
notably concerning COPD. Both 3 and 5 have been tested for their blocking effects on ozone-
induced airway neutrophilia in healthy human subjects (12, 19). Both compounds, taken 
orally, significantly inhibited neutrophilia and, importantly, were safe and well-tolerated. 
Interestingly, compound 3 was recently shown to only slowly dissociate from the CXCR2 
receptor (t1/2 ~22 h), possibly contributing to its high in vivo efficacy (14). Altogether, this 
suggests the therapeutic use of these compounds in patients having chronic neutrophilia-
related disorders (e.g. COPD and cystic fibrosis). For example, a Phase II trial with 5 in patients 
with cystic fibrosis has been recently conducted. More information can be found on the GSK 
website (20). Encouragingly, new CXCR2 binders still enter the clinic. Of note is the recent 
completion of a Phase I study with a selective CXCR2 antagonist GSK1325756 in development 
for COPD (structure undisclosed). More information can be found on the GSK website (21).
Figure 1: Approved antagonists for chemokine receptors. Given structures and affinities can be found in the references 
provided in the text.
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2.3: CXCR4
For several reasons, CXCR4 has moved to one of the spotlights in chemokine receptor 
antagonist research. First, CXCR4 was reported to be the second major coreceptor for the 
human immunodeficiency virus (HIV-1) virus next to CCR5 (22). Second, although targeting 
of CXCR4 in HIV-1 infection by CXCR4 antagonist AMD3100 (compound 2) has been proven 
unfeasible due to side effects (e.g. stem cell mobilization), its clinical utility has still been 
showcased because 2 was recently approved for stem cell mobilization in non-hodgkin’s 
lymphoma and multiple myeloma patients (23). Its activity and safety studies in human trials 
have been well documented (4, 24, 25). Third, in 2010, crystal structures of CXCR4 with a small 
molecule or a peptide ligand were reported (26), providing an unprecedented glimpse in the 
architecture of chemokine receptors and paving the way for focused structure-based design 
of improved molecules. A recent review summarizes small-molecule medicinal chemistry 
efforts on CXCR4 (27). Although it is beyond the scope of this review, it is of interest to note 
that efforts are also made to utilize biologicals to target CXCR4. An example involves a novel 
type of antibody-based therapeutics, called ‘nanobodies’, which are single-domain antibodies 
obtained from the Camelidae family. One such nanobody, ALX-0651, was shown to have 
efficacy comparable to AMD3100 in preclinical studies (28), and will soon be examined in a 
phase I clinical trial initiated by Ablynx (29). It will be interesting to see what the therapeutic 
benefit of this nanobody is compared to the small-molecule antagonist AMD3100 currently 
on the market.
In 2010, several CXCR4 small-molecule binders were reported as being in clinical trials with 
therapeutic areas listing stem cell transplantation and HIV-1 (8). A clinicaltrials.gov search on 
CXCR4 confirms that CXCR4 remains an active area of clinical research. For example, interim 
Phase II results for selective CXCR4 antagonist POL-6326 (undisclosed structure) show 
that it is safe as well as efficacious (e.g. rapid and predictable onset and a dose-dependent 
mobilization of stem cells) (30).
One of the more advanced compounds appeared to be AMD-070, a.k.a. AMD11070 (compound 
6) (31). Clinical activity of 6 against CXCR4-tropic HIV Type 1 has been documented (32) 
and a Phase II trial in HIV-infected patients has been completed (33). It should be noted, 
though, that development of 6 against HIV appears to be on hold due to histologic changes 
to the liver found in long-term animal studies (32). A recent paper summarizes the molecular 
pharmacology of 6 (31), outlining in detail e.g. its functional properties and some evidence for 
allosteric binding. In combination with the crystal structure of CXCR4 with other ligands (26), 
this can aid in future structure-based efforts on CXCR4. 
2.4: CCR1
CCR1 blockage has been studied as a means to battle diseases like RA (rheumatoid arthritis) 
or COPD. However, the clinical picture for this receptor seems to be one of the most humbling 
ones. Development of early CCR1-binders like BX471 and CP481,715 was halted due to lack of 
efficacy (7). Two compounds that in 2010 were reported to be in Phase II clinical trials (8), MLN-
3897 [7](34, 35), and AZD4818 (type of structure has been speculated upon by others(36)), 
have been the subject of recently disclosed discouraging clinical results. More specifically, a 
Phase IIa study with RA patients receiving MTX (methotrexate) with MLN-3897 (10 mg oral 
once daily) revealed no significant activity of the latter compared to placebo, despite relatively 
high receptor occupancy (37). Moreover, exposure of COPD patients to inhaled AZD4818 did 
not, despite expected exposure, yield any signs of beneficial effects (38). Thus, for several 
therapeutic areas a humbling picture for CCR1 antagonism has emerged. This adds to the 
evidence that CCR1-targeting may not be ‘trivial’, or at least requires appropriately high 
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receptor occupancy that might not have been reached in previous clinical trials. The critical 
need for effective dose concentrations of CCR1 antagonists was recently underscored (9). 
Results are awaited for ongoing trials on CCR1 binders like CCX354 (structure undisclosed) 
which is in development for RA.  The company’s website mentions that preliminary Phase II 
results so far have indicated that CCX354 is well tolerated and safe in subjects with RA on 
stable doses of MTX, and even demonstrates promising clinical and biological activity at a 
once-daily dose of 200 mg (39). Phase I results with CCX354 and involved implications for 
dose selection have also been disclosed (40).
2.5: CCR2
An early CCR2 antagonist like MK0812 had shown lack of efficacy in RA (7). Nonetheless, 
in 2010, many CCR2-binders were reported as being in trials (several of which in Phase II) 
for a diverse set of therapeutic areas, including pain, allergic rhinitis, liver disease, insulin 
resistance and MS (multiple sclerosis) (8). All this portrays CCR2 as somewhat of a ‘jack-of-
all-trades’, and the ongoing activities and current potential of this field are further illustrated 
by many recent interesting disclosures.
For example, CCR2 antagonist CCX140 (undisclosed structure) has now completed a Phase II 
trial en route to its development as an orally delivered therapy for the treatment of diabetic 
nephropathy (41). Subjects with type 2 diabetes mellitus were treated with 5 or 10 mg CCX140 
(once daily), providing a dose-dependent decrease in fasting plasma glucose. Furthermore, 
JNJ-17166864 (structure could not be retrieved), reported in 2010 as being in Phase II trial 
for allergic rhinitis (8), has also been tested topically for its effect on alveolar bone loss in 
Figure 2: Selected antagonists for chemokine CXCR receptors. Given structures and affinities can be found in the 
references provided in the text
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a mouse model of periodontitis, where it appeared to have beneficial effects (42). This may 
suggest use of CCR2 antagonists in periodontal diseases.
Several structures of advanced CCR2 clinical candidates have recently been disclosed. 
INCB3284 [8](43) has been known to be in a Phase II trial for MS (8). This ligand was 
obtained after optimization of an earlier lead (INCB3344) which bore value as a tool but was 
not suitable for clinical tests owing to hERG channel (human Ether-à-go-go-Related Gene) 
and CYP3A4 inhibition (43). Optimization of INCB3344 to INCB3284 involved most notably 
replacing a phenyl ring by a heteroaromatic ring to reduce hydrophobicity (Log P). Reversal 
of the aminopyrrolidine connectivity and further finetuning of the heteroaromatic part gave 
another clinical candidate: PF-4136309 (9, a.k.a. INCB8761) (44). This compound has been in 
Phase II trial for e.g. osteoarthritic pain of the knee, and the results are being awaited (45). 
Several more structures have been disclosed that, according to the wording in the articles, 
seem to have been nominated for clinical development, although any specific clinical status 
could not be retrieved. Interestingly, this includes three compounds 10-12 which all have a 
cyclopentane core with an amide, amine and isopropyl substituent. These features are also 
present in the ‘early’ CCR2 compound MK0812. Compound 10 (46) was based on previous 
series reported by Merck but the noteworthy phenyl-carboxylic acid unit was key to the design 
strategy in that it reduced off-target effects on the hERG channel. Further SAR optimization 
led to 10, which displayed potent in vivo efficacy in a rhesus whole blood shape change assay 
(46).
It is evident that 11 (INCB10820/PF-4178903) (47) and 12 (PF-4254196) (48) stem from 
similar chemical series. Indeed, their evolution started with an inspection of spacer length 
between the cyclopentylcarboxamide and the CF
3
-containing aryl-moiety in existing series of 
CCR2-binders (47). The chosen design involved insertion of e.g. a piperidine or a piperazine 
(as in 11). Subsequent SAR optimization of several remaining structural elements delivered 
11, which is a potent and orally bioavailable CCR2 antagonist. A concurrent paper (48) 
describes how the still significant hERG inhibition by 11 (IC
50
=1.7 μM) was reason to optimize 
the compound further. The left- and (most successfully) right-hand sides of the molecule 
were probed, resulting in compound 12 which possessed a pyrazidine (instead of a pyridine). 
This compound displayed a significantly better CCR2/hERG index, with only a marginal 
reduction in CCR2 affinity. Of note is that compounds 10 and 11 are reported as dual CCR2/
CCR5 antagonists, as they possess high CCR5 affinity as well. For 11, this was put forward 
as a potential asset because CCR5 is also involved in a variety of autoimmune diseases (47), 
while for 10 it was stated to likely not be a treatment liability, since no immune deficits were 
observed in individuals with the CCR5-Δ32 deletion mutant. Moreover, 10 has lower affinity 
and faster dissociation kinetics for CCR5, both compared to CCR2 (46). For 12, no mention is 
made about CCR5 affinity in the paper (48).
In conclusion, the CCR2 field is quite dynamic and much new information, and hopefully 
insights, can be expected from it in the next few years.
2.6: CCR5
It is fair to state that CCR5 has received most attention in chemokine receptor antagonist 
research. CCR5 is a key factor for the HIV-1 virus to enter host cells and it is therefore not 
surprising that virtually all CCR5 ligands reported as being in trials in 2010 were targeting 
HIV infection (8, 49). Indeed, the first ever approved chemokine receptor drug, the tropane-
derivative maraviroc [1], is a CCR5 inhibitor from Pfizer used for treating HIV-1 infection (3, 5), 
thereby delivering a solid therapeutic proof-of-concept for CCR5 targeting. Maraviroc displays 
prolonged receptor occupancy (t1/2 > 5 days), and it is proposed that this leads to sustained 
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reduction in viral load as a result of constant gp120-CCR5 inhibition (50, 51). Medicinal 
chemistry on CCR5 has recently been reviewed (52). 
Pfizer researchers have published follow-up tropane-like compounds, which were designed 
for an improved oral-absorption/hERG index as well as for activity against Maraviroc-resistant 
strains (53). With the tropane core intact, detailed SAR studies were undertaken while keeping 
an eye for achieving alternative interaction points with CCR5 as a means to battle resistance. 
Notably, an imidazopiperidine on the ‘right-hand’ side proved attractive to reduce hERG 
affinity. This is exemplified by 13 (PF-232798) (53), which displayed a favorable preclinical 
profile, enhanced antiviral activity compared to Maraviroc and activity against a maraviroc-
resistant HIV isolate. Ligand 13 is currently in Phase II trials (53). GSK researchers also aimed 
to improve the hERG profile of their tropane-like CCR5 leads. In their efforts, a secondary 
sulfonamide on the ‘left-hand’ side proved key to success, leading to GSK163929 [14] (54). 
Promising preclinical data prompted 14 to be nominated as a clinical compound (54). It is of 
interest to note that a key factor in success for both 13 and 14 was increasing the polarity, 
more particularly, introducing a polar group at the periphery, thereby arguably giving reduced 
‘fitting’ in the hERG pharmacophore.
Other chemotypes have also advanced into the clinic. Based on 15 (Vicriviroc), a CCR5 
antagonist that has reached Phase III trials for treatment of HIV-1 infection (8), researchers 
Figure 3: Selected antagonists for CCR-class chemokine receptors. Given structures and affinities can be found in the 
references provided in the text.
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from Incyte applied a rigidification strategy to the benzyl moiety on the left-hand side of the 
molecule. This plan was successful and, after a key introduction of an O-ethyl group, delivered 
16 (INCB009471) (55). This compound showed promising preclinical properties and advanced 
into Phase I and II studies, where it was found to be safe and efficacious in reduction of 
viral load (55). A recent account highlights a detailed pharmacological characterization of 
16, indicating (reminiscent of maraviroc) a slow dissociation rate (t1/2 > 24 h) from CCR5 
receptors (56). However, it was also suggested that 16 might have a different binding mode 
than maraviroc. The latter notion can potentially have therapeutic benefits in combating drug 
resistance (56).
The section on CCR2 antagonists already outlined that dual CCR2/CCR5 antagonists 
are regularly encountered (e.g. 10 and 11). TBR-652 [17] (49), also known as TAK-652 or 
Cenicriviroc (57), is another such example. Two recent publications reveal promising clinical 
pharmacokinetic properties of 17 as well as significant reductions in HIV-1 RNA levels in HIV-
infected subjects treated with 17 (58, 59). While it appears that 17 was developed as a CCR5 
ligand, significant CCR2 affinity was observed (59). It has been suggested that there might be 
a potential clinical benefit through such CCR2 co-inhibition (anti-inflammatory effect) (59). 
Patients are currently being recruited for Phase IIb studies with 17 (60, 61). Last, it has been 
speculated by others (62) that BMS-813160, a compound that has completed Phase I trials, 
(63) may also be a CCR2/CCR5 dual antagonist. 
Blockage of CCR5 has also been pursued for disease areas other than HIV-1 infection. 
Compound 18 (AZD5672) (64), for example, was developed to treat RA. Its design was based on 
an earlier lead with a methylsulphonyl-phenyl moiety being replaced by an N-methylsulphonyl-
piperidine unit to improve its cardiac safety profile. This resulted in compound 18, retaining 
excellent potency while reducing hERG inhibition compared to the lead (64). The compound 
entered the clinic for RA, but it was announced that it was discontinued from clinical 
development due to lack of efficacy, despite high levels of receptor occupancy in vivo (64, 
65). A recent disclosure outlines these results in more detail: in a Phase IIb study with 371 
RA patients receiving MTX, compound 18 was well tolerated but no statistically significant 
difference between the outcome for treated and placebo subjects was observed (66). It has 
also been shown that 18 is a P-glycoprotein inhibitor in vivo (67).
In all, while HIV treatment is clearly the main goal of current CCR5 efforts and has already 
been addressed by several chemotypes, blockage of CCR5 for other disease areas shows less 
promising results so far.
2.7: CCR9
The CCR9 field involves one of the currently most advanced clinical candidates in the whole 
chemokine receptor antagonist field: CCX282-B (Traficet-EN, structure undisclosed) (68), 
in development for treating Crohn’s disease. A detailed pharmacological characterization 
has recently been published, showing single-digit nanomolar in vitro CCR9 potencies of the 
compound in binding and functional assays (68). The compound displayed clinical efficacy 
in trials with patients having moderate-to-severe Crohn’s disease (69). As of early 2011, 
patients are being recruited for several Phase III trials (the compound name has changed to 
GSK1605786A (70)) (71-73). 
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2.8: Concluding remarks
This concise review has highlighted recent illustrative developments in the pursuit of clinically 
active chemokine receptor antagonists. The majority of recent efforts appears to take place 
on CCR receptors, most notably CCR1, CCR2, CCR5 and CCR9. Also CXCR receptors such as 
CXCR2 and CXCR4 have been subject to clinical endeavors in the last years. It is emphasised 
however that, given the setup of this review, we do not wish to imply that the discussed 
receptors are the only ones targeted in current research.
The chemotypes of ligands are diverse and most likely also the allosteric binding modes, 
as illustrated by intracellular binding of some CXCR2 antagonists and varying binding sites 
amongst e.g. CCR5 antagonists. Cross-receptor binding, which may sometimes be challenging 
to overcome given receptor homologies, can be an opportunity as well (e.g. CCR2/CCR5 dual 
targeting). The diseases targeted in all described efforts are quite diverse and include MS, 
HIV, COPD, Crohn’s disease and RA, albeit with varying degrees of success: recent trial results 
include both encouraging and disappointing features. Nonetheless, inspired by the approvals 
of maraviroc and AMD3100 and by ongoing trials as well as new candidates entering the 
pipeline, the stage is set for new therapeutic insights in this large family of inflammatory 
receptors.
Figure 2.4: Selected antagonists for chemokine CCR5 receptor. Given structures and affinities can be found in the 
references provided in the text.
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CHAPTER 3
Non-competitive antagonism and inverse ago-
nism as mechanism of action of non-peptidergic 
antagonists at primate and rodent CXCR3 
chemokine receptors
Adapted from 
D Verzijl, DJ Scholten, et al. J. Pharmacol. Exp. Ther. 2008. 325(2): 544-555
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3: Abstract
The chemokine receptor CXCR3 is involved in various inflammatory diseases, such as 
rheumatoid arthritis, multiple sclerosis, psoriasis and allograft rejection in transplantation 
patients. The CXCR3 ligands CXCL9, CXCL10 and CXCL11 are expressed at sites of inflammation 
and attract CXCR3-bearing lymphocytes, thus contributing to the inflammatory process. 
Here, we characterize 5 non-peptidergic compounds of different chemical classes that block 
the action of CXCL10 and CXCL11 at the human CXCR3, i.e. the 3H-pyrido[2,3-d]pyrimidin-
4-one derivatives VUF10472/NBI-74330 and VUF10085/AMG-487, the 3H-quinazolin-4-one 
VUF5834, the imidazolium compound VUF10132 and the quaternary ammonium anilide 
TAK-779. In order to understand the action of these CXCR3 antagonists in various animal 
models of disease, the compounds were also tested at rat and mouse CXCR3, as well as at 
CXCR3 from rhesus macaque, cloned and characterized for the first time in this study. Except 
for TAK-779, all compounds show slightly lower affinity for rodent CXCR3 than for primate 
CXCR3. Additionally, we have characterized the molecular mechanism of action of the various 
antagonists at the human CXCR3 receptor. All tested compounds act as noncompetitive 
antagonists at CXCR3. Moreover, this non-competitive behavior is accompanied by inverse 
agonistic properties of all 5 compounds as determined on an identified constitutively active 
mutant of CXCR3, CXCR3 N3.35A. Interestingly, all compounds except TAK-779 act as full 
inverse agonists at CXCR3 N3.35A. TAK-779 shows weak partial inverse agonism at CXCR3 
N3.35A, and likely has a different mode of interaction with CXCR3 than the other two classes 
of small molecule inverse agonists.
3.1: Introduction
Chemokines are secreted peptides that are important mediators in inflammation. They are 
classified into four families based on the number and position of conserved N-terminal 
cysteine residues, i.e. CC, CXC, CX
3
C and XC chemokines (2). Chemokines bind to a subset 
of G protein-coupled receptors (GPCRs) of class A, which are named based on their specific 
chemokine preferences (2). The chemokine receptor CXCR3 is mainly expressed on activated 
Th1 cells, but also on B cells and natural killer cells (3). CXCR3 is activated by the interferon-
gamma-inducible chemokines CXCL9, CXCL10 and CXCL11, with CXCL11 having the highest 
affinity (4, 5). Upon activation, CXCR3 activates pertussis toxin-sensitive G proteins of the Gα
i
 
class and mediates e.g. chemotaxis, calcium flux and activation of kinases such as p44/p42 
MAPK and Akt  (6). 
CXCR3 and its ligands are upregulated in a wide variety of inflammatory diseases, implying 
a role for CXCR3 in e.g. rheumatoid arthritis (3), multiple sclerosis (7), transplant rejection 
(8), atherosclerosis (9) and inflammatory skin diseases (10). The role of CXCR3 in cancer is 
two-fold: on one hand CXCR3 may be involved in the metastasis of CXCR3-expressing cancer 
cells (11), while on the other hand expression of CXCL10 (12) or CXCL11 (13) at tumor sites 
may attract CXCR3-expressing immune cells, that help control tumor growth and metastasis. 
Several animal models have been developed for CXCR3, among which a murine model of 
metastatic breast cancer (11), a murine model of renal cell carcinoma (RENCA) (14) and an 
arthritis model in Lewis rats (15). In a mouse rheumatoid arthritis model TAK-779, a small 
molecule antagonist with affinity for CCR5, CCR2b and CXCR3, inhibits the development of 
arthritis by downregulating T cell migration, indicating that targeting chemokine receptors in 
models of inflammation is feasible and effective (16-18). 
Several classes of small molecule compounds targeting CXCR3 have recently been described, 
including 4-N-aryl-[1,4]diazepane ureas (19), 1-aryl-3-piperidin-4-yl-urea derivatives (20), 
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quinazolin-4-one and 3H-pyrido[2,3-d]pyrimidin-4-one derivatives (21-24) and the above 
mentioned quaternary ammonium anilide TAK-779 (17). So far, no detailed information is 
available on the molecular mechanism of action of these small molecule antagonists at the 
CXCR3 receptor, despite the general notion that small molecule ligands most likely will not 
have overlapping binding sites with the chemokines, which are supposed to bind mainly to the 
N-terminus and extracellular receptor loops (2). Moreover, although most compounds have 
been tested on human CXCR3 using in vitro assays, little or no information on their affinity 
for CXCR3 of other species is available. Especially in view of rodent models of inflammatory 
diseases it is important to know the relative affinities of the compounds for the receptors of 
different species. 
Here, we report on the molecular characterization of the 3H-pyrido[2,3-d]pyrimidin-4-
one derivatives VUF10472 (NBI-74330) (22, 23) and VUF10085 (AMG-487) (22, 24), the 
3H-quinazolin-4-one VUF5834 (21, 24) the imidazolium compound VUF10132 (25) and the 
quaternary ammonium anilide TAK-779 (16) at CXCR3 of human (4), rat (26) and mouse 
(27). Additionally, CXCR3 from rhesus macaque was cloned, characterized and subjected to 
a detailed pharmacological analysis using the non-peptidergic compounds. Moreover, we 
constructed and characterized a constitutively active mutant (CAM) of CXCR3, which was 
used to further determine the inverse agonistic properties of the small molecule compounds.
Figure 1: Structures of small non-peptidergic compounds targeting CXCR3. The structures of VUF10472 (NBI-
74330; N-1R-[3-(4-ethoxy-phenyl)-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-2-yl]-ethyl-N-pyridin-3-ylmethyl-2-(4-
fluoro-3-trifluoromethyl-phenyl)-acetamide), VUF10085 (AMG-487; N-1R-[3-(4-ethoxy-phenyl)-4-oxo-3,4-dihydro-
pyrido[2,3-d]pyrimidin-2-yl]-ethyl-N-pyridin-3-ylmethyl-2-(4-trifluoromethoxy-phenyl)-acetamide), VUF5834 
(decanoic acid {1-[3-(4-cyano-phenyl)-4-oxo-3,4-dihydro-quinazolin-2-yl]-ethyl}-(2-dimethylamino-ethyl)-amide), 
VUF10132 (1,3-Bis-[2-(3,4-dichloro-phenyl)-2-oxo-ethyl]-3H-imidazol-1-ium bromide) and TAK-779 (N,N-dimethyl-
N-[4-[[[2-(4-methylphenyl)-6,7-dihydro-5H-benzocyclohepten-8-yl]carbonyl]amino]benzyl] tetrahydro-2H-pyran-
4-aminium chloride) are shown.
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3.2: Results
3.2.1: Non-peptidergic CXCR3 antagonists
A selection of CXCR3-targeting small molecule antagonists from two different structural 
classes was synthesized as previously described and subjected to detailed pharmacological 
analysis, including the quinazolinone-derived 3H-pyrido[2,3-d]pyrimidin-4-one compounds 
VUF10472 (NBI-74330) (22, 23) and VUF10085 (AMG 487) (22, 24), the 3H-quinazolin-4-one 
VUF5834 (21, 24), and the imidazolium compound VUF10132 (25) (Fig. 1). The well described 
CCR5 antagonist TAK-779 (16) has been reported to show affinity for mouse CXCR3 (17) and 
was therefore included in our set of small molecule compounds as well (Fig. 1). 
3.2.2: Characterization of human CXCR3
Binding studies were performed with radiolabeled CXCL10 and CXCL11 on membranes 
prepared from HEK293T cells transiently transfected with cDNA encoding human CXCR3 
(4). Homologous displacement of the radioligands with unlabeled chemokines resulted in 
pK
d
 values ± SEM of 9.8 ± 0.1 for CXCL10 and 10.6 ± 0.1 for CXCL11 (Fig. 2A, Table 1), in 
accordance with the values and rank-order for these chemokines reported in literature (5, 23). 
In HEK293 cells human CXCR3 does not couple efficiently to the phospholipase C (PLC)-
inositolphosphates (InsP) pathway (26). Therefore, CXCR3 was transiently co-transfected 
with cDNA encoding the chimeric G protein Gα
qi5
 (28), after which robust PLC activation could 
be observed upon stimulation with CXCL10 and CXCL11. Using this functional assay, pEC
50 
values of 7.5 ± 0.1 and 8.5 ± 0.1 were obtained for respectively CXCL10 and CXCL11 (Fig. 2B, 
Table 1). CXCL10 acted as a partial agonist, with an intrinsic activity (α) of 0.48 ± 0.8 compared 
to the full agonist CXCL11 (Fig. 2B, n=5).
Figure 2: Characterization of human CXCR3. A. Homologous displacement binding at human CXCR3. Binding experi-
ments were performed with approximately 50 pM 125I-CXCL10 (open circles…) or 125I-CXCL11 (…filled circles…) and increas-
ing concentrations of homologous unlabeled chemokine on membranes from HEK293T cells transfected with cDNA 
encoding human CXCR3. Data are presented as percentage of total binding. pK
d
 values for CXCL10 and CXCL11 were 
9.8 ± 0.1 (n=11) and 10.6 ± 0.1 (n=7) respectively. B. Activation of PLC by human CXCR3. HEK293T cells were trans-
fected with cDNA encoding human CXCR3 and G…α
qi5
. After 48 h, 3H-InsP accumulation was determined in the presence 
of increasing concentrations of CXCL10 (…open circles) or CXCL11 (…filled circles). Data are presented as percentage of 
the maximal response obtained with CXCL11 (100 nM). pEC
50
 values for CXCL10 and CXCL11 were 7.5 ± 0.1 (n=8) and 
8.5 ± 0.1 (n=12) respectively.
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3.2.3: Characterization of rhesus macaque, rat and mouse CXCR3
Since the affinities of small molecule compounds targeting chemokine receptors may 
differ among species, e.g. for TAK-779 at human and mouse CCR5 (16, 17) and significant 
differences between the amino acid sequences of human and rodent CXCR3 are apparent (Fig. 
3), we set out to characterize CXCR3 of rhesus macaque, mouse and rat. CXCR3 of mouse 
(27) and rat (26) have previously been cloned and described. Here, we report the cloning 
and characterization of rhesus macaque CXCR3 from PBMCs (GenBank accession number 
EU313340, see experimental procedures). The deduced amino acid sequence of rhesus 
macaque CXCR3 was found to be 99% identical to human CXCR3. The Thr83 residue in the 
first intracellular loop of human CXCR3 is Ala83 in rhesus macaque CXCR3, and Val259 at 
position 6.391 in TM6 of human CXCR3 is  Ala259 in rhesus macaque CXCR3 (Fig. 3).
After expression in HEK293T cells, CXCR3 from rhesus, rat and mouse showed similar binding 
affinities for human CXCL10 and CXCL11 as human CXCR3 (Table 1). B
max
 values of rodent 
CXCR3 were increased compared to human CXCR3, approximately 2-fold higher for CXCL10 
and 3 to 4-fold higher for CXCL11 (Table 1) when equal amounts of cDNA were transfected. 
The B
max
 for CXCL10 at rhesus CXCR3 was 2-fold lower than for human CXCR3, whereas 
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Figure 3: Snakeplot of CXCR3. Amino acids that were mutated in order to generate constitutively active mutants 
(T2.56, N3.35 and D3.49) are indicated as bold circled residues. Amino acids that differ between human and rhesus 
macaque CXCR3 (T83 in intracellular loop 1 and V6.39 are both Ala in rhesus macaque CXCR3) are shown as grey cir-
cles. Residues which are different between primate and rodent (i.e. rat and/or mouse) CXCR3 are indicated as black 
circles. Human and rhesus macaque CXCR3 have an additional Cys (C37) in their amino-terminus compared to rat and 
mouse CXCR3. Helix 8 at the membrane proximal part of the carboxy-terminus and potential palmitoylation of Cys338 
are shown as well.
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human and rhesus CXCR3 had comparable B
max
 values for CXCL11 (Table 1). Rhesus CXCR3 
stimulated PLC with similar maximum effect (E
max
) and similar EC
50
 values for human CXCL10 
and CXCL11 as human CXCR3 (Fig. 4A and 4B, Table 1). In contrast, the rodent CXCR3 species 
had approximately 10-fold higher potencies and showed increased E
max
 for human CXCL10 
compared to human CXCR3 (Fig. 4A and 4B, Table 1). The E
max
 for human CXCL11 at rat CXCR3 
was also increased compared to the effect of CXCL11 at CXCR3 of the other species (Fig. 4B).
3.2.4: Behavior of non-peptidergic compounds at CXCR3
The panel of small molecule antagonists inhibited [125I]-CXCL10 binding to human CXCR3 
with K
i
 values ranging between 4 nM for VUF10472 and 1.3 μM for TAK-779 (Fig. 5A and Table 
2). VUF10085, VUF5834 and VUF10132 showed intermediate K
i
 values of 20 nM, 158 nM and 
251 nM respectively (Fig. 5A and Table 2). Subsequently, the ability of the small molecules 
to inhibit CXCL10-induced PLC activation through human CXCR3 was determined. All 
compounds reduced CXCL10-mediated (10-50 nM) PLC activation with K
b
 values ranging from 
6 nM for VUF10472 to 800 nM for TAK-779 (Fig. 5B, Table 2). A good correlation (r2 = 0.997) 
was observed between the measured pK
i
 values and pK
b
 values determined against CXCL10 
(Fig. 5C). For the most potent compound, VUF10472, inhibition of CXCL11-induced (5 nM) 
PLC activation was also determined, resulting in a K
b
 value of 12.6 nM (Fig. 5D). This value 
corresponds well to the value obtained against CXCL10 (Fig. 5D and Table 2). Finally, the ability 
of the small molecule compounds to inhibit chemotaxis was investigated. The murine pre-B 
cell line L1.2 was transiently transfected with cDNA encoding human CXCR3 and migration of 
cells towards CXCL10 in the presence or absence of VUF10085 and VUF5834 was determined. 
CXCR3-transfected L1.2 cells did not migrate in the absence of CXCL10, whereas 10.3 ± 0.8 
% (n=3) of the cells migrated to CXCL10 (10 nM) in the absence of inhibitors (Fig. 5E, inset). 
Both compounds completely inhibited CXCL10-induced (10 nM) migration at a concentration 
of 10 μM, with pIC
50
 values of 6.8 ± 0.2 (n=2) and 5.8 ± 0.1 (n=3) for VUF10085 and VUF5834 
respectively (Fig. 5E). 
Next, the affinity of the small molecule compounds for CXCR3 of the different species was 
determined using [125I]-CXCL10. The pK
i
 values of the compounds tested at rhesus CXCR3 
were identical to the values found for human CXCR3 (Table 2). Similarly, the affinities of the 
compounds tested at rat and mouse CXCR3 were identical to each other. However, VUF10472, 
VUF10085, VUF5834 and VUF10132 showed an approximately 4-fold lower affinity for the 
rodent CXCR3 (mouse and rat) compared to the primate CXCR3 (human and rhesus). Only for 
TAK-779 no difference in affinity between CXCR3 from the different species was observed.
human CXCL10 human CXCL11
species pK
d
n Bmax n pEC50 n pKd n Bmax n pEC50 n
human 9.8 ± 0.1 11 358 ± 53 6 7.5 ± 0.1 8 10.6 ± 0.1 7 407 ± 126 4 8.5 ± 0.1 12
N3.35A 10.2 ± 0.2 4 327 ± 91 4 7.5 ± 0.0 2 11.3 ± 0.3 3 564 ± 242 3 8.7 ± 0.1 4
rhesus 10.0 ± 0.1 3 163 ± 7 2 7.4 ± 0.1 3 10.8 ± 0.3 3 255 ± 114 4 8.5 ± 0.1 3
rat 10.2 ± 0.2 7 631 ±141 7 8.8 ± 0.1 3 10.7 ± 0.2 4 1170 ± 644 3 9.5 ± 0.1 3
mouse 10.1 ± 0.1 3 658 ± 127 3 8.3 ± 0.1 5 10.7 ± 0.3 4 1882 ± 858 4 9.2 ± 0.2 3
Table 1: Properties of chemokine ligands at CXCR3. Shown are pK
d
 values and B
max
 values ± SEM for human CXCL10 
and human CXCL11 at the various CXCR3, calculated from homologous radioligand binding experiments. pEC
50
 values 
± SEM were obtained using the PLC activation assay.
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Since the non-peptidergic compounds showed slightly lower affinity for rodent CXCR3 and 
the previous experiments were performed with human chemokines, we also determined the 
ability of the antagonists to inhibit mouse CXCL10-induced signaling at mouse CXCR3. The 
pEC
50
 of mouse CXCL10 at mouse CXCR3 (8.4 ± 0.1, n=3) was comparable with the pEC
50
 of 
human CXCL10 at mouse CXCR3 (8.3 ± 0.1, n=5). The different antagonists inhibited mouse 
CXCL10-induced activation of mouse CXCR3 (measured as PLC stimulation) with K
b
 values 
ranging from 4 nM for VUF10472 to 400 nM for TAK-779. The Kb values obtained under these 
conditions are within two-fold of the K
b
 values for inhibition of human CXCL10 at human 
CXCR3 (Fig. 5F, Table 2).
In order to determine whether the antagonists show competitive or non-competitive behavior, 
a Schild analysis was performed. HEK293T cells expressing human CXCR3 and Gα
qi5
 were 
incubated with increasing concentrations of CXCL10 (Fig. 6A) or CXCL11 (Fig. 6B) in the 
absence or presence of different concentrations of VUF10472. A decreased maximal effect 
combined with a rightward shift of the curves was observed in the presence of VUF10472, 
indicating non-competitive antagonist behavior. The mechanism of antagonism of the other 
classes of small molecule compounds was investigated using only CXCL11.  VUF10132 (Fig. 
6C) and TAK-779 (Fig. 6D) all clearly showed non-competitive antagonistic behavior similar to 
that of VUF10472.
3.2.5: Specificity of the non-peptidergic CXCR3 antagonists
The CXCR3 antagonists were tested against a small panel of chemokine and histamine 
receptors to determine their specificity. HEK293T cells expressing the different GPCRs were 
incubated with their respective agonists in the presence or absence of CXCR3 antagonists 
and activation of PLC was determined. The percentage inhibition of agonist-induced PLC 
activation by the CXCR3 antagonists is shown in Table 3. As expected, the CXCR3 antagonists 
(10 μM) showed 50-100 % inhibition of CXCL11-induced (100 nM) PLC activation through 
CXCR3 and the CCR5/CCR2/CXCR3 antagonist TAK-779 inhibited CCL2-induced activation of 
CCR2 with 95%. Unexpectedly, VUF10132 inhibited CCL5-induced CCR1 activation with 61%, 
compared to 71% inhibition of CXCR3-mediated response. The other CXCR3 antagonists did 
not significantly inhibit the tested chemokine or histamine receptors (Table 3). Additionally, 
the compounds were tested in radioligand binding studies on membranes expressing 
CXCR2, CXCR4 or the histamine H
1
 receptor. At the tested concentration (10 μM), the CXCR3 
antagonists typically inhibit [125I]-CXCL10 binding to CXCR3 with 80-100% (Fig. 5A). Besides 
TAK-779, which inhibited binding of [3H]-mepyramine to the histamine H
1
 receptor with only 
pKi pKb pIC50
human n N3.35A n rhesus n rat n mouse n
hCXCR3 
hCXCL10 n
mCXCR3 
mCXCL10 n
hCXCR3 
N3.35A n
VUF10472 8.4 ± 0.1 7 7.9 ± 0.2 3 8.4 ± 0.1 3 7.8 ± 0.0 3 7.9 ± 0.1 3 8.2 ± 0.1 5 8.4 ± 0.1 4 8.1 ± 0.1 3
VUF10085 7.7 ± 0.0 18 7.3 ± 0.1 3 7.5 ± 0.0 3 6.9 ± 0.1 10 7.0 ± 0.1 3 7.7 ± 0.1 9 7.7 ± 0.1 4 8.0 ± 0.1 3
VUF5834 6.8 ± 0.1 3 6.4 ± 0.0 3 6.8 ± 0.0 3 6.2 ± 0.1 6 6.2 ± 0.1 3 7.0 ± 0.1 5 7.4 ± 0.2 3 7.3 ± 0.0 3
VUF10132 6.6 ± 0.0 4 5.9 ± 0.1 3 6.6 ± 0.1 3 6.0 ± 0.1 6 6.0 ± 0.1 3 6.7 ± 0.1 5 6.6 ± 0.1 4 6.6 ± 0.1 3
TAK-779 5.9 ± 0.0 6 5.9 ± 0.0 3 5.9 ± 0.1 3 5.8 ± 0.0 6 5.9 ± 0.0 3 6.1 ± 0.1 4 6.4 ± 0.1 4 5.9 ± 0.1 3
Table 2: Properties of small non-peptidergic compounds at CXCR3. pK
i
 values ± SEM were generated in heterologous 
radioligand binding experiments using human 125I-CXCL10. pK
b
 values were obtained at human CXCR3 with human 
CXCL10 and at mouse CXCR3 with mouse CXCL10 in the PLC activation assay and pIC
50
 values were generated using 
human CXCR3 N3.35A in the PLC activation assay.
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41% at 10 μM, no significant inhibition of radioligand binding to CXCR2, CXCR4 or the H
1 
receptor by the other CXCR3 antagonists was observed.
3.2.6: Non-peptidergic antagonists are inverse agonists at a constitutively active mutant of 
CXCR3
Inverse agonism has recently been shown to be an important molecular mechanism of action 
of small molecule antagonists at a variety of GPCR family members (29). Human chemokine 
receptors generally do not show high levels of constitutive activity. However, constitutively 
active chemokine receptor mutants have been described that signal in the absence of 
ligands. Examples are CXCR2 D3.49V (30), mutation of N3.35 of CXCR4 (31) and mutation of 
T2.56 in CCR2 and CCR5 (32). To determine if the studied CXCR3 antagonists act as neutral 
antagonists or inverse agonists at CXCR3, analogous CAMs of CXCR3 were constructed (Fig. 
3). Upon expression of the CXCR3 mutants N3.35A, N3.35S and T2.56P significant constitutive 
activity was shown, whereas no constitutive activity was found for the CXCR3 D3.49V mutant 
(data not shown). In view of the signal to noise ratio we choose CXCR3 N3.35A for further 
characterization. Upon transfection of HEK293T cells with increasing amounts of cDNA 
encoding CXCR3 WT or CXCR3 N3.35A an increase in receptor expression was detected in 
ELISA experiments (Fig. 7A). When similar amounts of cDNA were transfected, CXCR3 WT 
was expressed at higher levels than CXCR3 N3.35A (Fig. 7A). As expected, CXCR3 WT did not 
activate PLC in the absence of ligands (Fig. 7B). Even though CXCR3 N3.35A was expressed at 
lower levels than CXCR3 WT, CXCR3 N3.35A showed a marked increase of PLC activation upon 
transfection of increasing amounts of cDNA (Fig. 7B). 
The affinities of CXCL10 (pK
d
 = 10.2 ± 0.2) and CXCL11 (pK
d
 = 11.3 ± 0.3) for CXCR3 N3.35A 
were slightly higher than for CXCR3 WT (Table 1). CXCL10 and CXCL11 activated CXCR3 
N3.35A over basal levels in a similar manner as CXCR3 WT, with pEC
50
 values of 7.5 ± 0.0 
(n=2) and 8.7 ± 0.1 (n=4) respectively (Fig. 7C, Table 1). Subsequently, the affinity of the small 
Figure 4: Activation of PLC by primate and rodent CXCR3. A. CXCL10-induced activation of PLC. HEK293T cells 
were transfected with cDNA encoding human, rhesus, rat or mouse CXCR3 and Gα
qi5
. After 48 h, 3H-InsP accumulation 
was determined in the presence of increasing concentrations human CXCL10. pEC
50
 values for CXCL10 were 7.5 ± 0.1 
(human CXCR3, n=8), 7.4 ± 0.1 (rhesus CXCR3, n=3), 8.8 ± 0.1 (rat CXCR3, n=3) and 8.3 ± 0.1 (mouse CXCR3, n=5). B. 
CXCL11-induced activation of PLC. HEK293T cells were transfected with cDNA encoding human, rhesus, rat or mouse 
CXCR3 and Gα …qi5. After 48 h, 
3H-InsP accumulation was determined in the presence of increasing concentrations hu-
man CXCL11. pEC
50
 values for CXCL11 were 8.5 ± 0.1 (human CXCR3, n=12), 8.5 ± 0.1 (rhesus CXCR3, n=3), 9.5 ± 0.1 
(rat CXCR3, n=3) and 9.2 ± 0.2 (mouse CXCR3, n=3). Data are presented per receptor as percentage of 3H-InsP accumu-
lation in the absence of chemokine.
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Figure 5: Characterization of small non-peptidergic compounds at human CXCR3. A. Displacement of 125I-CX-
CL10. Binding experiments were performed with approximately 50 pM 125I-CXCL10 and increasing concentrations of 
VUF10472, VUF10085, VUF5834, VUF10132 or TAK-779 on membranes from HEK293T cells transfected with cDNA 
encoding human CXCR3. Data are presented as percentage of total binding. pK
i
 values were 8.4 ± 0.1 (VUF10472, n=7), 
7.7 ± 0.0 (VUF10085, n=18), 6.8 ± 0.1 (VUF5834, n=3), 6.6 ± 0.0 (VUF10132, n=4) and 5.9 ± 0.0 (n=6). B. Inhibition of 
CXCL10-induced PLC activation. HEK293T cells were transfected with cDNA encoding human CXCR3 and G…α
qi5
. After 
48 h, CXCL10-induced (10-50 nM) 3H- InsP accumulation was determined in the presence of increasing concentra-
tions of VUF10472, VUF10085, VUF5834, VUF10132 or TAK-779. pK
b
 values were 8.2 ± 0.1 (VUF10472, n=5), 7.7 ± 0.1 
(VUF10085, n=9), 7.0 ± 0.1 (VUF5834, n=5), 6.7 ± 0.1 (VUF10132, n=5) and 6.1 ± 0.1 (TAK-779, n=4). C. Relationship 
between pKi and pKb of small molecule compounds. pK
b
 values obtained using CXCL10 were plotted against pK
i
 values 
obtained against 125I-CXCL10 (r2 = 0.997). D. Inhibition of CXCL11-induced PLC activation by VUF10472. HEK293T 
cells were transfected with cDNA encoding human CXCR3 and G…α
qi5
. After 48 h, CXCL11-induced (5 nM) 3H-InsP ac-
cumulation was determined in the presence of increasing concentrations of VUF10472. The pK
b
 value of VUF10472 
was 7.9 ± 0.0 (n=3). For comparison, inhibition of CXCL10-induced (50 nM) PLC activation by VUF10472 is shown as 
well. Data are represented as percentage stimulation in the absence of antagonist. pK
b
 values were calculated using 
the Cheng-Prusoff equation (1). E. Inhibition of CXCL10-induced chemotaxis. L1.2 cells were transfected with cDNA 
encoding human CXCR3. After 24 h, inhibition of CXCL10-induced (10 nM) chemotaxis was determined. pIC
50
 values 
were 6.8 ± 0.2 (VUF10085, n=2) and 5.8 ± 0.1 (VUF5834, n=3).  Data are presented as percentage of migrated cells in the 
absence of antagonist. Inset, CXCL10-induced chemotaxis of L1.2 cells. Data are presented as percentage of total L1.2 
cells that migrated to CXCL10 (10 nM) in the absence of antagonist (n=3).F. Inhibition of mouse CXCL10-induced PLC 
activation through mouse CXCR3. HEK293T cells were transfected with cDNA encoding mouse CXCR3 and Gα…
qi5
. After 
48 h, mouse CXCL10-induced (20 nM) 3H-InsP accumulation was determined in the presence of increasing concentra-
tions of VUF10472, VUF10085, VUF5834, VUF10132 or TAK-779. pK
b
 values were 8.4 ± 0.1 (VUF10472, n=4), 7.7 ± 0.1 
(VUF10085, n=4), 7.4 ± 0.2 (VUF5834, n=3), 6.6 ± 0.1 (VUF10132, n=4) and 6.4 ± 0.1 (TAK-779, n=4).
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molecule antagonists at CXCR3 N3.35A was determined using [125I]-CXCL10. The affinity of all 
compounds, except TAK-779, was slightly reduced for CXCR3 N3.35A compared to CXCR3 WT 
(Table 2). Finally, the effect of the small molecule antagonists on the constitutive activation of 
PLC was investigated. VUF10472, VUF10085, VUF5834 and VUF10132 all acted as full inverse 
agonists, with IC
50
 values ranging between 8 nM for VUF10472 and 251 nM for VUF10132 (Fig. 
7D, Table 2). In contrast, TAK-779 acted as a partial inverse agonist with an intrinsic activity of 
-0.42 ± 0.0 and an IC
50
 of 1.3 μM (n=3) (Fig. 7D, Table 2). 
3.3: Discussion
CXCR3 has attracted considerable attention as a new drug target due to its involvement in a 
variety of serious disorders, including cancer (11), atherosclerosis (9), inflammatory disorders 
like rheumatoid arthritis (3), skin diseases (10) and transplant rejection (8). Following the 
recognition of CXCR3 as a potential attractive drug target, several small molecule CXCR3 
antagonists have recently been identified (17, 19-24). In this study, we have selected five non-
peptidergic antagonists from four different structural classes and studied their mechanism 
of action at the human CXCR3. In addition, the interaction of these antagonists with human, 
rhesus macaque, rat and mouse CXCR3 was investigated. 
All tested non-peptidergic antagonists inhibited CXCL10-induced activation of PLC with pK
b 
Figure 6: Non-competitive behavior of non-peptidergic compounds at human CXCR3. A. Schild analysis of VUF10472 
using CXCL10 as agonist. HEK293T cells were transfected with cDNA encoding human CXCR3 and G…α
qi5
. After 48 h, 
CXCL10-induced 3H-InsP accumulation was determined in the absence (filled squares…) or in the presence of 10 nM 
(open squares…) or 30 nM (filled circles…) VUF10472 (n=2-3).B-D. Schild analysis using CXCL11 as agonist. HEK293T 
cells were transfected with cDNA encoding human CXCR3 and G…α
qi5
. After 48 h, CXCL11-induced 3H-InsP accumulation 
was determined in the absence (…filled squares) or in the presence of 30 nM (filled circles…), 100 nM (open circles…), 1 μM 
(filled triangles…), 10 μM (open triangles…) or 100 μM (filled diamonds…) VUF10472 (Fig. 6B, n=6), VUF10132 (Fig. 6C, n=6) 
or TAK-779 (Fig. 6D, n=7). Data are presented as percentage of chemokine-induced (1 μM) stimulation in the absence 
of small molecule compound.
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values that correlated very well with their affinity, with a rank order VUF10472 > VUF10085 
> VUF5834 > VUF10132 > TAK-779 (Table 2). Subsequently, the mechanism of action of the 
antagonists was explored using Schild analysis. The dose-response curves for CXCL10 and 
CXCL11 did not reach the maximal response in the presence of VUF10472 (Fig. 6), as has been 
previously shown by others for human and mouse CXCR3 (23, 33). Antagonists from other 
structural classes also decreased the maximum response of CXCL11, in a manner that follows 
the rank-order of their affinities. This indicates that all tested non-peptidergic antagonists 
behave as non-competitive antagonists for the PLC activation by the endogenous agonists of 
CXCR3.
Antagonists of GPCRs can be classified as neutral antagonists or (partial) inverse agonists 
(29, 34). Although both antagonist classes are able to block an agonist-induced response 
by occupying the receptor, there is an ongoing debate about the exact clinical benefits or 
disadvantages of each class (29). Treatment with inverse agonists may be beneficial when a 
constitutively active receptor underlies the pathogenesis. To date, there are no reports about 
constitutive activity of CXCR3 and there are only few examples of constitutive activity of 
chemokine receptors. Constitutive activity is a function of the relative stoichiometry of receptors 
and G proteins (34) and chemokine receptors, including CXCR3, are often upregulated under 
inflammatory conditions (2, 35). Hence, under pathophysiological conditions constitutive 
activity of chemokine receptors might become apparent and therefore the use of inverse 
agonists beneficial. In order to study the relative efficacy of the non-peptidergic antagonists, 
we generated mutants of CXCR3, i.e. CXCR3 N3.35A, N3.35S, D3.39V and T2.56P, based on 
CAMs of chemokine receptors reported in literature (30-32). All generated mutants, except for 
CXCR3 D3.49V with a mutation in the conserved DRY motif at the cytoplasmatic end of TM3, 
displayed basal signaling. Mutation of the DRY motif of CXCR2 to VRY confers constitutive 
activity to CXCR2 (30), while the same mutation for CXCR1 (30) or CCR5 (36) did not result in 
constitutive activity. Conversely, mutation of the VRY motif to DRY in the highly constitutively 
active chemokine receptor ORF74 encoded by Kaposi´s sarcoma-associated herpesvirus did 
not diminish its constitutive activity but even increased it (37). Therefore, mutation of D3.49 to 
Val does not appear to be a universal switch for constitutive activity in chemokine receptors. 
In the same way, mutation of T2.56 in the conserved TXP motif resulted in a CAM for CXCR3 
(this study), CCR5 and CCR2 but not for CCR1, CCR3, CCR4, CXCR2 and CXCR4 (32). Mutation 
Inhibition of agonist-induced PLC activation (%) Inhibition of specific binding (%)
CXCR3
CXCL11
CXCR1
CXCL8
CXCR2
CXCL1
CXCR4
CXCL12
CCR1
CCL5
CCR2
CCL2
H1R
his
H3R
his
CXCR2
125I-L8
CXCR4
125I-L12
H1R
3H-mep
VUF10472 103 ± 8 -19 ± 16 8 ± 1 -7 ± 5 -6 ± 7 11 ± 3 -12 ± 24 -14 ± 2 6 ± 15 17 ± 11 30 ± 13
VUF10085 100 ± 13 -7 ± 17 6 ± 2 1 ± 8 -3 ± 2 10 ± 4 -37 ± 11 -33 ± 14 -15 ± 3 18 ± 7 20 ± 10
VUF5834 67 ± 9 -7 ± 29 13 ± 3 -19 ± 5 -3 ± 13 -1 ± 4 11 ± 17 -35 ± 12 -13 ± 7 0 ± 7 28 ± 11
VUF10132 71 ± 6 -2 ± 10 -33 ± 5 24 ± 2 61 ± 4 -1 ± 11 0 ± 2 -3 ± 8 -21 ± 14 4 ± 12 30 ± 6
TAK-779 53 ± 4 -8 ± 25 -8 ± 4 -2 ± 16 -12 ± 4 95 ± 6 -10 ± 26 -3 ± 15 -12 ± 6 -9 ± 32 41 ± 7
Table 3: Selectivity of CXCR3 antagonists. HEK293T cells coexpressing indicated human GPCRs and Gα…qi5 were stimu-
lated with indicated chemokines (100 nM) or histamine (10 μM) in the presence of CXCR3 antagonists (10 μM). The 
percentage inhibition of agonist-induced PLC activation is shown. Experiments were performed in duplicate and re-
peated two (CXCR2) or three times. Radioligand binding studies were performed on membranes of HEK293T (CXCR4) or 
COS-7 cells (CXCR2 and histamine H
1
 receptor). The percentage inhibition of specific radioligand binding by the CXCR3 
antagonists (10 μM) is shown. Experiments were performed in triplicate and repeated two (CXCR2) or three times. L8 = 
CXCL8, L12 = CXCL12, his = histamine, mep = mepyramine.
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of N3.35 in the N(L/F)Y motif in TM3 of CXC chemokine receptors resulted in CAMs for both 
CXCR3 (this study) and CXCR4 (31). The non-peptidergic compounds acted as full inverse 
agonists at CXCR3 N3.35A, except for TAK-779, which only partially inhibited constitutive 
signaling at the highest concentration used (Fig. 7D). Since VUF10132 and TAK-779 have 
similar affinities for CXCR3 N3.35A (Table 2), it appears that TAK-779 lacks certain structural 
features needed for full inverse agonism at CXCR3. Interestingly, TAK-779 acts as a full inverse 
agonist at CCR5 (36). As expected for a receptor in the active state (34), the affinities of the 
agonists CXCL10 and CXCL11 for CXCR3 N3.35A were increased compared to CXCR3 WT 
(Table 1). The full inverse agonists VUF10472, VUF10085, VUF5834 and VUF10132, which 
are predicted to have a higher affinity for an inactive receptor conformation (34), all showed 
reduced affinity for CXCR3 N3.35A compared to CXCR3 WT (Table 2). In contrast, the affinity 
of the weak partial inverse agonist TAK-779 did not change, indicating a different mode of 
interaction with CXCR3 compared to the other structural classes of compounds.
Figure 7: Characterization of the constitutively active mutant CXCR3 N3.35A. A. Expression of CXCR3 WT and CXCR3 
N3.35A. HEK293T cells were transfected with cDNA encoding G…α
qi5
 and increasing amounts of cDNA encoding human 
CXCR3 WT or CXCR3 N3.35A. Mock cells were transfected with cDNA encoding G…α
qi5
 and pcDEF
3
 empty vector. After 
48 h, CXCR3 expression was determined in an ELISA assay. Data are presented as percentage signal obtained in mock-
transfected cells (n=2-3). B. Constitutive activity of CXCR3 N3.35A. HEK293T cells were transfected with cDNA encod-
ing G…α
qi5
 and increasing amounts of cDNA encoding human CXCR3 WT or CXCR3 N3.35A. Mock cells were transfected 
with cDNA encoding Gα …qi5 and pcDEF3 empty vector. After 48 h, 
3H-InsP accumulation was determined in the absence 
of chemokines. Data are presented as percentage 3H-InsP in mock-transfected cells (n=3). C. Chemokine-induced PLC 
activation by CXCR3 N3.35A. HEK293T cells were transfected with cDNA encoding CXCR3 N3.35A and Gα…qi5. After 
48 h, 3H-InsP accumulation was determined in the presence of increasing concentrations CXCL10 or CXCL11. pEC
50
 
values for CXCL10 and CXCL11 were 7.5 ± 0.0 (n=2) and 8.7 ± 0.1 (n=4) respectively. Data are presented as percentage 
of the maximal response obtained with CXCL11 (100 nM). D. Inverse agonism at CXCR3 N3.35A. HEK293T cells were 
transfected with cDNA encoding CXCR3 N3.35A and Gα …qi5. After 48 h, 
3H-InsP accumulation was determined in the 
presence of increasing concentrations VUF10472, VUF10085, VUF5834, VUF10132 or TAK-779. pIC
50
 values (n=3) were 
8.1 ± 0.1 (VUF10472), 8.0 ± 0.1 (VUF10085), 7.3 ± 0.0 (VUF5834), 6.6 ± 0.1 (VUF10132) and 5.9 ± 0.1 (TAK-779). Data 
are presented as percentage of CXCR3 N3.35A-mediated constitutive 3H-InsP accumulation.
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If antagonists are to be tested in animal models, detailed information on the interaction of the 
compound with the receptor of that specific species is required, since species differences may 
occur. We therefore tested the non-peptidergic antagonists on rhesus macaque CXCR3, which 
was cloned in this study, as well as on rat and mouse CXCR3.  Human and rhesus macaque 
show 99% amino acid identity (Fig 3). Consistent with this high homology, no differences in 
affinity or potency of CXCL10 and CXCL11, or in the affinity of the non-peptidergic antagonists 
for the two receptors were found. Similarly, the protein sequences of rat and mouse CXCR3 are 
96% identical and no significant differences in affinity of the endogenous agonists or the non-
peptidergic compounds are observed between the CXCR3 of these rodent species. However, 
lower sequence identity is found when human and rhesus macaque CXCR3 are compared 
with rat and mouse CXCR3.  Approximately 85% identity exists between the primate (human 
and rhesus macaque) and rodent (rat and mouse) species (Fig. 3). Nevertheless, the affinities 
of CXCL10 and CXCL11 found for rodent CXCR3 were comparable to the affinities found for 
primate CXCR3 (Table 1). While the affinities of CXCL10 and CXCL11 were comparable, the 
affinities of VUF10472, VUF10084, VUF5834 and VUF101032 were only about 4-fold lower 
for rodent CXCR3 than for primate CXCR3 (Table 2). Also their pK
b
 values against hCXCL10/
hCXCR3 and mCXCL10/mCXCR3 are comparable (Table 2, Fig. 5B and 5F), indicating the 
usefulness of these compounds in mouse models. 
In contrast, the affinity of TAK-779 was equal for CXCR3 of all tested species, again indicating 
that TAK-779 interacts with CXCR3 in another manner than the other small molecule 
antagonists. TAK-779, developed as a CCR5 antagonist, has been thoroughly investigated 
because of its potential use as a HIV-entry inhibitor. TAK-779 shows high affinity for human 
CCR5 and to a lesser extend for human CCR2b (16). Furthermore, TAK-779 was reported to 
bind mouse CCR5, as well as mouse CXCR3 (17). Remarkably, TAK-779 shows a more than 
100-fold higher affinity for human CCR5 than for mouse CCR5 (16, 17). This species selectivity 
of TAK-779 for CCR5 is not observed for human and mouse CXCR3, which both bind TAK-
779 with affinities around 1 μM (Table 2). It appears that TAK-779 has nanomolar affinity 
for human CCR5 and micromolar affinity for human CXCR3, whereas it has only micromolar 
affinity for mouse CCR5 and mouse CXCR3. This should be kept in mind when analyzing and 
extrapolating data from rodent models, since at a certain effective concentration of TAK-779 
different receptors will be occupied in humans and mice. While in mice the observed effects 
would likely be mediated by a combination of blockage of CCR5 and CXCR3, in humans the 
effects of TAK-779 would be mostly through inhibition of CCR5 with low nanomolar affinity. 
The non-peptidergic CXCR3 antagonists investigated here only showed a 3 to 4-fold species 
selectivity for CXCR3 of primates versus rodents in radioligand binding studies, whereas no 
species difference was observed in functional studies. When testing for selectivity against 
a panel of GPCRs, VUF10132 inhibited CCR1-mediated signaling and should therefore be 
optimized with respect to its affinity and specificity for CXCR3. In contrast, we observed 
that VUF10472, VUF10085 and VUF5834 are selective for CXCR3. In line with our findings, 
VUF10472/NBI-74330 has previously been reported not to affect chemotactic responses 
by human H9 T-cell lymphoma cells in response to CXCL12 and CCL19 and not to interfere 
with calcium mobilization induced by lysophosphatidic acid or radioligand binding to several 
GPCRs (23).
In summary, we characterized three classes of small non-peptidergic and non-competitive 
CXCR3 antagonists at CXCR3 of four different species, with VUF10472 being the most potent 
compound at human, rhesus, rat and mouse CXCR3. The observed selectivity profile and 
relatively small difference in affinity observed between human and rodent CXCR3 imply 
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that VUF10472/NBI-74330, VUF10085/AMG-487 and VUF5834 are useful in rodent models 
of CXCR3-mediated pathogenesis. Interestingly, it was found that the non-peptidergic 
antagonists act as inverse agonists at a constitutively active CXCR3 mutant.
3.4: Materials and methods 
 Materials. Dulbecco’s modified Eagle’s medium (DMEM) and trypsin were purchased from PAA Laboratories 
GmbH (Paschen, Austria), RPMI 1640 with glutamax-I and 25 mM HEPES, non essential amino acids, sodium pyruvate 
and 2-mercaptoethanol were from Sigma-Aldrich, penicillin and streptomycin were obtained from Cambrex, fetal 
bovine serum (FBS) was purchased from Integro B.V. (Dieren, The Netherlands), certified FBS was from Invitrogen. myo-
[2-3H]inositol (10-20 Ci/mmol) was bought from GE Healthcare. [125I]-CXCL10 (2200 Ci/mmol) and [125I]-CXCL11 (±1000 
Ci/mmol) were obtained from PerkinElmer Life and Analytical Sciences. Chemokines were obtained from PeproTech 
(Rocky Hill, N.J.). TAK-779 was obtained from the NIH AIDS research and reference reagent program.
 DNA constructs. The cDNA of human CXCR3 inserted in pcDNA3 (4) was amplified by PCR and inserted into 
pcDEF
3
 (a gift from Dr. Langer). A cDNA containing the rhesus macaque (Macaca mulatta, GenBank accession number 
EU313340) CXCR3 open-reading frame was obtained from rhesus macaque peripheral blood mononuclear cells 
(PBMCs) stimulated overnight with phytohemagglutinin-P plus phorbol myristate acetate. Total RNA was extracted 
using Trizol (Life Technologies) and cDNA was generated by reverse transcription (RT) with avian myeloblastosis 
virus RT (Promega) and oligo(dT) primer. PCR was then performed with Taq polymerase (Promega) and primers 
TRCXCR3F2 (5’-AGCCCAGCCATGGTCCTTG-3’) and TRCXCR3R2 (5’-CCTCACAAGCCCGAGTAGGA-3’).  The resulting 
PCR product was spin-column purified (Qiagen) and ligated to pGEM-T vector (Promega).  Subsequently the cDNA 
was subcloned into pcDEF3. A cDNA containing the rattus norvegicus CXCR3 open-reading frame was cloned from 
an F344 heart allograft that was transplanted into a Lewis rat at 28 days post-transplantation (38). Total RNA was 
prepared from 0.25 g of rat tissue using the Trizol method. First strand cDNA was synthesized from 2 μg of total RNA 
using 1.0 μM oligo dT-T7 primer (GGCCAGTGAATTGTAATACGACTCACTATAGGG(A)24) and 200 U Superscript III reverse 
transcriptase (Invitrogen). Doubled-stranded cDNA was generated by the addition of second strand buffer (Invitrogen) 
according to the manufacturer’s protocol and purified by phenol/chloroform extraction. PCR was performed with 
Taq DNA polymerase and primers ratCXCR3Fwd: ATAGGATTCATGTACCTTGAGGTCAGTGAACGTCA and ratCXCR3Rev: 
ATAGAATTCTTACAAGCCCAAGTAGGAGGCCTCAGT. The resulting PCR fragment was cloned into pGEM-Teasy (Promega), 
and subcloned into pcDEF
3
. The cDNA of mouse CXCR3 was a kind gift from Dr. Luster (27) and was subcloned into 
pcDEF3. The chimeric G protein Gaqi5 (pcDNA1-HA-mGα
qi5
) was a gift from Dr. Conklin (28). Other plasmids that 
were used are pcDNA3.1-CXCR1, pcDEF
3
-CXCR2, pcDNA3-CXCR4, pcDEF
3
-CCR1, pcDNA3.1-CCR2, pcDEF
3
-H
1
R, 
pCIneo-H
3
(445). 
 Synthesis of small molecule compounds. Synthesis of VUF5834 (21), VUF10472 and VUF10085 (22) has 
been described previously. Synthesis of VUF10132 was adapted from the procedure described by Axten et al (Axten et 
al, 2003). Briefly, 1-(3,4-Dichloro-phenyl)-2-imidazol-1-yl-ethanone (0.19 g, 0.75 mmol). and 2-Bromo-1-(3,4-dichloro-
phenyl)-ethanone (0.20 g, 0.75 mmol) were stirred in acetonitrile (50 mL) overnight at rt. The mixture was diluted with 
ether, the solid product filtered, washed with ether and dried to afford VUF10132 as white solid. Yield: 0.31 g (78%). 1H 
NMR (DMSO) d: 6.20 (s, 4H), 7.67-7.80 (m, 4H), 7.88-8.12 (m, 3H), 8.23-8.25 (m, 2H), 9.12 (s, 1H).
Cell culture and transfection. HEK293T cells were grown at 5% CO2 at 37 ˚C in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% fetal bovine serum, penicillin and streptomycin. HEK293T cells were transfected 
with 2.5 μg cDNA encoding CXCR3 supplemented with 2.5 μg pcDNA1-HA-mGα
qi5
 (for PLC activation experiments 
and ELISA) or 2.5 μg pcDEF3 using linear polyethyleneimine (PEI) (MW 25,000;  Polysciences Inc, Warrington, PA, 
USA). The total amount of DNA in gene-dosing experiments was kept constant at 5 μg by addition of pcDEF
3
. Briefly, 
a total of 5 μg DNA was diluted in 250 μl 150 mM NaCl. Subsequently 30 μg PEI in 250 μl 150 mM NaCl was added to 
the DNA solution and incubated for 10 min at RT. The mixture was added to adherent HEK293T cells in 10 cm tissue 
culture dishes. Next day, cells were trypsinized, resuspended into culture medium and plated in the appropriate poly-
L-lysine (Sigma) coated assay plates. For membrane preparation, cells were harvested 48 h after transfection from 
the tissue culture dishes in which they were transfected. Murine pre-B L1.2 cells were grown in RPMI 1640 medium 
with glutamax-I and 25 mM HEPES, supplemented with 10% heat-inactivated certified FBS, penicillin, streptomycin, 
glutamine, non-essential amino acids, 2-mercaptoethanol and sodium pyruvate. L1.2 cells were transfected with 10 
μg per 20 million cells using a BioRad Gene Pulser II (330V and 975 mF) and grown in culture medium supplemented 
with 10 mM sodium butyrate. 
 Chemokine binding. Cell membrane fractions from transiently transfected HEK293T (CXCR3 and CXCR4) 
or COS-7 (CXCR2) cells were prepared as follows. Cells were washed with cold PBS, detached using cold PBS containing 
1 mM EDTA and centrifuged at 1500 g for 10 min at 4˚C. Subsequently, cells were washed with PBS and centrifuged 
at 1500 g for 10 min at 4˚C. The pellet was resuspended in cold membrane buffer (15 mM Tris pH 7.5, 1 mM EGTA, 
0.3 mM EDTA, 2 mM MgCl2) and homogenized by 10 strokes at 1100-1200 rpm using a teflon-glass homogenizer and 
rotor. The membranes were subjected to two freeze thaw cycles using liquid nitrogen and centrifuged at 40,000 g for 
25 min at 4˚C. The pellet was rinsed with cold Tris-sucrose buffer (20 mM Tris pH 7.4, 250 mM sucrose), resuspended 
in the same buffer and frozen in liquid nitrogen. Protein concentration was determined using a Bio-Rad protein assay. 
Membranes were incubated in 96 well plates in binding buffer (50 mM HEPES pH 7.4, 1 mM CaCl2, 5 mM MgCl2, 100 
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mM NaCl, 0.5% BSA for CXCR3 and CXCR4 radioligand binding assays and 50 mM Na2/K-phosphate buffer, pH 7.4, 
0.5% BSA for CXCR2 radioligand binding assay) with approximately 50 pM [125I]-chemokine and displacer for 2 h at RT. 
Subsequently, membranes were harvested via filtration through Unifilter GF/C plates (PerkinElmer Life and Analytical 
Sciences) pretreated with 1% polyethylenimine and washed three times with ice-cold wash buffer (50 mM HEPES pH 
7.4, 1 mM CaCl2, 5 mM MgCl2, 500 mM NaCl for CXCR3 and CXCR4 and 50 mM Na2/K-phosphate buffer, pH 7.4 for 
CXCR2). Radioactivity was measured using a MicroBeta (PerkinElmer Life and Analytical Sciences).
Histamine H
1
 receptor binding. Cell homogenates from COS-7 cells transiently transfected with cDNA encoding the 
human histamine H
1
 receptor were incubated with 7 nM [3H]-mepyramine and 10 μM CXCR3 antagonist in H
1
 buffer (50 
mM Na2/K-phosphate buffer, pH 7.4) for 30 min at RT and harvested via filtration using ice-cold H1 buffer as described 
above.
 Phospholipase C activation. Twenty-four h after transfection, HEK293T cells were labeled overnight in 
Earle’s inositol-free minimal essential medium (Invitrogen) supplemented with 10% fetal bovine serum, penicillin and 
streptomycin and myo-[2-3H]inositol (1 μCi/ml). Cells were washed with InsP assay buffer (20 mM HEPES pH 7.4, 
140 mM NaCl, 5 mM KCl, 1 mM MgSO
4
, 1 mM CaCl2, 10 mM glucose and 0.05% (w/v) BSA) and incubated for 2 h in 
InsP assay buffer supplemented with 10 mM LiCl in the presence or absence of indicated ligands. The incubation was 
stopped by aspiration of the assay buffer and addition of ice-cold 10 mM formic acid. After incubation for 90 min at 4˚C, 
3H-InsP were isolated by anion-exchange chromatography (Dowex AG1-X8 columns, Bio-Rad) and counted by liquid 
scintillation.
 Chemotaxis. Twenty-four h after transfection, chemotaxis of L1.2 cells towards CXCL10 (10 nM) was 
determined in the presence or absence of small molecule compounds, using 5 μM pore ChemoTx 96 well plates 
(Neuroprobe Inc, MD, USA). Briefly, ChemoTx plates were blocked using RPMI 1640 with glutamax-I and 25 mM Hepes 
supplemented with 1% (w/v) BSA. Chemokine and compound dilutions were made in RPMI 1640 with glutamax-I and 
25 mM Hepes supplemented with 0.1% (w/v) BSA and added to the wells. L1.2 cells were added on top of the membrane 
and incubated for 5 h in a humidified chamber at 37 ˚C. The number of migrated cells per well was determined using a 
haemocytometer.
 ELISA. Forty-eight hours after transfection, HEK293T cells were washed with TBS and fixed with 4% 
paraformaldehyde in PBS. After blocking with 1% skim milk in 0.1 M NaHCO
3
 (pH 8.6), cells were incubated with 
mouse monoclonal anti-CXCR3 antibody (MAB160, R&D Systems, Inc) in TBS containing 0.1% BSA, washed three 
times with TBS and incubated with goat anti-mouse horseradish peroxidase-conjugated secondary antibody (Bio-Rad). 
Subsequently, cells were incubated with substrate buffer containing 2mM o-phenylenediamine (Sigma, St. Louis, Mo), 
35 mM citric acid, 66 mM Na2HPO4, 0.015% H2O2 (pH 5.6). The reaction was stopped with 1 M H2SO4 and absorption at 
490 nm was determined.
 Data analysis. Nonlinear regression analysis of the data and calculation of Kd and Ki values was performed 
using Prism 4.03. The pK
b
 values in the PLC activation assay were calculated using the Cheng-Prusoff equation pK
b
 = 
IC
50
 / (1+[agonist]/EC
50
) (1)
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4: Abstract
The chemokine receptor CXCR3 is a GPCR predominantly found on activated T cells. 
CXCR3 is activated by three endogenous peptides; CXCL9, CXCL10 and CXCL11. Recently, 
a small-molecule agonist, VUF10661, has been reported in the literature and synthesized 
in our laboratory. The aim of the present study was to provide a detailed pharmacological 
characterization of VUF10661 by comparing its effects with those of CXCL11. VUF10661 acted 
as a partial agonist in CXCR3-mediated chemotaxis, bound to CXCR3 in an allosteric fashion in 
ligand binding assays and activated G
i
 proteins with the same efficacy as CXCL11 in the [35S]-
GTP…γS binding and cAMP assay, while it recruited more β-arrestin1 and β-arrestin2 to CXCR3 
receptors than the chemokine CXCL11 and CXCL10. Altogether, VUF10661, like CXCL11, 
activates both G protein-dependent and -independent signalling via the CXCR3 receptor, 
but probably exerts its effects from an allosteric binding site that is different from that for 
CXCL11. VUF10661 likely stabilizes a different receptor conformation leading to the observed 
differences in functional output. Such ligand-biased signalling might offer interesting options 
for the therapeutic use of CXCR3 agonists.
4.1: Introduction
The chemokine receptor CXCR3 is an inducible chemokine receptor expressed on e.g. activated 
T cells of the Th1-subtype, B cells and natural killer cells. The three major CXC chemokine 
ligands for CXCR3 are CXCL9, CXCL10 and CXCL11 (nomenclature follows (1)), of which the 
latter has been shown to have the highest affinity for CXCR3 (2, 3). Stimulation of CXCR3 
leads to activation of pertussis toxin (PTX)-sensitive G
i
 proteins, which subsequently results in 
e.g. mobilisation of intracellular calcium, the activation of AKT and p44/42 mitogen-activated 
protein kinase and chemotaxis (4-6). 
CXCR3 chemokines are mainly secreted by activated monocytes and macrophages (7). 
As such, they direct the migration of Th1 cells to tissues that harbour inflammation or 
infection. Upregulation of CXCR3 ligands is found in various inflammatory disorders like 
allograft rejection (8), atherosclerosis (9)) and autoimmune diseases such as systemic lupus 
erythematosus (SLE) (10), rheumatoid arthritis (11) and multiple sclerosis (12). In addition, the 
levels of chemokine mRNA and number of infiltrating CXCR3+ cells in tissues from transplant 
and SLE patients correlate with the severity of disease (13-16). Inhibition of CXCR3 by either 
antibodies or small-molecule antagonists significantly delays disease progression in various 
mouse models (8, 17, 18). As a consequence, considerable attention has been paid to the 
discovery and development of small-molecule CXCR3 antagonists for the treatment of chronic 
inflammation. To date, numerous compounds from different chemical classes have been 
described (19). Interestingly, during the process of screening for antagonists, two classes of 
small-molecule CXCR3 agonists have been identified (20). Although the majority of CXCR3-
associated disease would argue for the development of antagonists, agonists might also show 
therapeutic benefit in some cases, including wound healing and cancer (21, 22). Moreover, 
small-molecule agonists are valuable tools in exploring the molecular pharmacology of the 
CXCR3 receptor. In the present study we report on the pharmacological characterisation of 
VUF10661, one of the recently discovered small-molecule CXCR3 agonists (20). Using both G 
protein-dependent and -independent functional assays, we show that VUF10661 behaves as a 
full CXCR3 agonist. We report for the first time that CXCL11 as well as VUF10661 recruit both 
…β-arrestin1 and β…-arrestin2 to CXCR3 receptors and regulate CXCR3 cell surface expression. 
In addition, radioligand binding studies indicate that VUF10661 has a different binding mode 
than the major endogenous chemokine ligand CXCL11. The varying functional activities of 
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CXCL11 and VUF10661 in the different functional assays indicate ligand-biased recruitment 
of …β-arrestins to the CXCR3 receptor.
4.2: Results
4.2.1: VUF10661 is a partial agonist in CXCR3-mediated chemotaxis
The hallmark function of chemokines is their ability to induce directional migration of cells 
expressing chemokine receptors. Therefore, a chemotaxis assay with L1.2 cells transiently 
transfected with cDNA encoding the human CXCR3 receptor was used to investigate the 
agonistic properties of VUF10661. Both the endogenous ligand CXCL11 and the synthetic 
compound VUF10661 induced a dose-dependent migration of the CXCR3-expressing 
cells (Figure 2A), while this did not occur in mock-transfected cells (data not shown). The 
concentration at which the maximum effect was attained differed between CXCL11 and 
VUF10661 (10 nM and 1 μM respectively), however, this correlated with the relative difference 
in affinities for these ligands in competition binding experiments (Table 1, Figure 3). In 
agreement with previously reported results for VUF10661 analogues by Stroke and coworkers, 
the magnitude of efficacy elicited by both ligands was different (20). Quantitatively, this is 
reflected by the intrinsic activity of the two molecules, which represents the relative ability 
of an agonist to produce a maximum response in a functional assay, where α = 1 indicates 
a full agonist, and an a between 0 and 1 indicates a partial agonist. VUF10661 showed a 
significantly lower maximal effect than the full agonist CXCL11 (α = 1), rendering VUF10661 a 
partial agonist (α = 0.5) in this assay. To investigate the specificity of the observed migration, 
cells were simultaneously incubated with either CXCL11 (10 nM) or VUF10661 (1 μM) and 
the CXCR3-selective antagonist NBI-74330 (1 μM) (23). NBI-74330 produced complete 
antagonism of chemotaxis induced by both CXCL11 and VUF10661 (Figure 2b), showing that 
VUF10661, like CXCL11, promotes CXCR3-mediated chemotaxis.
Figure 1: Chemical structure of small-molecule CXCR3 agonist VUF10661
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4.2.2: VUF10661 binds to CXCR3 in an allosteric fashion
To further characterise the small-molecule agonist VUF10661, the compound was subjected 
to radioligand binding studies with [125I]-CXCL10 and [125I]-CXCL11 on membrane preparations 
from HEK293 cells stably expressing the human CXCR3 receptor. Radiolabeled CXCL10 was 
displaced by unlabelled CXCL11, resulting in an affinity of 40 pM (pK
i
 = 10.4 ± 0.1), while 
homologous [125I]-CXCL11 displacement with CXCL11 resulted in a similar affinity of 80 pM 
(pK
d
 = 10.1 ± 0.1) (Figure 3A-B; Table 1), comparable to data previously published (23, 24). 
Interestingly, VUF10661 inhibited binding of both [125I]-CXCL10 and [125I]-CXCL11, although 
with different affinities, 50 nM (pK
i
 = 7.3 ± 0.1) and 630 nM (pK
i
 = 6.2 ± 0.1), respectively 
(Figure 3A-B and Table 1). In addition, VUF10661 was not able to displace [125I]-CXCL12 from 
membranes expressing CXCR4 or CXCR7 chemokine receptors (data not shown), indicating 
that the compound is selective for CXCR3 over CXCR4 and CXCR7. 
To investigate the nature of interaction of VUF10661 with the endogenous ligands at the 
CXCR3 receptor, saturation binding assays with radiolabelled CXCL10 and CXCL11 were 
performed. Membranes were incubated with increasing concentrations of [125I]-CXCL10 or 
[125I]-CXCL11 in the presence or absence of a single concentration of VUF10661 (50 nM or 
500 nM, respectively). The affinity for [125I]-CXCL10 of 0.20 ± 0.02 nM (n=2) (Figure 3C and 
Table 1) was unaffected by the presence of VUF10661. However, in the presence of 50 nM 
VUF10661, the B
max
 for [125I]-CXCL10 decreased approximately 50% (Figure 3c). Likewise, 
the B
max
 of [125I]-CXCL11 decreased to a similar extent in the presence of 500 nM VUF10661, 
while its affinity remained constant (K
d
 = 0.08 ± 0.01 nM) (Figure 3D, table 1). To investigate 
whether this decrease in Bmax was due to (pseudo)-irreversible binding of VUF10661, ligand 
washout experiments were performed (25). Pre-incubation of intact HEK293/CXCR3 cells 
with VUF10661 for 1 hr, followed by an extensive washout of 30 min, did not have an effect 
on maximal [125I]-CXCL11 binding (95 ± 5%, Figure S2: gray bar) when compared to vehicle-
pretreated controls (99 ± 2%, Figure S2: white bar). This indicates that VUF10661 binds to 
CXCR3 in a reversible fashion. Since VUF10661 only affected the B
max
 of the chemokines and 
not the K
d
, these findings suggest an allosteric binding mode for VUF10661 (26, 27). Next, we 
studied the interaction of VUF10661 with CXCR3 in a whole cell context. In order to do this, a 
concentration series of cold CXCL11 and VUF10661 was used to displace a fixed concentration 
of [125I]-CXCL10 or [125I]-CXCL11 from HEK293 cells stably expressing CXCR3 receptors. The 
observed affinities of CXCL11 and VUF10661 were 0.25 nM (pK
i
 =9.6 ± 0.1) and 100 nM (pK
i
 
Figure 2: Chemotaxis assay with L1.2 cells expressing human CXCR3. (A) Migration of cells after 5 hours of incubation 
with a concentration series of CXCL11 (open circles) or VUF10661 (filled circles). (B) Co-incubation of CXCL11 (10 
nM) and VUF10661 (1 μM) with the CXCR3 antagonist NBI-74330 (1 μM). Values are mean ± SEM, n=3 (*** P<0.001).
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= 7.0 ± 0.1), respectively, when [125I]-CXCL10 was used as radioligand, and 0.4 nM (pK
i
 = 9.4 ± 
0.1) and 1.0 μM (pK
i
 = 6.0 ± 0.1) in the case of [125I]-CXCL11. Interestingly, where VUF10661 
completely inhibited binding of [125I]-CXCL10 (Figure 3E), it was unable to completely displace 
[125I]-CXCL11 from CXCR3 in this assay (±70%; Figure 3F). Similar behaviour was observed 
for CXCL10, which also partially inhibited [125I]-CXCL11 binding. In contrast, CXCL11 and 
NBI-74330 fully displaced both radioligands to non-specific binding levels (Figure 3E and F). 
Collectively, these data indicate that VUF10661 has a different binding mode than CXCL11, 
the major ligand for CXCR3.
4.2.3: VUF10661 activates Gi proteins with the same efficacy as CXCL11
Because VUF10661 showed partial agonistic behaviour in the chemotaxis assay with 
transfected L1.2 cells, we next determined its potency for CXCR3-mediated G protein activation 
using [35S]-GTPγS binding, a classical functional readout for GPCRs (28). Both CXCL11 
and VUF10661 produced a dose-dependent increase in [35S]-GTPγS binding to membranes 
prepared from HEK293 cells stably expressing human CXCR3 receptors. The potencies for 
these responses were 0.6 nM (pEC
50
 = 9.2 ± 0.1) for CXCL11 and 0.6 μM (pEC
50
 = 6.2 ± 0.1) 
for VUF10661 and correlated well with their respective affinities (Figure 4A). Co-incubation 
of CXCL11 and VUF10661 with 1 μM NBI-74330 abolished the agonist-induced [35S]-GTPγS 
binding (Figure 4B), demonstrating that agonist-induced signals detected in this assay are 
mediated through CXCR3. Moreover, treatment of CXCR3-expressing cells with 25 ng·ml-1 PTX 
prior to harvesting, resulted in a complete inhibition of agonist-induced [35S]-GTPγS binding, 
consistent with reports on CXCR3 coupling to G
i
 proteins (Figure 4C) (5, 6).
4.2.4: VUF10661 inhibits adenylyl cyclase activity: use of a novel BRET cAMP biosensor
Inhibition of adenylyl cyclase is another well-characterised response mediated by G
i/o
-coupled 
receptors. To investigate the effects of CXCL11 and VUF10661 on cAMP levels, a BRET-based 
cAMP biosensor was employed (29). The mechanism of this biosensor is schematically shown 
in Figure 5a and a detailed description can be found elsewhere (29-31). The biosensor was co-
expressed with human CXCR3 in HEK293 cells and used to measure changes in intracellular 
cAMP levels. Incubation of these cells with CXCR3 agonists did not lead to an increase in 
cAMP production. However, stimulation with 10 μM forskolin, a direct activator of adenylyl 
cyclase, led to a robust response (data not shown). Addition of increasing concentrations of 
CXCL11 dose-dependently inhibited the forskolin-induced cAMP accumulation with a potency 
Displacement  
(membranes) (pKi)
Displacement  
(whole cells) (pKi)
Saturation binding 
(membranes)
Displacer 125I-CXCL10 125I-CXCL11 125I-CXCL10 125I-CXCL11
Kd  
(nM)
Bmax  
(pmol·mg protein-1)
CXCL10 9.8 ± 0.1* 8.0 ± 0.1 9.4 ± 0.1* 8.0 ± 0.1 0.2 ± 0.02 0.1 ± 0.3
CXCL11 10.4 ± 0.0 10.1 ± 0.1* 9.6 ± 0.1 9.4 ± 0.1* 0.08 ± 0.01 1.0 ± 0.3
VUF10661 7.3 ± 0.0 6.2 ± 0.1 7.0 ± 0.0 5.9 ± 0.1 - -
Table 1: Radioligand binding assays performed on HEK293 cells stably expressing human CXCR3. Affinities for CXCR3 
ligands determined using displacement and saturation binding with [125I]-CXCL10 and [125I]-CXCL11 as radioligands on 
HEK293 whole cells stably expressing CXCR3 receptors or membranes prepared thereof. A ‘*’ indicates homologous 
displacement experiments leading to pK
d
 values instead of pKi values. B
max
 values were determined using saturation 
binding experiments and represent total receptor number per mg of protein. All data presented are mean ± SEM values 
from at least three independent experiments.
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Figure 3: Radioligand binding experiments. (A and B) Displacement of radioligand from HEK293 membranes prepared 
from HEK293 cells stably expressing CXCR3 receptors. [125I]-CXCL10 and [125I]-CXCL11 were used at a concentration 
of 70 pM (A) Displacement of [125I]-CXCL10 radioligand with cold CXCL11 (open circles) and VUF10661 (filled circles). 
(B) Displacement of [125I]-CXCL11 with cold CXCL11 (open circles) and VUF10661 (filled circles). (C and D) Saturation 
binding of [125I]-CXCL10 and [125I]-CXCL11 at HEK293 membranes expressing CXCR3 receptors. (C) Specific binding 
of [125I]-CXCL10 was determined in the absence (open circles) or presence (filled circles) of 50 nM of VUF10661. (D) 
Specific binding of [125I]-CXCL11 was determined in the absence (open circles) or presence (filled circles) of 500 nM 
VUF10661. (E and F) Whole cell radioligand displacement assay using HEK293 cells stably expressing CXCR3 recep-
tors. (E) Displacement of [125I]-CXCL10 with CXCL11 (open circles), and VUF10661 (filled circles). Dotted line indicates 
level of radioligand binding after incubation with 0.3 μM of cold CXCL11 or 1 μM of NBI-74330. (F) Displacement of 
[125I]-CXCL11 with CXCL11 (open circles), and VUF10661 (filled circles). Dotted line indicates level of radioligand bind-
ing after incubation with 0.3 μM of cold CXCL10, and the dashed line shows specific radioligand binding after incuba-
tion with 1 μM of NBI-74330. Shown values are mean ± SEM representative for at least three independent experiments.
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of 1.6 nM (pEC
50
 = 8.8 ± 0.1) (Figure 5B). In agreement with its lower affinity for CXCR3, 
VUF10661 also displayed lower potency in the BRET-biosensor cAMP assay (0.5 μM; pEC
50 
= 
6.3 ± 0.1) (Figure 5b). In contrast, CXCL10 behaved as partial agonist in this assay (α = 0.7), 
having a potency of 13 nM (pEC
50
 = 7.9 ± 0.2) (Figure 5B). The observed response for CXCL11 
and VUF10661 reflected specific activation of CXCR3, since 1 μM of NBI-74330 inhibited the 
response to basal levels (Figure 5C). In accordance with the G
i
-coupling properties of CXCR3, 
treatment of cells with 25 ng·ml-1 PTX completely abrogated the agonist-induced effects 
(Figure 5D).
4.2.5: VUF10661 induces internalisation of CXCR3
Upon sustained agonist stimulation, GPCRs are generally removed from the cell surface, a 
process called endocytosis or internalisation (32). CXCR3 has been shown to readily internalise 
after 30 min to several hours in response to CXCL10 or CXCL11 in various cell types, including 
HEK293 and peripheral blood mononuclear cells, as well as activated T lymphocytes (33). 
In the present study, we used an immunocytochemistry approach to qualitatively determine 
the effect of CXCR3 agonists on CXCR3 surface expression and distribution. When HEK293 
cells, stably expressing human CXCR3 and transiently transfected with cDNA encoding for β…-
arrestin1- or 2-YFP, were stained with anti-CXCR3 antibody, we observed a clear localisation 
of CXCR3 at the plasma membrane (Figure 6, panel A1). …β-arrestin2-YFP was homogenously 
distributed throughout the cells (Figure 6, panel A2). Upon stimulation with 30 nM CXCL11 
(Figure 6A4-6) or 3 μM VUF10661 (Figure 6, panels A7-9) for 1 hr, a marked redistribution of the 
receptor into intracellular vesicles was observed. Concomitantly, staining at the cell surface 
decreased, indicating CXCR3 internalisation (Figure 6, panels A4 and A7). Since β……-arrestins 
have been shown to be partly involved in CXCR3 internalisation (34, 35), we also investigated 
the redistribution of these scaffolding proteins upon CXCR3 stimulation. Both CXCL11 and 
VUF10661 induced a pronounced punctuated intracellular redistribution of β-arrestin1 and 
-2-YFP (data not shown and Figure 6, panels A5 and A8). Interestingly, CXCR3 and …β-arrestin1 
and -2 showed significant co-localisation after agonist treatment, suggesting that both β…-
arrestin isoforms are involved in CXCR3 internalisation (data not shown and Figure 6, panels 
A6 and A9). To further quantify the internalisation of CXCR3 in these cells, a whole-cell based 
ELISA was performed. As can be seen in Figure 6B, cell surface expression of CXCR3 was 
significantly reduced when stimulated with either CXCL11 or VUF10661, already after 30 
min, reaching a maximum after approximately one hour. CXCL11 and VUF10661-induced 
internalisation was shown to be concentration-dependent with potencies of 2.5 nM (pEC
50
 = 
8.6 ± 0.1) and 3.2 μM (pEC
50
 = 5.5 ± 0.1) respectively. (Figure 6C). This effect was inhibited by 
incubation at 4°C, an approach generally used to inhibit receptor internalisation. Collectively, 
these data show that both CXCL11 and VUF10661 induce …β-arrestin1 and -2 translocation to 
CXCR3 and subsequent receptor internalisation in HEK293 cells.
4.2.6: VUF10661 recruits β-arrestin1 and -2 to CXCR3 receptors
It is well accepted that β-arrestins are recruited to activated GPCRs after phosphorylation 
by GRKs, leading to desensitisation and ultimately to internalisation of the receptor (36). In 
addition to these properties, there is a growing body of evidence showing that β-arrestins 
can serve as scaffolds orchestrating the assembly of multiple proteins from several signalling 
pathways. Since recruitment of β-arrestins to GPCRs and its downstream effects are thought 
to be G protein independent (37), it offers a novel way to assess ligand-mediated activation 
of GPCRs. Following the observed co-localisation of CXCR3 and β-arrestins, we decided to 
study CXCR3-induced β-arrestin recruitment directly. In order to investigate agonist-induced 
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interactions of β-arrestin1 and -2 with the CXCR3 receptor we used a BRET1 approach in which 
β-arrestin1 and -2 were C-terminally tagged with YFP and the human CXCR3 receptor fused 
to Rluc. Tagging of CXCR3 with Rluc resulted in a receptor showing similar expression and 
functional responses as compared to wild type CXCR3 (data not shown). The cDNAs encoding 
for CXCR3-Rluc and either β-arrestin1-YFP or β-arrestin2-YFP were transiently co-transfected 
in HEK293T cells and incubated with CXCL10, CXCL11 or VUF10661. Agonist-promoted 
recruitment of β-arrestin concomitantly brings YFP in proximity to Rluc, facilitating BRET and 
leading to the emission of light at an average wavelength of 530 nm (Figure 7A). As follows 
from Figure 7B, CXCL10, CXCL11 and VUF10661 all recruited β-arrestin2 with potencies of 32 
nM (pEC
50
 = 7.5 ± 0.3), 3 nM (pEC
50
 = 8.5 ± 0.1) and 1 μM (pEC
50
 = 5.9 ± 0.1), respectively. Using 
the same methodology, all three agonists were observed to similarly induce the interaction of 
human CXCR3 with β-arrestin1 (Figure 7B). Interestingly, VUF10661 showed a significantly 
higher efficacy (α = 1) for the recruitment of both β-arrestin1 and 2, as compared to CXCL10 (α 
= 0.2) and CXCL11 (α = 0.6), which both behaved as partial agonists in this assay. The CXCR3 
antagonist NBI-74330 was able to completely inhibit both agonist-promoted responses 
in this assay (Figure 7C). Moreover, the treatment of the cells with 25 ng·ml-1 PTX did not 
block the observed β…-arrestin recruitment, suggesting that G
i
 proteins are not needed for the 
recruitment of β-arrestins to CXCR3 (Figure 7D).
Figure 4 : [35S]-GTP…γS binding assay at membranes of HEK293 cells stably expressing CXCR3. (A) Membranes incubat-
ed with a concentration series of CXCL11 (open circles) and VUF10661 (filled circles). Data are represented as fold over 
basal [35S]-GTP…γS binding from three independent experiments, and values shown are mean ± SEM. (B) CXCL11 (3 nM) 
and VUF10661 (3 μM) were co-incubated with 1 μM of CXCR3 antagonist NBI-74330 (black bars). Data are expressed 
as percentage of agonist response, with mean ± SEM, n=3. (C) Cells were treated with or without PTX (25 ng·ml-1) prior 
to membrane harvesting and subsequent agonist incubations. Values are mean ± SEM, n=3 (*** P<0.001).
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4.3: Discussion
Chemokine receptor binding and activation is generally thought to occur via a two-step 
mechanism, in which the first step is governed by binding of the large peptide ligand to the 
N-terminus and extracellular loops of the GPCR protein (38). Subsequently, the N-terminus of 
the chemokine is well positioned to interact with the transmembrane (TM) domains, leading 
to activation of the receptor (39, 40). In contrast, small-molecule modulators of family A 
GPCRs generally bind to the TM part of the GPCR, as recently shown for a small molecule 
CXCR4 antagonist using X-ray crystallography (41). Consequently, small-molecule chemokine 
receptor ligands are considered to allosterically modulate GPCR function from binding sites 
that are distinct or only partially overlap with the chemokine interaction points (23, 26, 42-
44). Recently the first small molecule inhibitors of the chemokine receptors CXCR4 and CCR5 
have reached the market for stem cell mobilisation (AMD3100 or Mozobil®) or HIV infection 
(maraviroc or Celsentri®), indicating the huge potential of allosteric modulation of chemokine 
receptors.
Figure 5: Cyclic AMP biosensor assay. (A) Schematic illustration of BRET-based cAMP biosensor assay. (B) Inhibition 
of forskolin-induced cAMP accumulation was determined after sequential administration of CXCL11 (open circles), 
CXCL10 (filled squares), or VUF10661 (filled circles) and forskolin to HEK293 cells stably expressing CXCR3 and tran-
siently transfected with the cDNA encoding the cAMP biosensor. The figure shows mean ± SEM of grouped data from 
three independent experiments. (C) The selective CXCR3 antagonist NBI-74330 (1 μM) was co-incubated with CXCL11 
(10 nM) or VUF10661 (3 μM). (D) Influence of PTX treatment on CXCR3-induced inhibition of adenylyl cyclase. Same 
agonist concentrations used as for C. Data are expressed as percentage of the maximal forskolin response. All values 
shown are mean ± SEM from three independent experiments (*** P<0.001).
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The CXCR3 receptor is one of the members of the CXC chemokine receptor family that has 
attracted considerable interest as therapeutic target in view of its role in several inflammatory 
conditions and (although more controversial) cancer (19). Small-molecule inhibitors targeting 
CXCR3 act as non-competitive, potentially allosteric inhibitors (23) and are effective tools 
to study the (patho)physiological role of CXCR3 (19). In a screen for CXCR3 antagonists 
Pharmacopeia scientists have recently identified tetrahydroisoquinolines as CXCR3 agonists 
(20). They show that these compounds act as agonists, leading to calcium mobilisation and 
chemotaxis upon binding to the CXCR3 receptor. In the present work we confirm their initial 
findings and describe a further, detailed pharmacological characterisation of one such small-
molecule synthetic agonist for CXCR3, synthesised in-house and named VUF10661.
The tetrahydroisoquinoline VUF10661 displaces radiolabelled CXCL10 and CXCL11 
with different affinities (50 nM and 630 nM, respectively). In addition, VUF10661 shows 
incomplete inhibition of [125I]-CXCL11 binding while completely displacing [125I]-CXCL10 
binding to cells expressing CXCR3. Altogether these data are in line with the findings of Cox 
and co-workers that showed that CXCL10 labels a subset of active CXCR3 conformations, 
whereas CXCL11 labels CXCR3 proteins in both an active and inactive conformation (24). 
Following this reasoning, VUF10661 has a clear preference for the active states of CXCR3, 
which would be in line with its reported agonistic behaviour. As CXCL11 seems to stabilise 
a different subset of active conformations than CXCL10 (24), it seems also likely that 
VUF10661 stabilises its own subset of active conformations leading to the observed ligand-
biased signalling in β-arrestin recruitment compared to G protein-dependent assays like 
[35S]-GTPγS and cAMP. Moreover, CXCL11 showed a 10-fold decrease in affinity determined 
in whole cells compared to membranes, while CXCL10 affinity remained constant. This again 
indicates that CXCL10 and CXCL11 recognise different CXCR3 conformations. In saturation 
binding experiments a single concentration of VUF10661 resulted in a significant decrease 
in B
max
, but not in K
d
, for both [125I]-CXCL10 and [125I]-CXCL11, indicating that VUF10661 
interacts in a non-competitive, potential allosteric fashion with both chemokines at CXCR3. 
Preliminary mutagenesis studies support the hypothesis of allosteric binding of VUF10661 to 
CXCR3 (Scholten et al., unpublished data). Our present findings agree with previous results 
with various classes of small-molecule CXCR3 inverse agonists (23) and have also been 
observed with CXCR2 antagonists (26) and inverse agonists for the viral chemokine receptor 
US28 (45). It should be noticed that hardly any data is available on the effect of allosteric 
GPCR ligands on agonist radioligand saturation curves. A simple allosteric ternary complex 
model cannot explain the observed decrease in B
max
 and, therefore, more complex alternative 
hypotheses need to be considered. Washout experiments show that the decrease in B
max 
is 
not due to irreversible binding of this compound to CXCR3. A possible explanation is that 
VUF10661 disrupts dimeric or higher order oligomeric CXCR3 complexes and thereby reduces 
the number of available radioligand binding sites. However, so far we have not been able to 
detect any biochemical evidence for ligand-induced (agonists or inverse agonist) modulation 
of CXCR3 oligomers (Leurs et al., unpublished data). Alternatively, VUF10661 might enrich a 
population of activated, G protein-coupled CXCR3 receptors, thereby reducing the number 
of radioligand-receptor-G protein complexes and hence a decrease in B
max
. To characterise 
the functional consequences of VUF10661 binding to the CXCR3 receptor, we investigated 
its ability to activate several signalling pathways, including G protein-dependent as well as 
G protein-independent events. Using a [35S]-GTPγS binding assay we show that VUF10661, 
like CXCL11, activates G
i
 proteins and both act as full agonists at the CXCR3 receptor. The 
observed difference in potencies between CXCL11 and VUF10661 reflects the relative 
difference in affinity as determined in the radioligand competition experiments. To assess 
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Figure 6: Redistribution of CXCR3 upon agonist stimulation. (A) HEK293 cells stably expressing CXCR3 and 
transiently transfected with cDNA encoding for β…-arrestin2-YFP were incubated with or without CXCL11 
(30 nM) and VUF10661 (3 μM) for 1 hr. Cells were fixed and stained with anti-CXCR3 and Alexa-546 anti-
bodies to visualise CXCR3 (images 1, 4 and 7), while …β-arrestin2-YFP is shown in images 2, 5 and 8. Cells 
were treated with empty medium (basal; panels 1-3), CXCL11 (panels 4-6) or VUF10661 (images 7-9) for 
1 hr. Panels 3, 6 and 9 show an overlay of the red and green channels. Images shown are representative of 
three independent experiments. (B) Cell surface expression of CXCR3 was determined with ELISA using 
the anti-CXCR3 antibody mAb160 in presence of CXCL11 (open circles, 30 nM) or VUF10661 (filled circles, 
10 μM) at different time points and compared to vehicle (filled squares). (C) Effect of concentration series 
of CXCL11 (open circles) and VUF10661 (filled circles) on cell surface expression of CXCR3 after three 
hours of agonist incubation. Shown are values ± SEM, n=3.
76  Pharmacological characterization of a small-molecule CXCR3 agonist
C4
the subsequent changes in the levels of cAMP after agonist stimulation, we used a novel 
BRET-based cAMP biosensor. This intracellular cAMP indicator has been successfully used 
for several GPCRs (29-31) and allows monitoring of receptor signalling in live cells. Using this 
approach we show that upon activation with CXCL10, CXCL11 or VUF10661, CXCR3 is able to 
inhibit the forskolin-induced adenylyl cyclase activity with different potencies that agree with 
the relative difference in their binding affinities. Both the small-molecule agonist and CXCL11 
act as full agonists in this assay while CXCL10 is a partial agonist.
Classically, G proteins have been considered as the main interacting proteins of GPCRs. 
However in recent years, the involvement of other interacting proteins, such as β…-arrestins, 
have been emerging, both in signalling and regulation of GPCRs (46). Whereas the role for 
β…-arrestins in GPCR desensitisation and internalisation has been known for a while, the GPCR 
field is currently also appreciating their role as GPCR signalling partners (36). Recruited β…-
arrestins act as scaffolds bringing together proteins from different signalling cascades, such 
as MAP kinases or Akt, in multiprotein complexes. It has previously been shown that CXCR3 
internalises after CXCL11 binding (33, 47). In the present work, we show that also VUF10661 
induces a dose- and time-dependent internalisation of CXCR3. Activation of CXCR3 by 
Figure 7: BRET-based …-arrestin recruitment assay in HEK293T cells transiently expressing CXCR3-Rluc and …β-arrestin1-
YFP or …β-arrestin2-YFP. (A) Schematic illustration of …β-arrestin recruitment to CXCR3 receptors using a BRET1 approach. 
(B) Effects of increasing concentrations of CXCL11 (open circles), CXCL10 (filled gray circles), and VUF10661 (filled 
black circles) on the recruitment of β…-arrestin1-YFP or CXCL11 (open squares), CXCL10 (filled gray squares), and 
VUF10661 (filled black squares) on the recruitment of …β-arrestin2-YFP. Data is represented as mean ± SEM, grouped 
from at least three independent experiments. (C) The CXCR3 antagonist NBI-74330 (1 μM) was co-incubated with 30 
nM of CXCL11 or 3 μM of VUF10661 (black bars). (D) PTX sensitivity of the recruitment of …β-arrestin2 induced by both 
CXCL11 (30 nM) and VUF10661 (3 μM) was assessed with or without treatment of the cells with 25 ng·ml-1 of PTX. 
Values are mean ± SEM, n=3 (*** P<0.001).
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VUF10661 leads to a prolonged internalisation to a similar extent as CXCL11. Moreover, as 
observed previously for CXCL11 (34, 35), prolonged exposure to VUF10661 induced CXCR3 
downregulation, as the total level of CXCR3 detected in the ELISA, using permeabilised 
samples, was significantly reduced (data not shown). Fluorescence microscopy experiments 
revealed a significant co-localisation of CXCR3 and …β-arrestin1 and -2 after agonist treatment, 
indicating a role for β-arrestins in the redistribution and internalisation of the CXCR3 receptor. 
Recently, GPCRs have been classified into two families with respect to their internalisation 
profile, namely a class of receptors that have transient interaction with (mainly) β-arrestin2, 
leading to recycling, and a class of receptors that have more sustained interaction with 
β-arrestin1 and -2, generally leading to slow recycling and/or subsequent degradation (36). 
Since CXCR3 does not seem to have a preference for either β-arrestin1 or -2, and shows 
prolonged co-localisation with both, this suggests that CXCR3 belongs to the latter class. 
Moreover, this is in agreement with the presence of serine/threonine clusters in the C-terminus 
of CXCR3. Such motifs have been linked to stabilisation of the interaction between GPCRs and 
β…-arrestin, leading to slow recycling or degradation of the GPCR (48). Previous reports have 
shown that transfection of individual β-arrestin1 or β-arrestin2 dominant negative isoforms 
had no effect on CXCR3 internalisation in HEK293 cells (34, 35). Our results suggest that the 
two isoforms exert compensatory effects and can both participate in the process of CXCR3 
receptor internalisation. 
To directly assess the CXCR3-mediated β-arrestin recruitment we used a BRET-based approach 
and show in this study for the first time that both β-arrestins are actively recruited to CXCR3 
after agonist stimulation. The agonist-induced recruitment of both arrestins is insensitive to 
treatment with PTX, showing that the classical signalling pathway of CXCR3 via G
i
 proteins 
(5) is not involved in this process. Both CXCL11 and VUF10661 promote recruitment of 
β-arrestin1 and β-arrestin2 to the CXCR3 receptor with similar potencies, suggesting that 
the relative expression levels of the β-arrestin isoforms in different cell types will determine 
the stoichiometry of coupling to CXCR3. Importantly, VUF10661 is much more efficacious 
in recruiting both β-arrestin isoforms than CXCL11 (α = 1 versus α = 0.6 for CXCL11). The 
higher efficacy of VUF10661 in the BRET-based β-arrestin recruitment assay could reflect a 
difference in the relative orientation of the two BRET fluorophores, instead of a stronger β…-
arrestin recruitment. However, using a β-arrestin2 protein complementation assay (DiscoveRx 
PathHunter”), similar results were obtained, unequivocally demonstrating that VUF10661-
induced CXCR3 activation results in a stronger recruitment of β-arrestin compared to the 
endogenous peptide CXCL11 (Scholten et al., unpublished observations). To exclude that the 
higher intrinsic activity of VUF10661 in β-arrestin recruitment compared to CXCL11 is due to 
differential desensitisation associated with full versus partial agonism instead of functional 
selectivity, we also included CXCL10 in a G protein-dependent readout (cAMP) and a G protein-
independent readout (β-arrestin recruitment). CXCL10 is not only a partial agonist in these 
cAMP experiments, but remains a partial agonist in the recruitment of β-arrestin, confirming 
that the higher efficacy for VUF10661 in this assay is most likely the first report of functional 
selectivity at the CXCR3 receptor.
One of the hallmarks of chemokine receptor signalling output is cell migration. Whereas 
this process is known to involve G
i
 proteins (see e.g. for CXCR3 (5, 6, 34)), it is becoming 
increasingly apparent that also …β-arrestins play a key role in chemokine receptor-mediated 
cell migration. Splenocytes from …β-arrestin2-/- mice are significantly impaired in their 
migratory responses towards CXCL12, the ligand for CXCR4 (49). In contrast, neutrophils from 
…β-arrestin2-/- mice display an enhanced chemotaxis towards the CXCR2 ligand CXCL1 (50), 
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suggesting a complex interplay between β-arrestins and G
i
 proteins in migratory responses. 
In the present study, we show that the small-molecule CXCR3 agonist VUF10661 induces a 
dose-dependent migration of CXCR3 transfected L1.2 cells, albeit to a significantly lower 
extent than CXCL11. The observed partial agonistic activity contrasts with the full agonistic 
activity in the G protein-dependent assays (cAMP and [35S]-GTPγS) and the higher efficacy of 
VUF10661 in the β-arrestin recruitment assay compared to CXCL11. 
Based on the data from the β…-arrestin recruitment assay, G-protein dependent signalling 
assays, the radioligand binding assays, as well as chemotaxis experiments, we propose that 
CXCL11 and VUF10661 stabilise different receptor- and/or …β-arrestin conformations leading to 
differences in functional output. Such ligand-biased signalling has recently been recognised 
as a new opportunity for GPCR drug discovery (51, 52) and might also offer interesting options 
for the therapeutic use of CXCR3 agonists. Based on studies with small-molecule agonists 
for CCR3 (53) and CCR5 (54) it has been proposed that chemokine receptor agonists able to 
induce downregulation of their corresponding receptor, but lacking significant chemotactic 
effects, can act as functional antagonists by removing the receptor from the cell surface. From 
a therapeutic point of view, pathway-biased agonists might therefore reveal new interesting 
strategies for the treatment of chemokine-associated diseases.
4.4: Materials and Methods
 Synthesis of small-molecule CXCR3 agonist and antagonists. The identification of several 
tetrahydroisoquinoline-based small-molecule non-peptide CXCR3 agonists has been reported previously by Stroke and 
coworkers (20). The synthesis of those compounds was not disclosed. Consequently, we developed a strategy for the 
synthesis of one of these compounds (designated VUF10661; Figure 1), which is outlined in the Supporting Information 
of (55) and figure S1. NBI-74330, belonging to the (aza)quinazolinone class of CXCR3 antagonists, was synthesised as 
described previously (56).
 Materials. Dulbecco’s modified Eagle’s medium and trypsin were purchased from PAA Laboratories GmbH 
(Pasching, Austria), poly-L-lysine, 2-mercaptoethanol, o-phenylenediamine, nonessential amino acids, formaldehyde, 
calcein-AM, sodium pyruvate and sodium butyrate were from Sigma-Aldrich (St. Louis, MO, USA), penicillin and 
streptomycin were obtained from Lonza (Verviers, Belgium), foetal bovine serum (FBS) was purchased from Integro B.V. 
(Dieren, The Netherlands), and RPMI 1640 medium with GlutaMAX-I and 25 mM HEPES was from Invitrogen (Paisley, 
UK). G-418 was purchased from Duchefa Biochemie (Haarlem, The Netherlands). Coelenterazine-h was obtained from 
Promega (Madison, WI, USA). [125I]-CXCL10 (2200 Ci·mmol-1), [125I]-CXCL12 (2200 Ci·mmol-1) and [35S]-GTP…γS were 
obtained from PerkinElmer Life and Analytical Sciences (Boston, MA, USA). Unlabeled chemokines were purchased 
from PeproTech (Rocky Hill, NJ, USA). 
 DNA Constructs. The cDNA of human CXCR3 inserted in pcDNA3 (3) was a gift from Prof. Dr. B. Moser 
(Cardiff University School of Medicine, Cardiff, UK). It was amplified by PCR and inserted into pcDEF
3
 (a gift from 
Dr. Langer, Robert Wood Johnson Medical School, Piscataway, NJ, USA). cDNA encoding for the Bioluminescence 
Resonance Energy Transfer (BRET)-based cyclic AMP (cAMP) biosensor was purchased from ATCC (pcDNA3.1-(L)-His-
CAMYEL #ATCC-MBA-277). The pcDNA3.1(+)-β……-arrestin1-eYFP and ……β-arrestin2-Cerulean constructs were kind gifts 
from Dr. C. Hoffmann (University of Würzburg, Würzburg, Germany). CXCR3-Rluc and ……β-arrestin2-eYFP BRET1-fusion 
constructs were generated by substituting the stopcodon of CXCR3 and β……-arrestin2 with a SpeI/NotI linker and fusing 
them in frame to Rluc and YFP, respectively. 
 Cell Culture and Transfection. HEK293T cells, and HEK293 cells stably expressing human CXCR3 (a gift 
from dr. K. Biber, University Medical Center Groningen, The Netherlands), were grown at 37°C and 5% CO2 in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% FBS, penicillin, streptomycin, and 400 μg·ml-1 G418 for 
maintaining stable expression of CXCR3. For β-arrestin recruitment experiments, HEK293T cells were transfected with 
a 1:4 ratio of cDNA coding for CXCR3-Rluc and β-arrestin1- or 2-YFP (total DNA 5 μg for every two million cells). Cells 
were transfected using linear polyethyleneimine (PEI) with a molecular weight of 25 kDa (Polysciences, Warrington, 
PA) as described previously (23). The day after transfection, cells were trypsinised, resuspended into culture medium, 
and plated in poly-L-lysine-coated white-bottom 96-well assay plates. For the cAMP biosensor assay, HEK293 cells 
stably expressing CXCR3 were transfected with 1 μg of DNA encoding for the cAMP biosensor, added up to a total of 5 
μg cDNA with empty vector.
For chemotaxis experiments, murine L1.2 cells were grown in RPMI 1640 medium with 25 mM HEPES and GlutaMAX-I, 
supplemented with 10% heat-inactivated FBS, penicillin, streptomycin, non-essential amino acids, sodium pyruvate 
and 2-mercaptoethanol. Transfection of L1.2 cells was performed with 10 μg for every 20 million cells using a Bio-Rad 
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Gene Pulser II (330V and 975 mF, Bio-Rad, Hemel Hempstead, UK). Cells were grown over night in culture medium 
supplemented with 10 mM sodium butyrate.
 Chemotaxis. Twenty-four hours after transfection, the migration of L1.2 cells towards different 
concentrations of CXCL11 and VUF10661 was determined using ChemoTx 96-well plates with 5 μM pore size (Neuro 
Probe, Inc., Gaithersburg, MD). Briefly, the plates were blocked with culture medium supplemented with 1% (w/v) BSA. 
The compound dilutions were made in culture medium with 0.1% (w/v) of BSA, and added to the wells. L1.2 cells were 
added on top of the filter for each well. The plate was then incubated for 5 hours at 37°C in a humidified chamber. 
Quantification of migrated cells was done by using calcein-AM, and measuring fluorescence at 525 nm with the Victor3 
plate reader.
 Membrane preparation and chemokine binding. Membrane preparation and competition radioligand 
bindings were performed as described previously (23). In brief, cell membrane fractions from HEK293 cells stably 
expressing CXCR3 were prepared by washing the cells twice with ice-cold PBS and centrifuging them at 1500g for 10 
min. The pellet was resuspended in ice-cold membrane buffer (15 mM Tris, pH 7.5, 1 mM EGTA, 0.3 mM EDTA, and 2 mM 
MgCl2), and homogenised using a Teflon-glass homogeniser and rotor. The membranes were subjected to two freeze-
thaw cycles using liquid nitrogen, and centrifuged at 40,000g for 25 min. The pellet was resuspended in Tris-sucrose 
buffer (20 mM Tris, 250 mM sucrose, pH 7.4) and aliquots were frozen in liquid nitrogen. For [125I]-CXCL10 and for [125I]-
CXCL11 binding, 10 and 2 μg… well-1 of membranes were used, respectively in 96-well plates. For competition binding 
experiments, membranes were incubated in binding buffer (50 mM HEPES, pH 7.4, 1 mM CaCl2, 5 mM MgCl2, 100 mM 
NaCl, and 0.5% (w/v) BSA) with approximately 70 pM [125I]-chemokine and various concentrations of displacer for 
two hours at room temperature. When saturation binding analysis was performed, the membranes were incubated for 
two hours with increasing concentrations of [125I]-chemokine in the presence or absence of VUF10661. Subsequently, 
membranes were harvested by filtration through Unifilter GF/C plates (Perkin-Elmer) presoaked with 0.5% PEI, using 
ice-cold wash buffer (50 mM HEPES, pH 7.4, 1 mM CaCl2, 5 mM MgCl2, and 500 mM NaCl). Radioactivity was measured 
using a MicroBeta scintillation counter (Perkin-Elmer).
 Whole cell binding. HEK293 cells stably expressing the CXCR3 receptor were plated at 100,000 cells… well-1 
into a 48-well assay plate (Greiner). The next day, the medium was aspirated and the cells were incubated in binding 
buffer (50 mM Hepes pH 7.4, 1 mM CaCl2, 5 mM MgCl2 and 100 mM NaCl) containing ~70 pM of [
125I]-CXCL10 or [125I]-
CXCL11 in the presence and absence of unlabeled ligands. After four hours at 4°C, the cells were washed with ice-cold 
wash buffer (50 mM Hepes pH 7.4, 1 mM CaCl2, 5 mM MgCl2 and 500 mM NaCl), lysed and bound radioactivity was 
counted in a Wallac Compugamma counter (PerkinElmer).
 [35S]-GTPγγS binding assay. For this assay, performed in 96-well plates, 5 μg… well-1 of membranes from 
HEK293 cells stably expressing CXCR3 were incubated with CXCL11 and VUF10661 in assay buffer (50 mM Hepes, 10 
mM MgCl2, 100 mM NaCl, pH 7.2) supplemented with 3 μM GDP and 500 pM of  [
35S]-GTPγ…S. When antagonism was 
investigated, the compound was added 30 min prior to the addition of [35S]-GTP…γS. The plate was incubated at room 
temperature for 1 hour before the membranes were harvested by filtration through Unifilter GF/B plates and [35S]-
GTP…γS incorporation was determined using a Microbeta scintillation counter. 
 cAMP biosensor assay. The experimental procedure for this assay has been adapted from Masri and 
coworkers (31). Twenty-four hours post-transfection, cells were trypsinised and seeded in poly-L-lysine-coated white 
96-well plates. The next day, cells were rinsed once with Hank’s Balanced Salt Solution (HBSS), and incubated with 
fresh HBSS for 30 min prior to stimulation. Next, the Renilla luciferase (Rluc) substrate coelenterazine-h was added to 
reach a final concentration of 5 μM. The non-specific phosphodiesterase inhibitor isobutylmethylxanthine was added 
simultaneously to a final concentration of 40 μM. For measuring the effects of chemokines and VUF10661 on cAMP 
levels, these ligands were added 5 min after coelenterazine-h. Forskolin was added 5 min after agonists, yielding a 
final concentration of 10 μM. When antagonistic behavior of compounds on agonist responses was investigated, the 
compounds were added 10 min before coelenterazine-h. After 5 min of incubation with forskolin the YFP emission 
(505-555 nm), as well as the Rluc emission (465-505 nm), were sequentially recorded using a Victor3 multilabel counter 
(Perkin-Elmer). The BRET signal (BRET ratio) was determined by calculating the ratio between the YFP and the Rluc 
emission.
γ βγ-arrestin recruitment BRET. Cell plating and transfection was performed as mentioned above. To assess 
β…-arrestin recruitment BRET, after 10 min of incubation with coelenterazine-h, agonists were added, and incubated 
for 10 additional minutes. In the case of experiments with antagonists, these were added simultaneously with 
coelenterazine-h. After 10 min the plate was measured on the Victor3 and BRET ratios were calculated. Net BRET 
signals were determined by subtracting the BRET ratio obtained with cells only expressing Rluc-tagged CXCR3 from 
BRET signals obtained with cells co-expressing both Rluc-tagged CXCR3 and YFP-tagged β…-arrestin. 
 CXCR3 and γβγ-arrestin translocation. HEK293 cells stably expressing CXCR3 were transfected with 1 μg 
of cDNA encoding for… β…-arrestin1- or 2-YFP added to a total of 5 μg using empty vector. After twenty-four hours, the 
cells were transferred to microscope cover slips. The next day, the cells were incubated in the presence or absence 
of CXCL11 and VUF10661 for 1 hr and subsequently acid washed three times (DMEM pH~2). Cells were fixed with 
4% formaldehyde in PBS and blocked with 3% skim milk in PBS or simultaneously blocked and permeabilised using 
3% skim milk in 0.15% Triton X-100/PBS. Then the cells were incubated consecutively with primary (anti-CXCR3 
mAb160; R&D Systems, Minneapolis, MN, USA) and secondary (anti-mouse Alexa488; Molecular Probes, Invitrogen) 
antibodies, each for 1 hour in 3% ELK in PBS or 3% ELK in 0.15% Triton X100/PBS with 3 washes of ice-cold PBS after 
incubation with each antibody. An Olympus FSX100 BioImaging Navigator was used for detection of fluorescence and 
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the capturing of images.
 Whole cell-based enzyme-linked immunosorbent assay (ELISA). Cell surface receptor expression. 
HEK293 cells stably expressing CXCR3 were trypsinised and seeded in 48-well plates. After twenty-four hours, the 
medium was refreshed with fresh medium and medium containing CXCR3 compounds was added at different time 
points. After treatment with CXCL11 or VUF10661, the cells were subjected to three sequential acid washes (DMEM 
pH~2) and fixed with 4% formaldehyde in TBS (50 mM Tris, 150 mM NaCl, pH 7.5). After blocking with 1% skim milk 
in 0.1 M NaHCO
3
 pH 8.6, cells were incubated overnight at 4ºC with anti-CXCR3 antibody in TBS containing 0.1% BSA. 
The next day, the cells were washed three times with TBS, and incubated with goat anti-mouse horseradish peroxidase-
conjugated secondary antibody (Bio-Rad Laboratories, Hercules, CA, USA). Subsequently, cells were incubated with 
substrate buffer containing 2 mM o-phenylenediamine, 35 mM citric acid, 66 mM Na2HPO4, and 0.015% H2O2 at pH 
5.6. The colouring reaction was stopped by adding 1M H2SO4, and the absorption at 490 nm was determined using a 
Powerwave X340 absorbance plate reader (BioTek).
 Data Analysis. Nonlinear regression analysis of the data and calculation of affinity values was performed 
using Prism version 4.03 (GraphPad Software Inc., San Diego, CA). The Ki values in the radioligand binding studies were 
calculated using the Cheng-Prusoff equation K
i
 = IC
50
/(1 + [radioligand]/K
d
 of radioligand) (57). For statistical analysis, 
one-way ANOVA with a bonferroni post test, included in the GraphPad Prism software, was used with a confidence 
interval of 99%. The intrinsic activity (α…) of an agonist in the functional assays was calculated by dividing its maximum 
response by that of the maximum of the particular system (58).
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4.6: Supporting information
Figure S1: Synthesis scheme for VUF10661 (9). 
Figure S2: VUF10661 washout experiment using HEK293 cells stably expressing CXCR3 receptors. The cells were pre-
treated for 1 hour with buffer (TB) or 500 nM of VUF10661 (black and gray bars). Next, indicated cells were washed 
10 times 3 min with buffer. Subsequently, 500 pM of [125I]-CXCL11 was added to all cells, in the presence (black) or 
absence (white and gray bars) of 500 nM of VUF10661 (black bars).
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5.1: Introduction
The chemokine system has gained considerable attention over the past decades from academia 
and pharmaceutical industry, due to its intimate involvement in leukocyte homeostasis and 
directing immune cells to sites of infection or inflammation (1). Inappropriate expression of 
chemokine ligands or their chemokine receptors may result in disproportionate infiltration of 
specific immune cells into (inflamed) tissues or confer chemokine sensitivity to cells, normally 
non-responsive to chemokines. Ultimately, this may lead to development of autoimmune 
diseases, chronic inflammation, or tumor growth and metastasis. 
The CXCR3 receptor is an interesting chemokine receptor, since it seems to be a key regulator 
of T-cell responses. Many diseases, including rheumatoid arthritis and transplant rejection 
involve this type of immune cells. Moreover, overexpression of CXCR3 receptor and/or its 
ligands (CXCL9, CXCL10, CXCL11) is often observed in these diseases (2). 
In view of the therapeutic potential many efforts in the past decade have been focused on 
discovery of small-molecule antagonists leading to the report of a multitude of different 
chemotypes (3). Initially, 8-azaquinazolinone compounds from Amgen (AMG487) and 
Neurocrine Biosciences (NBI-74330) have been shown to bind CXCR3 with affinities in the 
nanomolar range (4-6), and are quite effective in animal models of disease (7, 8).  AMG487 was 
even assessed in clinical trials for treatment of psoriasis, but was discontinued after phase 
IIa (9). Recently, a piperazinyl-piperidine class of ligands with high affinity for the CXCR3 
receptor has been disclosed by Schering Plough (now Merck-Sharp & Dohme) (10). Reports 
on the SAR of this compound series have appeared shortly after that (11, 12). In addition, this 
compound series is reported to be effective in rodent models of CXCR3-associated disease, 
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Figure 1: Chemical structures of CXCR3 antagonists (*) and agonist (#), used in this study and a helical wheel repre-
sentation of the transmembrane domains of CXCR3 with TM site 1 (TMS1) and TM site 2 (TMS2) generally involved in 
binding of small ligands to chemokine receptors. Note that the indicated nitrogens of VUF11211 and VUF10661 are 
likely to be charged at physiological pH.
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including transplant rejection and rheumatoid arthritis (13). Small-molecule agonists for 
CXCR3 also have been reported, and have been recently characterized, including VUF10661 
(tetrahydroisoquinoline class) and two other molecules (tetrahydroisoquinoline and 
piperidinyl diazepanone class) (14-16). Although less obvious than for CXCR3 antagonists, 
therapeutic potential for CXCR3 agonists is starting to emerge (17).
The endogenous ligands for chemokine receptors, known as the ‘chemokines’ (chemotactic 
cytokines), are peptides of approximately 10 kDa, and are about 10-50 fold larger than 
the average small molecule that binds these receptors. Nonetheless, many of these small 
ligands, portrayed in a recent review (18) from our laboratory, are able to inhibit chemokine-
induced responses and/or the binding of these chemokines with nanomolar potencies. 
Intuitively, such size differences would rule out simple competitive binding by the small 
molecule, and rather suggest allosteric effects by binding to a distinct site. In general, the 
interaction of chemokines with their receptors can be described by a two-step model, where 
the chemokine first binds to the N-terminus of the receptor, and subsequently the N-terminus 
of the chemokine is positioned such that it interacts with the extracellular loops (ELs) and 
transmembrane (TM) domains of the receptor. The lack of structural data on chemokines 
binding to their respective receptors hampers our understanding of the precise mechanisms 
by which small molecules exert their effects observed in pharmacological experiments. 
Fortunately, structural information on chemokine receptors has started to emerge with the 
recent release of chemokine receptor CXCR4 crystal structures (19), which opens up new 
possibilities for structure-based drug design on the chemokine receptor family. One crystal 
structure has been elucidated with a large cyclic peptide CVX15 and several crystal structures 
have been elucidated with the small- molecule antagonist IT1t (19). In general, three pockets 
are distinguished in GPCRs, with two in the transmembrane domains, including the minor 
pocket or transmembrane site 1 (TMS1) lined by TM helices 1, and 2, and the major pocket 
also referred to as transmembrane site 2 (TMS2) delimited by TM helices 4, 5, and 6 (see figure 
2A). Residues in TM helices 3 and 7 constitute the interface between both pockets, pointing 
either to one or the other pocket. Furthermore, a third pocket was recently discovered, lining 
the intracellular surface of the GPCR (20, 21). The small-molecules 1T1t was found to bind in 
TMS1, whereas the CVX-15 peptide interacts with residues in TMS2, showing that ligands for 
the same receptor can bind to different pockets in TM domains of chemokine receptors.
Despite the interest in small-molecule ligands for CXCR3, no information is available on 
their interaction with the CXCR3 receptor on the molecular level, as whether they bind to 
either TMS1, or TMS2 or both. This information might facilitate the rational optimization of 
CXCR3 ligands in the drug development process. As such, we aimed to elucidate the binding 
mode of (S)-5-chloro-6-(4-(1-(4-chlorobenzyl)piperidin-4-yl)-3-ethylpiperazin-1-yl)-N-
ethylnicotinamide, a ligand from the piperazinyl-piperidine class (synthesized in-house (43) 
and named VUF11211; figure 1B), the azaquinazolinone class (NBI-74330; figure 1B), and the 
tetrahydroisoquinoline agonist VUF10661 (figure 1B) (15), using site-directed mutagenesis 
(SDM) studies complemented with in silico modeling of the CXCR3 receptor.
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5.2: Results
To dissect the binding modes of ligands for CXCR3, we considered the homology between 
different chemokine receptors, focusing on residues that already been reported to be involved 
in binding of small molecules. In figure 2 an alignment of CC and CXC chemokine receptors is 
shown, with residues highlighted when ligand binding is affected upon mutation. 
5.2.1: Negatively charged ligand anchors
In general, small-molecule ligands for chemokine receptors are characterized by a positively 
charged quaternary ammonium and aromatic groups around it (24). This positive charge 
often contributes significantly to the affinity of the ligand, as observed for a biaryl and 
piperazinyl-piperidine class of CXCR3 ligands (11, 25). In addition, VUF11211 and VUF10661 
are most likely charged at physiological pH at the piperidine nitrogen, and the lysine residue, 
respectively (figure 1). As can be deduced from figure 2 a negatively charged glutamatic acid 
at position 7.39 is highly conserved in the chemokine receptor family and is often found to 
be the ionic anchor for a positive charge in chemokine receptor ligands. However, CXCR3 
contains a serine residue at this position, so other potential anchors should be considered. 
Closer inspection of the chemokine receptor alignment and the detailed information from the 
recently solved CXCR4 co-crystal structures, shows that other negatively charged residues can 
also be involved in anchoring chemokine receptor ligands, as determined for small molecule 
1T1t and peptide CVX-15 binding to i.e. aspartates D2.63, D4.60, and D6.58 at CXCR4 (19). 
These residues are also present in CXCR3. To identify the negatively charged residues in 
Figure 2: Alignment of binding pocket residues of chemokine receptors. Residue numbers are in Ballesteros-Weinstein 
notation. Amino acids residing in the minor pocket (TMS1), major pocket (TMS2) or interface, are indicated in blue, 
orange, or gray, respectively. Residues are highlighted in their respective color per receptor when mutation of that par-
ticular residue is reported to affect ligand affinity or antagonism. For CXCR4 interactions of small molecule 1T1t within 
the crystal structure are given as black squares with pink bold text, interactions with peptide CVX15 are shown with 
green bold text, whereas residues that interact with both IT1t and CVX15 are indicated as bold black. Data is obtained 
from primary literature, overviewed in two recent reviews (22, 23). Note that no data is included on ligands like metal 
chelators requiring modification of receptors to bind at all.
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CXCR3 that act as partners for ionic interaction with e.g. the positively charged VUF11211 
and VUF10661 we started this study by mutating 11 negatively charged aspartate or glutamic 
acid residues, eight residing in the TM domains, one in the N-terminus close to TM1, and two 
in extracellular loop (EL) 2. All these residues were mutated to asparagine, thereby preventing 
any ionic interaction  (see table 1). 
Human embryonic kidney (HEK293T) cells were transiently transfected with DNA coding 
for the CXCR3 wildtype (WT) or mutant receptors. Next, protein expression levels were 
determined for each mutant using a whole-cell based ELISA (table 1). The majority of the 
mutants displayed expression between 68 and 121% of WT CXCR3 (table 1). In contrast, 
one mutant, D892.40N, was hardly expressed at all (4% of WT), prohibiting its use in further 
studies. Membranes were prepared from the transfected cells (see materials and methods), 
and used for competition binding experiments using [125I]-CXCL11 as the radioligand (table 
1). The affinity of CXCL11 for all mutants was determined to investigate the effect of the 
introduced mutations on CXCL11 binding. The affinity of CXCL11 was hardly affected (max 
only ±2 fold) by any of these mutations as shown in table 1 (and figure 3A), with D2826.62N as 
the exception. Despite its apparent good expression, hardly any [125I]-CXCL11 binding could 
be detected under the experimental conditions, impeding further studies with this mutant. 
Next, the potencies of VUF11211, NBI-74330, and VUF10661 to displace [125I]-CXCL11 from 
CXCR3 WT and mutants were determined. Only one mutant, D1864.60N, resulted in a 10-fold 
decrease in affinity for VUF11211 (pIC
50
 from 7.8 to 6.8, table 1; figure 3B), where the other 
aspartic- and glutamic acid to asparagine mutations hardly affected the potency of VUF11211 
to displace [125I]-CXCL11 from the mutant CXCR3 proteins (table 1). Surprisingly, mutation of 
aspartic acid D1122.63 reduced potency of NBI-74330 to displace [125I]-CXCL11 binding by more 
than 10-fold compared to WT (pIC
50
 7.2 and 6.1 respectively, table 1; figure 3C) despite the 
absence of a positive charge in the compound. Finally, only the E196N mutation caused a mild 
reduction (5 fold) in the potency of the agonist VUF10661 to displace radiolabeled CXCL11, 
despite the report of involvement of both D195 and E196 in functional responses and binding 
of a VUF10661 analogue (14).
5.2.2: Aromatic cages in CXCR3 
Next to ionic interactions, many chemokine receptors engage in interactions with hydrophobic 
aromatic amino acids present in the TM binding cavities of this receptor class. Figure 2 shows 
that many ligands appear to interact with such residues, including the conserved Y1.39 
and W2.60 residues in TMS1, Y/F3.32 and F3.36 in the interface, and W6.48 and Y/F6.51 
in TMS2 (18, 23). These conserved residues form the so-called ‘aromatic cages’ within the 
transmembrane region in which hydrophobic and aromatic moieties are positioned upon 
binding to various GPCRs, such as chemokine receptors (26). The aromatic phenylalanine 
F1313.32 and F1353.36 and tyrosine residues Y601.39, Y2716.51, and Y3087.43 were mutated to 
alanines in order to investigate involvement of aromatic stacking interactions with the ligands 
at the CXCR3 receptor. All the mutants showed expressions ranging from 41% to 106% of WT 
CXCR3 (table 2). Moreover, these phenylalanine and tyrosine to alanine mutations had no 
appreciable effect on the affinity of [125I]-CXCL11. The Y601.39A and F1353.36A mutations led 
to 10-fold and 300-fold decrease in affinity for VUF10661, respectively, while VUF11211 or 
NBI-74330 affinities were unaffected (table 2; figure 3D). Conversely, mutation of Y2716.51 
to alanine resulted in a reduction in affinity of 7- and 10-fold for NBI-74330 and VUF11211, 
respectively. In addition, al l three small ligands displayed lower affinity (8- to 30-fold) at 
F1313.32A and Y3087.43A mutants (table 2; figure 3). Residue F1313.32 was also mutated to a 
histidine to investigate the behavior of the ligands towards a difference in aromaticity. This 
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mutant was comparable to WT with respect to [125I]-CXCL11 binding affinity, and only resulted 
in very minor decreases in affinity for VUF11211 and NBI-74330, whereas for VUF10661 this 
decrease was significant (8-fold), yet lower than the 32-fold observed for the mutant with an 
alanine at this position.
In chemokine receptors, W1092.60 is a highly conserved tryptophan residue (figure 2) close to 
the TxP motif (27), indicating that it is important for chemokine receptor stability and function, 
and W2686.48 has been hypothesized as important for receptor function for numerous GPCRs 
(28, 29). Several chemokine receptors feature a glutamine residue in these positions which is 
similar in size to a tryptophan, yet lacks aromaticity (figure 2). Therefore, W1092.60 and W2686.48 
were selected for mutation to a glutamine. These mutant proteins were expressed at 81% and 
60% compared to WT levels, respectively. Moreover, affinity of [125I]-CXCL11 was unaltered at 
these mutants. The W2686.48Q mutation only lowered the binding affinity of VUF11211 (6-fold; 
pIC
50
 from 7.8 to 7.0; table 2), but the W1092.60 residue appears to be very important for all 
three ligands, as its mutation to glutamine led to a decrease in [125I]-CXCL11 displacement 
potency between 30- and 630-fold (table 2; figure 3).
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Figure 3: [125I]-CXCL11 binding to membranes prepared from HEK293T cells transiently transfected with WT or se-
lected CXCR3 receptor mutants. (A) [125I]-CXCL11 homologous binding on WT (filled circles), D1122.63N (open upward 
triangles), D1864.60N (filled diamonds), F1313.32A (filled downward triangles), W1092.60Q (open circles), and Y3087.43A 
(filled upward triangles). (B) [125I]-CXCL11 displacement by VUF11211 from CXCR3 WT (filled circles), D1864.60N (open 
upward triangles), F1313.32A (filled downward triangles), Y3087.43A (filled downward triangles), and W1092.60Q (open 
circles) by VUF11211 ligand. (C) [125I]-CXCL11 displacement by NBI-74330 from CXCR3 WT (filled circles), D1122.63N 
(open upward triangles), F1313.32A (filled downward triangles), Y3087.43A (filled downward triangles), and W1092.60Q 
(open circles) by NBI-74330 ligand. (D) [125I]-CXCL11 displacement by VUF10661 from CXCR3 WT (filled circles), 
Y601.39F (open upward triangles), Y3087.43F (filled diamonds), W1092.60Q (open circles), and F1353.36A (open downward 
triangles). Graphs represent grouped data from three or more experiments.
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5.2.3: Hydrogen bonding 
Next to aromatic stacking, also opportunities exist for the ligands to engage in hydrogen 
bonding with residues in the TM domains. As such, the serine (S3017.36 and S3047.39) and 
tyrosine residues (Y601.39 and Y3087.43) were mutated to non-hydroxylated amino acids (alanine 
and phenylalanine, respectively) to investigate involvement of potential hydrogen bonding 
with the ligands. All mutants showed expressions similar to WT (table 2). None of these 
mutations had a significant effect on potency of both NBI-74330 and VUF11211 to displace 
[125I]-CXCL11, while the affinity of CXCL11 and VUF10661 decreased 5- and 32-fold at the 
S3047.39A mutant, respectively (table 2). Moreover, Y601.39A led to a 13-fold decrease in affinity 
for VUF10661, suggesting hydrogen bonding.
The lack of significant effects on binding of NBI-74330 or VUF11211 by testing individual 
mutations might be the result of possible hydrogen bonding networks between CXCR3 and 
the ligands. As a consequence, other residues in the vicinity might compensate for the 
loss of a single hydrogen bond interaction. Therefore, a triple mutant of residues in close 
proximity to each other in our CXCR3 homology model, namely Y601.39F/S3047.39A/Y3087.43F, 
was constructed. Interestingly, this triple mutation had no effect on [125I]-CXCL11 binding, 
whereas it caused a 10-fold decrease in potency of VUF11211 to displace the radioligand, 
suggestive of a hydrogen-bonding network for this small compound. However, in the case of 
NBI-74330 this decrease was only three fold.  Remarkably, only a four-fold decrease in affinity 
was observed for VUF10661 at this triple mutant, while the individual mutations each showed 
12- to 32-fold lower affinity.
5.2.4: Additional CXCR3 mutations
For several residues, additional mutants were constructed to investigate specific interactions. 
G1283.29 is a variable residue among chemokine receptors indicating a location potentially 
important for selectivity between chemokine receptors. In addition, CXCR4 contains a 
histidine residue at this position, important for interaction with both 1T1t and CVX-15 ligands. 
Moreover, introduction of a histidine at this position (G1283.29H) in CXCR3 anchored small 
metal chelators to the receptor (30). As histidine is greater in size than glycine, the residue at 
this position was mutated to a histidine (G1283.29H) in analogy with CXCR4, to investigate the 
allowed space around this residue. This mutant was well expressed in HEK293T cells (80% of 
WT). Interestingly, radioligand displacement potencies of CXCL11, VUF10661, NBI74330, and 
VUF11211 were all affected by this mutation, by 5, 16, 100, or 800 fold, respectively (table 2), 
indicating that the larger histidine likely introduces a steric clash within the binding pocket of 
CXCR3 affecting the binding of all the ligands under investigation.
Furthermore, residue S3047.39 was given special attention due to its analogous residue E7.39 
which is relatively conserved in the chemokine receptor family and often involved in binding 
of small molecules (figure 2). Moreover, in CXCR4 the E7.39 interacts with the small-molecule 
antagonist 1T1t compound in CXCR4 co-crystallized with this compound. It was mutated 
to a glutamic acid residue (S3047.39E) to investigate the influence of a larger polar residue 
in the center of the protein cavity and also a leucine mutation (S3047.39L) was included to 
determine whether this influence is actually due to the polarity or the size of the residue. Both 
mutants were expressed to a similar extent as WT, and also bind CXCL11 with similar affinity. 
The S3047.39L mutation resulted in decreased potency to displace the radioligand by 8-, or 
20-fold for VUF10661, or NBI-74330 and VUF11211, respectively (table 2). The presence of 
the glutamatic acid at the same position was tolerated for VUF11211, but not for NBI-74330 
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and VUF10661, for which losses in affinity of 80, or more than 100 fold, respectively, were 
observed.
Finally, in analogy with CXCR4 (figure 2), residue K3007.35 was mutated to the apolar, non-
aromatic isoleucine to see the effect on binding of the ligands. While expressed 94% of WT, 
and CXCL11 having comparable affinity for this mutant, no significant effects on binding of 
any of the ligands were detected. 
5.3: Discussion
Based on alignment of TM residues of the chemokine receptor family and information on 
binding of small molecules to these receptors (figure 2), multiple mutations within the CXCR3 
receptor were generated, leading to differential effects on the binding of the different CXCR3 
ligands CXCL11, NBI-74330, VUF11211, and VUF10661. A summary of all the observed effects 
of the different mutations on the binding of the small ligands is presented in figure 4 in helical 
wheel diagrams (figure 4B, D, and F). 
To further rationalize the observed effects of the binding of the small molecules a homology 
model for CXCR3 was constructed based on the crystal structures of CXCR4 co-crystallized 
with ligand 1T1t in the minor pocket (TMS1, TMs 1, 2, 3 and 7) and the peptide CVX15 in the 
major pocket (TMS2, TMs 3-7) (19, 26). The obtained SDM data was used to dock the ligands 
into the homology model of CXCR3, and the models were fine-tuned by using SAR data 
available in the literature (figure 4).
Region Construct Expression CXCL11 VUF11211 NBI-74330 VUF10661
CXCR3 (...…) % WT± SEM pKd ± SEM pIC50 ± SEM pIC50 ± SEM pIC50 ± SEM
WT 100 ± 0 9.7 ± 0.1 7.8 ± 0.0 7.2 ± 0.1 6.0 ± 0.1
N-term. D46N 100 ± 3 9.3 ± 0.1 7.8 ± 0.1 7.2 ± 0.1 6.0 ± 0.1
TM1 D521.31N 121 ± 8 9.6 ± 0.0 8.1 ± 0.1 7.5 ± 0.2 6.9 ± 0.0
TM2
D892.40N 4 ± 1 N.D. N.D. N.D. N.D.
D1122.63N 96 ± 6 9.6 ± 0.1 7.8 ± 0.1 6.1 ± 0.1* 5.5 ± 0.1
TM4 D1864.60N 68 ± 5 9.8 ± 0.0 6.8 ± 0.1* 7.7 ± 0.1 5.7 ± 0.0
EL2
D195N 94 ± 8 9.8 ± 0.1 8.0 ± 0.3 7.1 ± 0.1 6.2 ± 0.1
E196N 93 ± 13 9.9 ± 0.1 7.7 ± 0.2 6.9 ± 0.2 5.3 ± 0.1#
TM6
D2786.58N 84 ± 7 9.6 ± 0.1 7.9 ± 0.1 7.7 ± 0.1 6.2 ± 0.1
D2826.62N 68 ± 4 N.D. N.D. N.D. N.D.
TM7
E2937.28N 88 ± 8 9.3 ± 0.2 7.9 ± 0.1 7.4 ± 0.1 6.2 ± 0.1
D2977.32N 110 ± 8 9.6 ± 0.2 8.1 ± 0.0 7.6 ± 0.1 6.9 ± 0.1
Table 1: Mutants of negatively charged residues in CXCR3. Overview of both total receptor expression levels deter-
mined using whole cell-based ELISA, and affinity data for the three compounds. The latter was generated by perform-
ing [125I]-CXCL11 radioligand displacement binding studies on membranes prepared from HEK293T cells transiently 
expressing CXCR3 WT or mutants. Shown values are averages ± SEM from at least three individual experiments. N.D. 
the affinity could not be determined due to lack of specific [125I]-CXCL11 binding (in the case of D892.40N the CXCR3 
expression was too low). “*”pIC
50
 value decreases with 10 fold or more. “#” pIC
50
 value decreases between 5 to 10 fold.
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5.3.1: Binding hypothesis of VUF11211
We hypothesize that the CXCR3 residue D1864.60 serves as the anchor for the positive charge 
of VUF11211, as a 10-fold potency drop was observed at the CXCR3 mutant D1864.60N (table 
1; figure 4B). SAR studies with the piperazinyl-piperidine compound class, have previously 
highlighted the importance of the basicity of the piperidine ring, suggesting that the basic 
piperidine nitrogen interacts with D1864.60 (figure 4A) (11). Rigidification of the benzyl moiety 
either by ring closure or intramolecular hydrogen bonding at the cost of basicity could maintain 
ligand potency, indicating the importance of directionality for the chlorobenzyl moiety (11, 
31). In the proposed binding mode, the chlorobenzyl moiety resides in a small space between 
TM4 and TM5 (figure 4A). The importance of the S-ethyl moiety on the piperazine core was 
proven by various substitutions that showed a preference for a small apolar group over 10-fold 
or more compared to larger or polar moieties (11, 12). This implies a restriction for rotation 
of the core rings with apparently little space around the ethyl moiety. This is exemplified by 
the closeness of TM6 to the piperazine moiety where the W2686.48Q and Y2716.51A mutants 
decrease affinity 7-fold and 10-fold, respectively, emphasizing the size and shape limitation of 
the pocket by TM6. The potency drops at mutants W1092.60Q (>600-fold, aromatic interaction), 
Region Construct Expression CXCL11 VUF11211 NBI-74330 VUF10661
CXCR3 (…...) % WT±SEM pKd ± SEM pIC50 ± SEM pIC50 ± SEM pIC50 ± SEM
WT 100 ± 0 9.7 ± 0.1 7.8 ± 0.0 7.2 ± 0.1 6.0 ± 0.1
TM1
Y601.39A 75 ± 7 9.8 ± 0.0 7.5 ± 0.2 6.9 ± 0.1 5.0 ± 0.2*
Y601.39F 81 ± 9 9.5 ± 0.2 7.5 ± 0.1 7.3 ± 0.1 4.9 ± 0.1*
TM2 W1092.60Q 81 ± 6 9.9 ± 0.1 ≤5.0* ≤4.5* ≤4.5*
TM3
G1283.29H 80 ± 4 9.0 ± 0.1# 4.9 ± 0.4* 5.2 ± 0.0* 4.8 ± 0.1*
F1313.32A 74 ± 4 9.6 ± 0.2 6.5 ± 0.1* 6.3 ± 0.0* 4.5 ± 0.1*
F1313.32H 55 ± 8 9.6 ± 0.1 7.2 ± 0.2 7.0 ± 0.1 5.1 ± 0.1#
F1353.36A 106 ± 7 9.4 ± 0.1 7.5 ± 0.0 7.5 ± 0.1 ≤4.5*
TM6
W2686.48Q 60 ± 4 9.8 ± 0.1 7.0 ± 0.1# 7.4 ± 0.1 5.6 ± 0.1
Y2716.51A 41 ± 5 9.6 ± 0.1 6.8 ± 0.1* 6.4 ± 0.1# 5.7 ± 0.3
TM7
K3007.35I 94 ± 7 9.3 ± 0.1 7.7 ± 0.0 7.0 ± 0.1 5.5 ± 0.1
S3017.36A 96 ± 1 9.2 ± 0.1 8.1 ± 0.1 6.9 ± 0.2 5.8 ± 0.1
S3047.39A 111 ± 2 9.0 ± 0.1# 7.7 ± 0.1 7.3 ± 0.1 ≤4.5*
S3047.39E 91 ± 7 9.6 ± 0.1 7.6 ± 0.2 5.3 ± 0.4* ≤4.0*
S3047.39L 95 ± 7 9.5 ± 0.1 6.5 ± 0.1* 5.9 ± 0.1* 5.1 ± 0.0#
Y3087.43A 75 ± 11 9.5 ± 0.1 6.9 ± 0.2# 5.7 ± 0.1* 5.0 ± 0.1*
Y3087.43F 95 ± 5 9.3 ± 0.1 7.3 ± 0.1 6.7 ± 0.1 4.9 ± 0.1*
Combi
Y601.39F/
S3047.39A/
Y3087.43F
96 ± 2 9.5 ± 0.0 6.8 ± 0.1* 6.7 ± 0.1 5.4 ± 0.2#
Table 2: Mutants of aromatic and nucleophilic residues. Overview of both total receptor expression determined using 
whole cell-based ELISA, and affinity data for the three compounds. pK
d
 and pIC
50
 values were obtained by performing 
[125I]-CXCL11 radioligand displacement binding studies on membranes prepared from HEK293T cells transiently ex-
pressing CXCR3 WT or mutants. Shown values are averages ± SEM from at least three individual experiments. “*”pIC
50 
value decreases with 10 fold or more. “#” pIC
50
 or pK
d
 values decrease between 5 to 10 fold.
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Figure 4:  Homology models of CXCR3 with the three ligands VUF11211 (A), NBI-74330 (C), and VUF10661 (E). The 
ligands are shown in green, and the TM helices in yellow. Side chains of proposed interacting residues are shown in 
gray. B, D and F. Helical wheel diagrams showing a top view of the TM domains of CXCR3 with effects of mutations 
highlighted for (B) VUF1121, (D) NBI-74330, and (F) VUF10661. Residues that show a 10 fold or more decrease in af-
finity upon mutation are indicated in red, and mutations that result in a decrease in affinity between 5 and 10 fold are 
indicated in yellow. Residues that give a significant decrease (10 fold or more) in affinity when mutated together are 
shown in blue. Other residues that were mutated but did not give a significant change in affinity are colored green.
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G1283.29H (±800-fold, space), and F1313.32A (20-fold, aromatic interaction) portray the specific 
fit of pyridyl moiety in the binding pocket of CXCR3 (figure 4A,B). Finally, modification of the 
amide moiety by removal or repositioning of the nitrogen atom indicated a role for hydrogen 
bonding of the nitrogen atom (±10-fold difference in affinity) (11, 12). Removal of the hydroxyl 
moiety from the residues Y601.39, S3047.39 or Y3087.43 showed that none of them specifically 
formed an interaction with the amide moiety of VUF11211, while Y601.39A barely reduced 
affinity by 2-fold. Only when the triple mutation (Y601.39F/S3047.39A/Y3087.43F) showed a 10-
fold reduction in affinity, it became clear that at least these three residues that are in close 
proximity to VUF11211 in our binding model, might form a hydrogen-bonding network within 
the CXCR3 binding pocket (figure 4A). Apparently, these residues are able to compensate for 
the removal of the hydrogen-bonding capabilities of a nearby residue, thereby obscuring the 
results from proper interpretation. Hydrogen bonding is also indicated by further mutation of 
S3047.39 to glutamic acid or leucine. The glutamic acid residue shows that the negative polarity 
still forms the hydrophilic interaction with the amide moiety. However, the introduction of 
large hydrophobicity with S3047.39L reduces affinity by 20-fold.
5.3.2: Binding hypothesis of NBI-74330
Since NBI-74330 does not possess any positively charged atoms, or any hydrogen bond donor 
atoms, the reduction of affinity observed at D1122.63N is remarkable (table 1; figure 3C). 
Investigation of literature SAR shows that addition of nitrogen atoms to the quinazolinone 
moiety proves the importance of the positive polarity on the 7-position of the ring (5, 32, 33). 
As such, we propose that the polar hydrogen atom on the quinazolinone moiety might act as a 
polar anchor to D1122.63 and form a hydrogen bond in a similar fashion as is known to occur for 
hydrogen atoms on pyridine rings (34) (figure 4C). This positioning places the quinazolinone 
ring stacking with W1092.60, which is corroborated by the SDM data revealing a more than 500-
fold reduction in affinity of NBI-74330 at the W1092.60Q mutant. The ethoxy-phenyl moiety is 
located close to TM3, which is confirmed by the introduction of the larger histidine at position 
G1283.29, resulting in a 100-fold reduction of NBI-74330 affinity, likely due to a steric clash in 
the mutant receptor (figure 4C). 
Storelli et al. have shown that the electronegativity of the trifluoromethyl moiety is also an 
important determinant for ligand potency (more than 100-fold better over unsubstituted 
benzyl) (33, 35). Polar aromatic interactions between CXCR3 and NBI-74330 are identified by 
Y1313.32A, Y2716.51A and Y3087.43A, reducing affinity by 10-fold, 6-fold and 30-fold, respectively 
(table 2; figure 4C,D). Substitution of the serine at position 3047.39 by a glutamic acid showed 
a large reduction in potency (80-fold), which is mainly caused by the increased hydrophobicity 
(20-fold reduction by S3047.39L). Finally, replacement of the pyridine ring of NBI-74330 was 
shown to be allowed in the case of aromatic, polar and basic moieties, indicating a varying 
number of tolerated groups at this position (33, 35). This could possibly orient the pyridine 
moiety towards residues in TM7 although a hypothesized interaction with K3007.35 could not 
be substantiated and residues in this area, involved in the interaction with NBI-74330, remain 
to be elucidated.
5.3.3: Binding hypothesis of VUF10661 
For VUF10661, little SAR data can be extracted from literature since only one close analogue, 
and a piperidinyl diazepanone agonist sharing some similarities with VUF10661, are currently 
known (16). A SDM study on these two other agonists has been performed by Nedjai et al., 
which showed that receptor activity and to binding, to some extent, was affected by mutation 
of D1122.63, D195, and E196 to asparagines, highlighting potential interaction partners for the 
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Figure 5: (A) side-view of the CXCR4 crystal structure with the binding locations of the small ligand 1T1t in the minor 
pocket (orange) and the peptide CVX-15 in the major pocket (green). (B) side-view of CXCR3 with the binding modes 
for VUF11211 bridging both subpockets (green), VUF10661 in the minor subpocket (TMS1) and touching extracellular 
loop 2 (orange) and NBI-74330 in the minor pocket (TMS1; magenta).
A B
A B
Figure 6: (A) Docking of the proximal part of CXCL11 (FPFMK) into the CXCR3 receptor. (B) docking of VUF10661 in 
CXCR3. For the CXCL11 N-terminus similar interactions as for VUF10661 are observed, suggesting that this might be 
the part of the receptor that is involved in CXCR3 activation. 
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basic nitrogen atom of these compounds (14). Since this coincides with the 5-fold decrease in 
potency for our E196N mutant, this suggests that this is the anchor point for VUF10661 in the 
CXCR3 pocket (figure 4E). In contrast, D1122.63 does not seem to be involved in the binding of 
VUF10661, in contrast to the other analogues, which might be due to differences in chemical 
structure and hence a different binding mode. 
All mutations on the three residues Y601.39F, S3047.39A and Y3087.43F show clearly that these 
amino acids are involved in hydrogen-bonding to VUF10661 (figure 4E,F). Considering that 
VUF10661 is a peptido-mimetic compound with few hydrophilic ‘side chains’, it seems most 
plausible that the backbone carbonyl moieties make these interactions with the protein. This 
is corroborated by the S3047.39E mutation, which portrays an electrostatic clash between the 
negatively charged side chain of the glutamic acid residue and the electronegative carbonyl 
moieties of VUF10661. Remarkably, the triple mutation Y1.39F/S7.39A/Y7.43F only led to a 
four-fold drop in affinity for VUF10661 instead of the expected additive effect of combining 
individual mutations Y1.39F (12-fold decrease), S7.39A (32-fold decrease), and Y7.43F (12-
fold decrease). It is possible that by the introduction of extra space in this CXCR3 mutant, 
VUF10661 adopts a binding mode distinct from those at the individual mutants, resulting in 
partial compensation for the expected loss in affinity.
Furthermore, the mutations W1092.60Q, F1313.32A/H and F1353.36A show that these residues 
form aromatic interactions with the VUF10661 aromatic ‘side chains’ (Figure 4E,F). As for 
VUF11211 and NBI-74330, G1283.29 is found to influence the shape of the CXCR3 binding 
pocket, as the introduced histidine gives rise to steric hindrance of VUF10661 binding to 
CXCR3 G1283.29H (16-fold drop in affinity). 
5.3.4: Concluding remarks 
In this study we report for the first time the molecular details of the binding of two high affinity 
CXCR3 antagonists with distinct chemotypes, and one small-molecule agonist with moderate 
affinity. Altogether, the data point at the TM region as the location for the binding of small-
molecule CXCR3 ligands. Interestingly, and similar to CXCR2 and CXCR4, these ligands bind 
to different pockets in the TM domains of CXCR3. In this report, we provide further evidence 
on the molecular interactions of the small ligands with CXCR3. These data suggest that NBI-
74330, VUF11211, and VUF10661 are likely allosteric binders to CXCR3, as the vast majority of 
the mutations did not influence CXCL11 binding to CXCR3 receptors. More specifically, in our 
homology model of CXCR3, NBI-74330 binds to residues like D1122.63, W1092.60, F1313.32, and 
Y3087.43 in the minor pocket (TMS1; figure 5B), as also observed for the IT1t small-molecule 
antagonist co-crystallized with the CXCR4 receptor (19) (figure 5A: orange, versus figure 
5B: magenta), while VUF11211, with its elongated shape, traverses both TMS1 and TMS2, 
interacting with residues including W1092.60, F1313.32, D1864.60, and Y2716.51. An example of 
a ligand that also binds to TMS2 is the CVX-15 peptide in CXCR4, as determined with X-ray 
crystallography (19), shown in figure 5A (green). The relatively large CVX-15 peptide stretches 
up to the extracellular loops, while VUF11211 seems to bind in a more horizontal fashion 
and in both pockets (figure 5B: green). As described in this chapter, the available SAR data 
published by others (11, 12, 31) was in good agreement with our mutation and modeling data, 
and could be used to fine-tune the binding mode of the ligands. 
The agonist VUF10661 also seems to bind in TMS1, but more towards EL2, interacting 
with TMS1 residues Y601.39, W1092.60, F1353.36, S3047.39, and Y3087.43, and EL2 residue E196. 
Indeed, Nedjai and colleagues have shown recently that EL2 of CXCR3 is important for L1.2 
cell migration elicited by and binding of an analogue of VUF10661 (14). Interestingly, the 
proximal part of the N-terminus of CXCL11 (FPFMK) showed a comparable docking in CXCR3 
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as VUF10661 (figure 6A vs 6B), with similar interactions. The results from the SDM study 
only show a 5-fold decrease in affinity for the G1283.29H mutant, where most mutations did 
not affect CXCL11 binding at all. However, it is known that this N-terminal part of CXCL11 is 
mainly involved in receptor activation, and only to a limited extent in receptor binding (36-
38), which might explain why not many mutations affected CXCL11 binding. In an earlier 
publication (chapter 5) we showed that VUF10661 is a ligand biased towards …β-arrestin 
recruitment, acting as a superagonist, while triggering G protein signaling with efficacy 
comparable to CXCL11 (15). It has been reported that residues involved in chemokine receptor 
activation reside in TM2 and TM3 (e.g. W2.60; F/Y3.32) (39, 40), as mutations of some residues, 
including T2.56P and N3.35A for CXCR3, have led to constitutively active receptors (chapter 
3). Moreover, mutation of residue P2.58 in CCR5 resulted in complete abrogation of receptor 
signaling, while ligand affinity was only affected to a limited extent (40). Alternatively, residue 
P2.60 in the AT1 receptor abolished the G
q
 signaling mediated by the ligand angiotensin II, 
while ERK phosphorylation was unaffected, suggesting that this region might be involved in 
governing ligand bias (41). Since both VUF10661, and possibly the N-terminus of CXCL11, 
seem to interact with CXCR3 in this region, it might be speculated that this part of the receptor 
is indeed responsible for receptor activation, and slight differences in relative binding modes 
between the two ligands might result in the observed differences in functional properties 
(functional selectivity). To validate this hypothesis, a SDM approach complemented with 
functional assay(s) should be considered for future studies. At the same time the question 
arises whether the small CXCR3 molecules behave solely allosteric, as the possibility of 
overlapping interactions with the N-terminus of CXCL11 highlights a potential competitive 
component in the mechanism of action of these small molecules.
Altogether, our studies combined in silico-guided SDM validated with experimental SAR 
data for NBI-74330 and VUF11211, resulting in binding models for relevant CXCR3 small-
molecules. In all, the fundamental knowledge on ligand interactions with the CXCR3 receptor 
fuels the rational design and optimization of these ligands in the future.
5.4: Materials and methods
 Materials. Dulbecco’s modified Eagle’s medium and trypsin were purchased from PAA Laboratories GmbH 
(Pasching, Austria), penicillin and streptomycin were obtained from Lonza (Verviers, Belgium), foetal bovine serum 
(FBS) was purchased from Integro B.V. (Dieren, The Netherlands), [125I]-CXCL11 (±1000 Ci/mmol) was obtained from 
PerkinElmer Life and Analytical Sciences (Boston, MA, USA). Unlabeled chemokines were purchased from PeproTech 
(Rocky Hill, NJ, USA). Unless stated otherwise, all other chemicals were obtained from Sigma Aldrich (St. Louis, MO, 
USA).
 CXCR3 ligands. VUF11211 (compound 18j; (11)) was synthesized in our labs. The synthesis of NBI-74330 
and VUF10661 has been described before (15, 33).
 DNA Constructs and Site-Directed Mutagenesis. The DNA coding for human CXCR3 was a gift from Prof Dr. 
B. Moser (Cardiff University School of Medicine, Cardiff, UK) and was inserted in the expression vector pcDEF
3
. Mutants 
were generated by using PCR primers containing one or more mismatches in the center of the primer, flanked by 15-20 
base pairs. At first, two individual polymerase chain reactions (PCRs) were performed simultaneously to amplify the 
first part of the receptor until the desired mutation, and the second part of the receptor from the mutation until the 
end. The forward primer used to generate the first part (pcDEF
3
-FW; 5’-gggtggagactgaagttaggcc-3’) recognizes part 
of the EF1… promoter, wheras the reverse primer for the second part (pcDEF
3
-RV; 5’ggaaggcacgggggaggggc-3’) targets 
part of the BGH polyA sequence. The reverse primer for the first part and forward primer for the second, are reverse 
complementary and recognize CXCR3 around the desired mutation as mentioned above. Subsequently, a second 
PCR with primers pcDEF
3
-FW and pcDEF
3
-RV was performed to fuse both receptor DNA fragments, making use of the 
overlapping sequence in both individual parts as internal primer. Finally, the resulting products were digested using 
BamHI and XbaI restriction enzymes and ligated into pcDEF
3
. Sequences were confirmed using Sequencing reactions 
(Macrogen, Amsterdam, the Netherlands).
 In-Silico CXCR3 model Construction. A three-dimensional model for the CXCR3 receptor was constructed 
with MOE version 2011.10 (Chemical Computing Group Inc., Montreal, ON, Canada) based on the structure of CXCR4 
co-crystallized with the small molecule 1T1t (Protein Databank code 3ODU (19)). The primary sequence of CXCR3 
(Genbank accession no. P49682) was aligned to that of the CXCR4 crystal structure. The N-terminal residues 1 to 41 
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were omitted from the model due to a lack of crystallographic data. An initial model was constructed for the CXCR3-
VUF11211 complex as a basis for the binding models for NBI-74330 and VUF10661. However, since the CXCR4-1T1t 
template contains lipids protruding into protein between TM5 and TM6 and the C-terminus blocking the extracellular 
opening (23), the binding pocket of a CXCR3 model is too spacious to explain all observed SAR. To accommodate and 
explain all site-directed mutagenesis data, the CXCR3 model was optimized within this region by moving TM6 by 2Å 
closer to TM3 and TM5, followed by energy minimization. This resulted in a TM arrangement comparable to that of the 
aminergic receptors (42). Finally, the binding pose of VUF11211 in the finalized CXCR3 model was optimized in MOE 
by energy minimization during which all heavy atoms were tethered with a 10.0 kcal/mol restraint. Using the finalized 
CXCR3 model, the other ligands NBI-74330 and VUF10661 were placed into the protein pocket manually in accordance 
to the site-directed mutagenesis data and optimized with the same minimization protocol. 
Residue numbering throughout the manuscript is displayed as absolute sequence numbers with the Ballesteros-
Weinstein notation in superscript (e.g. W1092.60). If residues are compared between different receptors, only the 
Ballesteros-Weinstein notation is used (e.g. W2.60).
 Cell Culture and Transfection. HEK293T cells were grown at 37°C and 5% CO2 in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% FBS, penicillin, and streptomycin. Cells were transfected with 2.5 ug 
of pcDEF
3
-CXCR3 WT or pcDEF
3
 containing the mutant CXCR3 DNA, and 2.5 ug of pcDEF
3
 using linear polyethyleneimine 
(PEI) with a molecular weight of 25 kDa (Polysciences, Warrington, PA) as described previously (6). 
 ELISA Expression Assay. The day after transfection, cells were trypsinized, resuspended into fresh culture 
medium, and plated in poly-L-lysine-coated 48-well assay plates. The ELISA procedure was performed as reported earlier 
(15). Briefly, 48 h after transfection the cells were fixed with 4% formaldehyde solution, permeabilized by 0.5% Nonidet 
P40 and stained with anti-CXCR3 antibody mAb160 (R&D Systems, Minneapolis, USA), and subsequently with goat 
anti-mouse horseradish peroxidase-conjugated antibody (BioRad Laboratories, Hercules, USA). O-phenylenediamine 
was used as a substrate for the enzyme coupled to the secondary antibody. The resulting color was detected using a 
Powerwave X340 absorbance plate reader (BioTek, Bad Friedrichshall, Germany).
 Membrane Preparation. Membrane preparation was performed as described previously (6). In brief, cell 
membrane fractions from HEK293T cells, transiently transfected with WT or mutant CXCR3, were prepared by washing 
with ice-cold PBS. Subsequently, the cells were collected in tubes and centrifuged at 1500g for 10 min. The pellet 
was resuspended in ice-cold membrane buffer (15 mM Tris, pH 7.5, 1 mM EGTA, 0.3 mM EDTA, and 2 mM MgCl2), and 
homogenized using a Teflon-glass homogenizer and rotor. The membranes were subjected to two freeze-thaw cycles 
using liquid nitrogen, and centrifuged at 40,000 g for 25 min. The pellet was resuspended in Tris-sucrose buffer (20 mM 
Tris-HCl, 250 mM sucrose, pH 7.4) and aliquots were stored at -80°C. 
 Radioligand Binding Assays. For [125I]-CXCL11 binding, between 2 and 10 μg of membranes were used 
per well depending on the mutant, in 96-well clear plates (Greiner Bio One, Alphen a/d Rijn, the Netherlands). For 
displacement binding experiments, membranes were incubated in binding buffer (50 mM HEPES, pH 7.4, 1 mM CaCl2, 5 
mM MgCl2, 100 mM NaCl, and 0.5% (w/v) BSA) with approximately 70 pM of [
125I]-CXCL11 and a concentration range of 
cold CXCL11, VUF11211 or NBI-74330 for 2 h at room temperature. Next, the membranes were harvested by filtration 
through Unifilter 96-well GF/C plates (Perkin–Elmer) presoaked with 0.5% PEI, using ice-cold wash buffer (binding 
buffer supplemented with 0.5M of NaCl). Bound radioactivity was determined with a MicroBeta scintillation counter 
(Perkin–Elmer).
 Data analysis. The Prism v5.0d from GraphPad software was used to plot and analyze the data.
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6.: Abstract
The chemokine receptor CXCR3 is a G-protein-coupled receptor that signals through the Gα
i 
class of heterotrimeric G proteins. CXCR3 is highly expressed on activated T cells and has 
been proposed to be a therapeutic target in autoimmune disease. CXCR3 is activated by 
the chemokines CXCL9, CXCL10 and CXCL11. CXCR3 signaling properties in response to 
CXCL10, CXCL11 and the synthetic agonist VUF10661 have previously been evaluated using 
conventional endpoint assays.
In the present study, label-free impedance measurements were used to characterize holistic 
responses of CXCR3-expressing cells to stimulation with chemokines and VUF10661 in real 
time and to compare these responses with both G protein and non-G protein (…β-arrestin2) 
mediated responses. Differences in response kinetics were apparent between the chemokines 
and VUF10661. Moreover, CXCR3-independent effects could be distinguished from CXCR3-
specific responses with the use of the selective CXCR3 antagonist NBI-74330 and the Gα
i 
inhibitor pertussis toxin. By comparing the various responses, we observed that CXCL9 
is a biased CXCR3 agonist, stimulating solely G-protein-dependent pathways. Moreover, 
CXCR3-mediated changes in cellular impedance correlated with G protein signaling, but not 
β-arrestin2 recruitment.
6.1: Introduction
The chemokine receptor CXCR3 is one of the 19 known human chemokine receptors, a 
subfamily of G-protein-coupled receptors (GPCRs) involved in the migration of immune cells 
along chemotactic gradients to sites of infection and inflammation (1). CXCR3 is expressed 
on many cell types, including T lymphocytes, dendritic cells, endothelial cells and cancer 
cells. CXCR3 expression is enhanced during inflammation by interferon-… and plays a role in 
wound healing, autoimmune disease, immune responses to various pathogens, and has an 
angiostatic effect (2-5). CXCR3 is activated by the chemokines CXCL9, CXCL10 and CXCL11, 
which are produced and released by monocytes and macrophages at sites of inflammation (6). 
CXCR3 mediates chemotaxis towards these chemokines in a Gαi2–dependent manner (3-5). 
Additionally, it was recently shown that CXCR3 recruits β-arrestins in response to CXCL10 and 
CXCL11 (7). CXCL9, CXCL10, and CXCL11 utilize different extracellular and intracellular CXCR3 
regions for binding and signaling, respectively, and induce CXCR3 internalization through 
different mechanisms (8-11). The interest in CXCR3 as a pharmacological target has resulted 
in the generation of a range of pharmacological tools to study CXCR3 function (6, 12, 13). 
CXCR3 antagonists may have therapeutic potential in the treatment of autoimmune diseases 
(14) and cancer (15), whereas CXCR3 agonists may aid wound healing (16), respectively. 
Evolving insights in GPCR pharmacology have unmasked the complex and multidimensional 
signaling capabilities of these receptors in response to distinct agonists. Importantly, in 
the last decade, numerous ligands have been identified and/or reclassified that appear 
to activate one pathway more efficiently than the other while binding to the same GPCR. 
Identification and full characterization of these so-called “biased” ligands requires analysis 
of all signaling pathways that are potentially activated by the GPCR of interest. The great 
majority of biochemical and biophysical assays to detect the activation of a selected pathway 
requires the introduction of chemical or biological biosensors to detect signaling and/or 
accumulation of second messengers. These manipulations can change the stoichiometry 
between receptor and intracellular effector molecules to such an extent that the coupling 
efficiency of the pathway is unintentionally altered, resulting in an incorrect estimation of 
potency and/or efficacy of ligands (17). In recent years, label-free technologies based on 
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impedance and optical sensors have been developed and applied to allow detection of GPCR-
mediated signaling (18, 19). Great advantages of these label-free approaches are their holistic 
and non-invasive nature, allowing recording of integrated cellular responses upon receptor 
activation without preselecting and/or interfering with signaling pathways. A good example 
of these advantages - for studying chemokine receptor signaling in particular - is the sensitive 
detection of Gα
i
 functional responses. With other “classical” assays, Gα
i
-mediated effects 
can be detected indirectly either by inhibition of forskolin-induced functional responses or 
with the transfection of chimeric G proteins (20). In addition, G
i
-mediated stimulation of 
phospholipase C… via the release of G…… subunits is inefficient as compared to G
q
-coupled GPCRs, 
or even undetectable (21, 22). Recent publications demonstrate the use of this label-free 
technology for measuring ligand potency as well as determining target selectivity and ligand-
biased function (23-26). 
In the present study, integrated responses of CXCR3-expressing cells were measured as real-
time changes in electrical impedance upon stimulation with CXCL9, CXCL10, CXCL11, and 
the synthetic agonist VUF10661. Use of the selective CXCR3 antagonist NBI-74330 and the 
Gα
i
 inhibitor pertussis toxin allowed identification of CXCR3-dependent and -independent 
effects of these ligands. The label-free responses were correlated with the activities of the 
CXCR3 ligands in both G-protein and non-G-protein-coupled responses.
6.2: Results and discussion
Binding affinities (pK
i
) of the chemokines CXCL9, CXCL10, CXCL11, and the small synthetic 
compound VUF10661 for CXCR3 were determined using [125I]-CXCL10 competition assays on 
membranes from HEK293-CXCR3 cells. All four ligands are able to completely inhibit [125I]-
CXCL10 binding to CXCR3 (data not shown). CXCL11 displayed a 20 and 200-fold higher 
affinity for CXCR3 in comparison to CXCL10 and CXCL9, respectively, whereas the affinity of 
VUF10661 was approximately 1000-fold lower than CXCL11 (Table 1). 
To evaluate G-protein-dependent CXCR3 signaling, HEK293-CXCR3 cells were transiently 
transfected with the CRE-Luc reporter gene plasmid. All four ligands act as full agonists in 
inhibiting forskolin (1.5 μM)-induced CRE activity with potencies (pEC
50
) in the same rank 
order as the CXCR3 binding affinities (Table 1). This CXCR3-induced attenuation of adenylate 
cyclase activity can be fully inhibited by pertussis toxin pre-treatment (100 ng/ml, 16 hrs), 
indicating the involvement of G
i
 proteins (data not shown). Full agonism of both CXCL11 and 
125I-CXCL10 CRE-Luc BRET β-arrestin2 Impedance
Ligand pKi pEC50 α pEC50 α pEC50 α
CXCL9 8.1 ± 0.1 8.1 ± 0.1 1.0 N.D.a 0a 6.8 ± 0.1d 1.3b
CXCL10 9.1 ± 0.2 9.1 ± 0.2c 1.0 6.9 ± 0.1 0.5 7.3 ± 0.1d 0.6
CXCL11 10.4 ± 0.1 9.6 ± 0.1c 1.0 8.2 ± 0.1 1.0 7.2 ± 0.2d 1.0
VUF10661 7.3 ± 0.1 7.1 ± 0.2 1.0 5.9 ± 0.2 1.9 6.1 ± 0.1 1.0
Table 1. Affinities, potencies and intrinsic activities of CXCL9, CXCL10, CXCL11 and the small CXCR3 agonist VUF10661 
in pathway-specific and label-free assays. pK
i
 values were determined in [125I]-CXCL10 homologous displacement ex-
periments, pEC
50
 values for CRE-Luc inhibition, BRET-based β-arrestin2 recruitment and impedance assays are given 
as averages ± SEM of 2-6 independent experiments. Intrinsic activities (α) were calculated from averaged normalized 
data. Statistical differences in pEC
50
 were determined for each assay by one-way ANOVA followed by a Bonferroni’s 
multiple comparison test (p < 0.05). a N.D. = not detectable. b CXCL9 not included in calculation due to large CXCR3-
independent effect. c potencies in the CRE-Luc reporter gene assay did not differ significantly from each other. d poten-
cies in the electrical impedance assay did not differ significantly from each other
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VUF10661 was recently also shown in G
i
 activation as measured by [35S]-GTPγS binding to 
CXCR3-expressing membranes, in which CXCL11 displayed a ~1000-fold higher potency than 
VUF10661 (7). 
As a G-protein-independent readout, ligand-induced β-arrestin2 recruitment to CXCR3 was 
measured using a BRET-based assay in transiently transfected HEK293T cells. In contrast to 
the G
i
 protein-dependent inhibition of CRE activity, the four ligands have different intrinsic 
activities to induce β…-arrestin2 recruitment to CXCR3 (Table 1). CXCL11 and CXCL10 are full 
and partial agonists, respectively, in recruiting β-arrestin2 to CXCR3, whereas VUF10661 
acts as “superagonist” (…α = 1.9), as shown previously (7). However, saturating concentrations 
(1 μM) of CXCL9 did not result in any significant β-arrestin2 recruitment, revealing for the 
first time that CXCL9 is a biased CXCR3 agonist with preference for G
i
 protein signaling. 
Indeed, CXCL9-induced CXCR3 internalization was previously suggested to be β-arrestin2 
independent (8). CXCL11, CXCL10, and VUF10661 showed the same rank order in potency 
in CRE-Luc reporter gene and β-arrestin2 recruitment assays, although their potencies were 
1.2 to 2.2 orders of magnitude lower for β-arrestin recruitment than G protein signaling. 
To explore CXCR3-induced integrated cellular responses in real time, changes in electrical 
impedance were measured using the xCELLigence system upon treatment of HEK293-CXCR3 
cells with increasing concentrations of CXCL9, CXCL10, CXCL11, and VUF10661 (Figure 1). 
The chemokines CXCL9, CXCL10 and CXCL11 resulted in changes of cellular impedance with 
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Figure 1: Chemokines and VUF10661 induce transient impedance changes of CXCR3-expressing cells. Cells were 
treated with increasing concentrations of the chemokines (A) CXCL10, (B), CXCL11 (C) CXCL9, and (D) the small CXCR3 
agonist VUF10661. 100 pM (+), 1 nM (filled squares), 3.2 nM (filled circles), 10 nM (filled diamonds), 32 nM (open 
squares), 100 nM (open circles), 316 nM (open diamonds), 1μM (stars), 3.2 μM (open triangles) and 10 μM (filled 
circles). Data are presented as averages of 2-4 independent experiments ± SEM.
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comparable shapes, showing a peak at 8 minutes followed by a shoulder at 15-20 minutes 
after ligand addition (Figure 1A-C). These impedance traces of CXCL9, CXCL10 and CXCL11 
did not return to baseline CI, even in measurements up to three hours after ligand addition 
(data not shown), but stabilized at a higher level, approximately one hour after ligand addition. 
Interestingly, peak CI values induced by CXCL9 were equally high or higher than those reached 
in response to equal concentrations of the other two chemokines. This was surprising, given 
the low potency of CXCL9 in inhibiting CRE activity on one hand, and the lack of efficacy in 
recruiting β-arrestin2 on the other hand. Moreover, the CXCL9 trace stabilized at higher CI 
values than CXCL10 and CXCL11. In contrast, VUF10661 induced traces that lack a shoulder 
and stabilized more quickly, approximately 30 minutes after ligand addition (Figure 1D). The 
high efficacy of β-arrestin2 recruitment by VUF10661 (Table 1 and (7)) can be hypothesized 
to result in a more rapid CXCR3 desensitization, which could explain both differences in CI 
response kinetics as compared to the chemokines. Peak CI values in the first 100 minutes 
after ligand addition were used to generate concentration-response curves from which ligand 
potencies were determined (Figure 2; Table 1). CXCL9, CXCL10, and CXCL11 have comparable 
potencies in the electrical impedance assay. This is in contrast to the potency rank order 
observed in the CRE-Luc reporter gene and β-arrestin2 recruitment assays, in which CXCL11 
has the highest and CXCL9 has the lowest or even no potency, respectively. VUF10661 has a 
significantly lower potency than the chemokines in the electrical impedance assay, which is 
in agreement with the rank order observed in the CRE activity and β-arrestin2 recruitment 
assays. 
To confirm that CI changes by CXCL9, CXCL10, CXCL11, and VUF10661 are induced upon 
their interaction with CXCR3, the cells were pre-incubated with a saturating concentration 
(10 μM) of the CXCR3-selective antagonist NBI-74330 (13). NBI-74330 completely inhibited 
CXCL10 and CXCL11-induced impedance responses in HEK293-CXCR3 cells (Figure 3A-B). 
In contrast, NBI-74330 only partially inhibited responses to CXCL9 and VUF10661 (Figure 
3C-D), suggesting that both these ligands affect impedance of HEK293-CXCR3 cells in both 
CXCR3-dependent and independent manner. Interestingly, NBI-74330 was previously shown 
to fully inhibit VUF10661-induced G
i
 protein signaling and β-arrestin recruitment in CXCR3-
expressing cells (7). To confirm the CXCR3-independent effects of CXCL9 and VUF10661 on 
impedance, all four ligands were tested in the parental HEK293 cell line, which does not 
endogenously express CXCR3 (27). CXCL10 and CXCL11 did not change the impedance of 
parental HEK293 cells (Figure 3A-B). However, CXCL9 and VUF10661 induced CI traces with 
a similar shape in parental HEK293 cells in comparison to HEK293-CXCR3 cells that were 
pre-treated with NBI-74330, with higher amplitude for CXCL9 in parental cells (Figure 3C-D). 
Under these conditions the CI values had not stabilized 100 minutes after CXCL9 stimulation, 
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Figure 2: Concentration-response curves of peak 
CI values induced by CXCL9, CXCL10, CXCL11, and 
VUF10661 in CXCR3-expressing cells. Cells were 
treated with increasing concentrations of CXCL9 
(open diamonds), CXCL10 (open squares), CXCL11 
(open circles), and VUF10661 (filled squars). Data 
are presented as averages of 2-4 independent experi-
ments ± SEM.
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which is in contrast to the HEK293-CXCR3 cells that were only stimulated with CXCL9. 
The involvement of G
i
 proteins in impedance responses to the four agonists was determined by 
pre-treating the HEK293-CXCR3 cells with PTX, which has previously been shown not to affect 
β-arrestin recruitment to CXCR3 (7). Both CXCL10 and CXCL11 responses were completely 
inhibited by PTX (Figure 4A-B), indicating that the CXCR3-induced changes in impedance are 
fully mediated via G
i
 proteins. In contrast, CXCL9 and VUF10661-induced impedance changes 
were only partially inhibited by PTX, and to a similar extent as when antagonizing CXCR3 
with NBI-74330 (Figure 4C-D). Hence, CXCL9 and VUF10661 appear to activate some cellular 
responses in a CXCR3-independent and PTX-insensitive manner, which has previously been 
described for CXCL9 in peripheral blood mononuclear cells and the monocytic cell line THP-1 
(28). These effects were found to be dependent on p38 and ERK1/2 phosphorylation. However, 
the alternative receptor targeted by CXCL9 remains unidentified. In contrast to changes in 
impedance mediated by agonist stimulation of the …2 adrenergic receptor, to which both G
i 
and G
s
 were shown to contribute (29), electrical impedance changes mediated by CXCR3 
are apparently completely dependent on G
i
 activity. NBI-74330 and PTX did not affect the 
impedance response to 10 μM carbachol, which is mediated via the endogenously expressed 
Gα
q
-coupled muscarinic M3 receptor (Figure S1), indicating that the observed inhibitory 
effects on CXCR3-mediated impedance are not due to non-specific effects of the treatments. 
Since PTX completely inhibited CXCR3-dependent responses of all four agonists in the 
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Figure 3: The CXCR3-specific antagonist NBI-74330 reveals CXCR3-mediated and CXCR3-independent effects of 
CXCR3 chemokines and VUF10661. HEK293-CXCR3 cells were treated with 0.1% DMSO control (open squares), 10 μM 
NBI-74330 (open circles) 10 minutes prior to addition of (A) 32 nM CXCL10, (B) 32 nM CXCL11, (C) 316 nM CXCL9 or 
(D) 10 μM VUF10661. HEK293 cells were treated with CXCR3 agonists without pre-treatment (filled squares…). Data are 
presented as averages of 2-3 independent experiments ± SEM.
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electrical impedance assay, this suggests that the increase in cellular impedance reflects Gα
i 
protein activity and not β-arrestin recruitment. However, β-arrestin may influence the kinetics 
of the impedance response. Interestingly, agonists on the G
i
-coupled niacin receptors that 
activate both G protein signaling and β-arrestin recruitment, induced a transient dip in CI 
in the first six minutes after stimulation (26). This dip was absent in the CI traces of ligands 
that only activate niacin receptor-mediated G protein signaling but were unable to recruit 
β-arrestin. Although VUF10661 has been shown to have a higher β-arrestin recruitment 
efficacy than CXCR3 chemokines (7), no differences were apparent between chemokines and 
VUF10661 in the first six minutes of the CXCR3-mediated impedance traces. It is possible that 
the β-arrestin-biased niacin receptor ligands are more efficacious than VUF10661, resulting 
in a more pronounced signal in impedance measurements. However, it is clear that additional 
information (e.g. data from cells treated with RNAi targeting β-arrestin) is required to identify 
a possible role of β-arrestin in the electrical impedance kinetics downstream of GPCR activity.
In conclusion, real-time impedance measurements readily allow detection of Gα
i
 activity. In 
addition to the Gα
i
 response mediated by CXCR3, CXCR3-independent and PTX-insensitive 
effects were integrated into the signals of CXCL9 and VUF10661. Such phenotypic information 
is advantageous for insights in integrated signaling and potentially unwanted effects of 
ligands, though it also highlights the need for caution in interpreting data obtained from 
these label-free experiments.
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Figure 4: Changes in CI induced by chemokines and a small CXCR3 agonist are mediated by Gα
i
. HEK293-CXCR3 cells 
were grown overnight in the absence (open squares) or presence (open circles) of 100 ng/mL PTX. Cells were treated 
with (A) 32 nM CXCL10, (B) 32 nM CXCL11, (C) 316 nM CXCL9 or (D) 10 μM VUF10661 were measured. Data are pre-
sented as averages of 2-3 independent experiments ± SEM.
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6.3: Materials and methods
 Materials. Parental HEK293 cells and HEK293 cells stably expressing human CXCR3 
(HEK293-CXCR3) were a gift from dr. K. Biber (University Medical Center Groningen, the 
Netherlands). HEK293T cells were purchased from ATCC-LGC Standards (Wesel, Germany). 
Cell culture media, penicillin/streptomycin and bovine serum albumin (BSA) were purchased 
from PAA Laboratories GmbH (Paschen, Austria). Fetal bovine serum (FBS) was obtained from 
Integro B.V. (Dieren, the Netherlands). Linear 25-kDa polyethyleneimine was purchased from 
Polysciences (Warrington, PA). G418, poly-L-lysine, pertussis toxin, Triton X-100, disodium 
pyrophosphate, adenosine 5’-triphosphate disodium salt, Tris base, glycerol, phosphoric acid 
and carbamylcholine chloride (carbachol) were purchased from Sigma-Aldrich (St. Louis, 
MO). Beetle luciferin and coelenterazine h were purchased from Promega (Madison, WI). 
Chemokines were purchased from Peprotech (Rocky Hill, NJ). VUF10661 and NBI-74330 were 
synthesized as described previously (7, 30). [125I]-CXCL10 (2200 Ci/mmol) was purchased from 
PerkinElmer (Waltham, MA). Dithiothreitol was purchased from Duchefa Biochemie (Haarlem, 
the Netherlands). 
 DNA constructs. The cyclic AMP response element-luciferase (CRE-Luc) reporter 
gene plasmid was a kind gift from Dr. W. Born (National Jewish Medical and Research 
Center, Denver, CO, USA). CXCR3-Renilla luciferase (RLuc) and β…-arrestin2-enhanced yellow 
fluorescent protein (eYFP) fusion constructs have been described previously (7).
 Cell culture and transfection. Cells were maintained in 5% CO2 at 37°C in Dulbecco’s 
Modified Eagle Medium (DMEM) containing 10% FBS, penicillin, and streptomycin. To maintain 
stable expression of CXCR3 (HEK293-CXCR3) the medium was supplemented with 250 μg/ml 
G418. HEK293 and HEK293-CXCR3 cells were transiently transfected with 500ng/1·106 cells 
CRE-Luc reporter plasmid using linear polyethylenimine, as described previously (13). For …β-
arrestin2 recruitment assays, HEK293T cells were transfected with cDNA encoding CXCR3-
RLuc and β-arrestin2-eYFP, as described in (7).
HEK293 cell membrane preparation and [125I]-CXCL10 binding. Preparation of HEK293 cell 
membrane fractions and [125I]-CXCL10 competition binding were performed as described 
previously (13). 
 CRE-Luc reporter gene. One day after transfection, cells were transferred to poly-L-
lysine-coated white 96-well plates. The following day, culture medium replaced with serum-
free DMEM (penicillin/streptomycin) containing 0.05% BSA and the indicated ligands. After 
5 hours, stimulation medium was replaced by 25 μl substrate solution (39 mM Tris.H
3
PO
4
 pH 
7.8, 39% glycerol, 2.6% Triton X-100, 860 μM dithiothreitol, 18 mM MgCl2, 825 μM ATP, 77 μM 
disodium pyrophosphate, 230 μg/mL beetle luciferin) and luminescence was measured using 
a Victor3 multilabel plate reader (PerkinElmer, Waltham, MA).
 BRET-based γβ-arrestin2 recruitment. One day after transfection, cells were 
transferred to poly-L-lysine-coated white 96-well plates. The following day, medium was 
replaced with Hank’s Balanced Salt Solution and fluorescence was measured on a Victor3 
multilabel plate reader (ex. 485 nm; em. 535 nm). Ten minutes after coelenterazine h (5 μM final 
concentration) addition, ligand solutions in Hank’s Balanced Salt Solution supplemented with 
0.05% BSA were added in the stated concentrations and incubated for a further 5 minutes. 
Bioluminescence resonance energy transfer (BRET) (em. 535 nm) and RLuc expression (em. 
460 nm) were measured with a Victor3 multilabel plate reader. Baseline-corrected BRET ratios 
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were calculated by first dividing BRET by RLuc emission values, followed by subtraction of the 
BRET ratio of cells expressing CXCR3-RLuc alone.
 Impedance measurement. The xCELLigence system (Roche Applied Science, 
Penzberg, Germany) uses E-plates (ACEA Biosciences Inc, San Diego, CA) with electrode 
arrays integrated into the bottom of the wells, which allow measurement of impedance at the 
electrode-cell interface. Data is recorded at an electrical current of 10 kHz and automatically 
converted to Cell Index (CI) by the xCELLigence software. CI = (R
tn
 – R
t0
)/15 (Ω), where R
t0 
is 
the background electrical resistance measured in the absence of cells prior to the start of 
each experiment; R
tn
 is the electrical resistance at time point n. Parental HEK293 cells or 
HEK293-CXCR3 were seeded in DMEM containing 10% FBS, penicillin and streptomycin at 
5·104 cells per well of 96-well E-plate. The plate was inserted into the xCELLigence station 
and maintained in 5% CO2 at 37°C while CI was measured with 15-minute intervals. The cells 
were allowed to grow until a CI of 1.7 – 2.2 was reached, approximately twenty hours after 
seeding the cells. At this point, medium was replaced with 90 or 95 μl DMEM containing 0.1% 
FBS, penicillin and streptomycin, and cells were allowed to adjust to low-serum conditions 
for three hours. Next, the E-plate lid was replaced with an open lid and ligands were added 
with the aid of an automated multichannel pipette (5 μl/well), while the E-plate remained in 
the xCELLigence station. Immediately prior to ligand addition, the measurement frequency 
was increased to 30-second intervals, followed by 1-minute, 5-minute and, finally, 15-minute 
intervals. CI values were normalized to CI values just prior to ligand addition (time is 0 minutes) 
and were baseline-corrected with CI traces obtained from cells treated with the appropriate 
vehicle solution.
 Data analysis. Nonlinear curve fitting and statistical analyses of the data were 
performed using Prism 4.03 (GraphPad Software Inc., San Diego, CA). K
i
 values were calculated 
using the Cheng-Prusoff equation K
i
 = IC
50
/(1 + [125I-CXCL10]/K
d
 of 125I-CXCL10) (31). Peak 
values of the CI traces from 0 to 100 minutes after ligand addition were determined by the 
xCELLigence software, and used to construct dose response curves in Prism 4.03. Intrinsic 
activities (…α) were calculated for all tested ligands by dividing their maximum response in the 
functional assays by the maximum response of the endogenous full agonist CXCL11.
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Figure S1: NBI-74330 and PTX do not affect CI response of the Gα
q
-coupled muscarinic M3 receptor to carbachol. 
(A) HEK293-CXCR3 cells were serum starved for three hours prior to ligand treatment. Cells were pre-treated with 
0.1% DMSO (open squares) or 10 μM NBI-74330 (open circles) 10 minutes prior to addition of 100 μM carbachol. (B) 
HEK293-CXCR3 cells were grown overnight in the absence (filled squares) or presence (filled circles) of 100 ng/mL 
PTX. Data are presented as averages of 2-3 independent experiments ± SEM.
CHAPTER 7
Chemical subtleties in small-molecule modula-
tion of peptide receptor function: the case of 
CXCR3 biaryl-type ligands
Adapted from*
DJ Scholten, M Wijtmans, L Roumen, M Canals, H Custers, M Glas, MCA Vreeker, C de Graaf, MJ 
Smit, IJP de Esch, and R Leurs
* J. Med. Chem. submitted.
Table of Contents
7.  : Abstract
7.1: Introduction
7.2: Results and discussion
 7.2.1: Synthesis
 7.2.2: Structure-Activity Relationships
  7.2.2.1: Exploration of biaryl substitution
  7.2.2.2: Exploration of the polycycloaliphatic group
  7.2.2.3: QM- and NOESY NMR-based studies
7.3: Conclusion
7.4: Materials and methods
7.5: References
7.6: Supporting information
C7
116  Chemical subtleties in modulation of CXCR3 function by biaryl-type ligands
C7
7.: Abstract
The G-protein coupled chemokine receptor CXCR3 plays a role in numerous inflammatory 
events. The endogenous ligands for the chemokine receptors are peptides, but in this study 
we describe small-molecule ligands that are able to activate CXCR3. A class of biaryl-type 
compounds that is assembled by convenient synthetic routes is described as a new class of 
CXCR3 agonists. SAR and SFR studies reveal that intriguingly subtle chemical modifications 
on the outer aryl ring (e.g. either the size or position of a halogen atom) results in a full 
spectrum of agonist efficacy on CXCR3. QM calculations and NOESY NMR studies suggest that 
the biaryl dihedral angle and the electronic nature of ortho-substituents play an important 
role in determining agonist efficacies. Compounds 38 (VUF11222) and 39 (VUF11418) are the 
first non-peptidomimetic agonists on CXCR3, rendering them highly useful chemical tools for 
detailed assessment of CXCR3 activation as well as for studying downstream CXCR3 signaling.
7.1: Introduction
G protein-coupled receptors (GPCRs) form one of the therapeutically most relevant protein 
families and around one third of the available small molecule drugs target GPCRs.1 Despite 
this huge therapeutic importance it is often still unclear which structural determinants of the 
small molecules underlie the functional outcome of ligand-GPCR binding. This question is 
perhaps most intriguing in the case of peptide GPCRs, which signal as a result of the binding 
of large peptide molecules. 
A well-known class of peptide GPCRs are the chemokine receptors, of which 19 subtypes are 
currently known.2 Chemokine receptors are activated by chemokines, which are chemotactic 
cytokine peptides that control leukocyte homeostasis, as well as leukocyte recruitment 
to sites of inflammation or infection. As such, the chemokine system is a key player in the 
human immune system.3 The chemokine receptor CXCR3 is expressed on various immune 
cells, including T-cells, and recognizes three endogenous agonist ligands, CXCL9 (11.7 kDa), 
CXCL10 (8.6 kDa), and CXCL11 (8.3 kDa). Upregulation of CXCR3 and its ligands is linked 
to a variety of immune-related disorders. The notion of CXCR3 as an interesting therapeutic 
target is reflected in the high number of reports describing the discovery and optimization 
of small-molecule CXCR3 antagonists from many different chemotypes.4-6 Small-molecule 
agonism of CXCR3 has been studied less widely, likely because evidence for the therapeutic 
value of CXCR3 agonism is scarce and relatively preliminary.7, 8 Another explanation for this 
apparent deficiency might be that it is easier to block or inhibit peptide receptor activation 
by small molecules than it is to mimic the specific action of the endogenous peptide agonist. 
Only one paper disclosing small-molecule agonists of CXCR3 has appeared, reporting on two 
agonist chemotypes which both clearly bear peptidomimetic character (1-2 and 3, figure 1).9 
In fact, structure-activity relationship (SAR) studies have revealed that the basic amino acid 
side-chain is crucial in activating CXCR39 and conformational calculations on 2 have shown 
that this compound probably mimics the ‘30s loop’ of CXCL10 which includes R38.10 Several 
of these peptidomimetics have been pharmacologically studied in vitro and in vivo since.7, 
11, 12 Even though several X-ray structures for the related chemokine receptor CXCR4 have 
been elucidated recently,13 ligand-based information such as SAR and structure-function 
relationship (SFR) is still crucial to provide insights into molecular determinants of ligand-
induced (chemokine) GPCR modulation.14, 15 As such, studies aimed at unraveling ligand-
mediated CXCR3 activation and its cellular consequences would greatly benefit from studies 
on non-peptidomimetic small-molecule activators of CXCR3. 
We have recently reported on a biaryl type of CXCR3 ligands (4, figure 1), obtained after several 
rounds of modification following a medium-throughput screen performed in our labs.16 The 
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SAR of scaffold 4 showed varying effects in affinity upon modulation of the aryl ring (Ar). 
Key members of this chemotype were found to behave as antagonists.16 In the current paper, 
we describe how these compounds can be rendered CXCR3 (full) agonists using intriguingly 
subtle activation triggers involving manipulation of halogen atom size as well as of halogen 
atom position. These compounds display the full spectrum of functional efficacies in CXCR3 
activation and include the first reported non-peptidomimetic full agonists on CXCR3. We 
present pharmacological, Nuclear Overhauser Effect Spectroscopy NMR (NOESY NMR) and 
quantum mechanics (QM) studies to identify the molecular features that are responsible for 
the specific functional activity.
7.2 Results and discussion
7.2.1 Synthesis
All final salts 6, 28-46 were prepared as outlined in Schemes 1 and 2. The preparation of salts 5 
and 23-27 has been described previously by our group.16 Hydrogenation of key amine building 
block 716 provided 8, with 2D-NMR spectroscopy indicating an endo-geometry. Stereoisomeric 
analogue 9 and regioisomeric analogue 10 were prepared from the corresponding aldehydes 11 
and 12.17, 18 Biaryl aldehydes 13-17 were prepared through a Suzuki reaction of an appropriate 
boronic acid and a complementary halogen-precursor. This ‘reversed’ preassembly19 of the 
biaryl moiety in 13-17 was initially pursued because we observed that 2-bromophenylboronic 
acid and 2,6-dichlorophenylboronic acid proved difficult to couple to 21 in the alternative 
Suzuki strategy depicted in Scheme 2. Thereafter, this procedure was also applied to several 
other substrates. Substantial amounts of disubstituted product were obtained in the formation 
of 15 despite the 5-fold excess of 1,2-diiodobenzene. Chlorine-containing building block 20 
was prepared through a reduction of the corresponding carboxylic acid (18) to the alcohol 
followed by an oxidation.
Figure 1: Chemical structures of selected CXCR3 ligands.
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The syntheses of all final compounds (Scheme 2) proceeded mostly along the general 
routes previously published.16 Thus, tertiary amine precursors 47-66 were obtained through 
two approaches. One approach uses a reductive amination to connect a preassembled 
biarylaldehyde (13-17) to building blocks 7-10. The other approach is a two-step process, 
starting with reductive alkylation of 7 using aldehyde 19 or 20 to give bromides 21 and 22, 
respectively. This was followed by a microwave Suzuki reaction with an appropriate boronic 
acid. Tertiary amine precursors 47-66 were then methylated with MeI to the final ammonium 
salts 6, 28-46 in moderate to excellent yield.
7.2.2 Structure-Activity Relationships
In the SAR efforts on scaffold 4, the difference in affinity between ortho-F compound 5 and 
its meta-counterpart had previously indicated meta-substitution of the outer phenyl ring as 
a means to achieve affinity.16 More recently, we prepared and tested the ortho-Cl derivative 
6. Interestingly, when subjected to our previously used16 functional CXCR3 assay recording 
[3H]-inositolphosphates accumulation after stimulation with CXCL10, 6 did not show any 
inhibition of CXCL10 responses despite full receptor occupancy (not shown), suggesting that 
6 may possess residual agonist activity. Indeed, in a [35S]-GTPγS (guanosine 5'-O-[gamma-
thio]triphosphate) functional assay, in which the native coupling of CXCR3 to G proteins is left 
Scheme 1: Synthesis of building blocks. a) H2, Pd/C, MeOH, 23 h, r.t., 72 %. b) [1] H2NMe, MeOH/EtOH, 1-20 h, r.t. 
[2]  NaBH
4
, 2 h, r.t., 9: 50 %, 10: 14 % as HCl salt. c) Pd(PPh
3
)
4
, 4-CHO-PhB(OH)2, Na2CO3, DME, H2O, 60 – 90 min, μW, 
56 - 91 %. d) Pd(PPh
3
)
4
, 4-BrPhCHO (19), Na2CO3, DME, H2O, 7 h, reflux, 85 %. e) BH3.THF, THF, 2.5 h, r.t. f) MnO2, DCM, 
5 d, r.t., 65 % from 18.
Chemical subtleties in modulation of CXCR3 function by biaryl-type ligands   119
C7
intact, 6 proved to be a partial agonist (…α = 0.73) with μM potency (pEC
50
= 5.8) (Table 1, Figure 
2). This partial agonist activity could be abolished by addition of CXCR3-selective antagonist 
NBI-7433020 (Figure S1A) and by our previously16 reported antagonist 27 (VUF10990) (data 
not shown). Moreover, no functional response for 6 was detected in membranes of cells 
that did not express CXCR3 (Figure S1C), suggesting that the observed functional effect for 
compound 6 was a consequence of CXCR3 receptor activation. These interesting findings on a 
non-peptidomimetic scaffold, which is readily assembled through straightforward syntheses, 
inspired us to an in-depth investigation of the molecular determinants for activation of the 
CXCR3 receptor by this scaffold. 
7.2.3 Exploration of biaryl substitution
The newly synthesized compounds bind to CXCR3 with affinities ranging from pK
i
 5.7 to 7.3 
([125I]-CXCL10 displacement). Figure 2A shows representative binding curves. All compounds 
were also analyzed in the [35S]-GTPγS functional assay to investigate potency (pEC
50
) and 
efficacy (α…) at CXCR3 (Table 1). Concentration ranges in the [35S]-GTPγS functional assay were 
chosen such that sufficient receptor occupancy was ensured. The profile of 6 was compared 
to a small set of ammonium salts previously reported by us (23-27).16 Compounds 23 and 24 
(lacking the biaryl-moiety) as well as 25 and 26 (having an undecorated (un)constrained biaryl 
system) showed little to no agonistic response (α… ≤ 0.1). Remarkably, a shift of the Cl-atom in 
6 to the meta-position (giving 27, VUF10990) abolished the agonistic activity. The findings 
indicate the ortho-position on the outer phenyl ring of the biaryl system to be important for 
receptor activation. With the Cl-atom maintained at this position, the effect of an additional 
Cl-substituent was explored (28-30). This yielded partial agonists, which are all weaker than 
compound 6 with … values ranging from 0.31 to 0.64 (Table 1). Recognizing hindered rotation 
around the biaryl axis as potential key factor for CXCR3 agonism, three compounds with a Cl-
atom on the ortho-position of the inner ring were also investigated (31-33). However, only 33 
showed any substantial agonism (…α = 0.30) (Table 1), arguably because it contains an ortho-Cl 
moiety on the outer ring as well. Subsequent SAR/SFR studies focused on the ortho-position 
of the outer ring and aimed to introduce groups differing in electronic properties and size. 
Introduction of one (34) or two (35) methyl groups resulted in weak partial agonism (…α ~ 
0.2). An ortho-OH group (36) induced no significant functional agonism, and the affinity for 
this compound was the lowest in this series (pK
i
 = 5.7) (Table 1). Moderate to weak partial 
Scheme 2: Synthesis of final compounds. a) NaBH(OAc)
3
, DCE, r.t., 4 h – 2 d , 43 - 92 %. b) NaBH(OAc)
3
, DCE, r.t., 20 h, 
21: 71 % as HCl salt, 22: 78 %. c) Pd(PPh
3
)
4
, ArB(OH)2, Na2CO3, H2O, DME or iPrOH/toluene, μW, 60 - 90 min, 34 - 92 %. 
d) DCM, MeI, 1 - 5 d, r.t. 22 - 88 %. 
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agonism was observed with an ortho-OMe (37; α… = 0.36) or ortho-F (5; α = 0.20) substituent. 
However, the introduction of bigger halogen atoms, like ortho-Br (38, VUF11222) or ortho-I 
(39, VUF11418), resulted in CXCR3 agonists that are able to reach the same maximum level 
of G protein activation (…α = 0.95 and 0.99, respectively) as the endogenous peptide ligand 
CXCL11 (Figure 2B). Both 38 and 39 were comparably effective in terms of potency and 
efficacy, matching those of peptidomimetic agonist 1. In contrast, mere shifting of the Br-
atom in 38 to the meta-position (as in 40, VUF13746) led to a complete loss of agonism, as 
had also been observed in the couple 6 versus 27 (Figure 2C). In all, the bigger halogens at 
the ortho-position of the outer ring were clearly preferred to provide full functional agonists.
7.2.3.1: Exploration of polycycloaliphatic group
A selected set of compounds was subsequently prepared to explore the ‘left-hand’ 
polycycloaliphatic side of the molecule. We have previously reported on the preference 
of CXCR3 for certain polycycloaliphatic groups,21 and, within this class of biaryl ligands, 
the myrtenyl seems an attractive group.16 Given the subtle changes in activation pattern 
encountered in the biaryl moiety, we aimed for subtle changes in the polycycloaliphatic side of 
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Figure 2: Radioligand binding curves and functional assay curves for selected compounds. (A) Binding displacement 
assay using [125I]-CXCL10 for key compounds. (B-C) [35S]-GTPγ…S functional assay for (B) compounds containing dif-
ferent (halogen) atoms on the ortho-position of the outer phenyl ring; or for (C) compounds with a chloro- or bromo-
group on the ortho- or meta-position of the outer phenyl ring. (D) CRE-luciferase reporter gene functional assay with 
key compounds on HEK293 cells transfected with CXCR3 receptor and the CRE-luciferase reporter gene DNA. Shown 
graphs are the result of grouped data of at least three independent experiments. The dashed line (at 1.0) indicates 
basal levels of [35S]-GTPγ…S accumulation, whereas the dashed/dotted line (at 2.8) represents the maximal response 
(E
max
) of the endogenous peptide agonist CXCL11 (…α = 1). NBI-74330 and VUF10661 (1) are included as a reference 
antagonist and agonist, respectively.
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the molecule as well. Toward this end, saturated endo-myrtanyl analogues (41, 42) as well as 
derivatives with either regioisomeric (43, 44) or stereoisomeric forms (45, 46) of the myrtenyl 
group were prepared (Table 2). A meta-Cl or ortho-I moiety was kept as ‘representative’ biaryl-
portion of the antagonist and agonist-subsections of this class, respectively. The results in 
Table 2 clearly show that the nature of the polycycloaliphatic group had only little effect 
on affinity and, more importantly, on the functional profile of both the antagonist and the 
agonist subseries (compare 39 to 42/44/46, and 27 to 41/43/45). The most notable change 
observed was the small decrease in efficacy of 42 (…α = 0.83) compared to 39 (α… = 0.99) as a 
result of double bond reduction. The collective results suggest not only that these types of 
polycycloaliphatic architectures are indeed preferred anchors within this chemotype21, but 
also reinstate the biaryl-portion as the major determinant for functional efficacy. 
Functional effects on CXCR3 were inspected in more detail for key compounds 27 (no 
agonism) and 39 (full agonism). Activation of CXCR3 by 39 could be inhibited by addition 
of antagonist NBI-74330 and was absent in mock cells (Figure S1B/C). We also used a CRE-
luciferase reporter gene assay as an alternative to the [35S]-GTPγS functional assay. In this 
assay, 27 again did not show any agonism, whereas 39 showed full agonism comparable to 
peptidomimetic 1 (Figure 2D). All this unambiguously shows that the observed functional 
effect by 39 is elicited through specific interaction with the CXCR3 receptor. Collectively, 
our data on this non-peptidomimetic class of CXCR3 ligands suggest a biaryl ortho-halogen-
switch from antagonism to full agonism on CXCR3, not necessarily limited to biphenyls per se 
and not significantly influenced by subtle adaptations in the polycycloaliphatic moiety. 
Figure 3. Ligands with considerable efficacy (α greater than 0.5) have an angle of 60° on average. The calculated 
optimal angle between the two aryl rings is plotted against the efficacy measured in [35S]-GTP…γS functional assays. 
The grey squares indicate ligands that show a relative efficacy greater than 0.5. Data points are accompanied by the 
corresponding compound codes.
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# R R
1
Affinity (pKi)
a Potency (pEC50)
b Efficacy (α)b,c
CXCL11 - - 10.4± 0.0 9.2 ± 0.1 1.00 ± 0.01
NBI-74330 - - 8.0 ± 0.1 - d 0.00 ± 0.01
1 - - 7.4 ± 0.1 6.2 ± 0.1 0.96 ± 0.02
5
F
H 6.3 ± 0.1 5.9 ± 0.2 0.20 ± 0.01
6
Cl
H 7.0 ± 0.1 5.8 ± 0.1 0.73 ± 0.02
23 H H 5.6 ± 0.1 - d 0.04 ± 0.01
24 Cl H 6.7 ± 0.1 - d 0.02 ± 0.01
25 H 6.2 ± 0.1 - d 0.11 ± 0.01
26e 6.4 ± 0.1 - d 0.03 ± 0.01
27
Cl
H 6.6 ± 0.1 - d 0.05 ± 0.01
28
Cl
Cl
H 6.4 ± 0.1 6.2 ± 0.1 0.31 ± 0.01
29
Cl
Cl
H 6.6 ± 0.1 5.3 ± 0.1 0.64 ± 0.03
30
Cl
Cl
H 6.4 ± 0.1 5.7 ± 0.3 0.42 ± 0.03
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# R R
1
Affinity (pKi)
a Potency (pEC50)
b Efficacy (α)b,c
31 Cl 6.2 ± 0.1 - d 0.06 ± 0.01
32
Cl
Cl 6.3 ± 0.1 - d 0.03 ± 0.02
33
Cl
Cl 6.7 ± 0.1 6.1 ± 0.3 0.30 ± 0.03
34 H 6.8 ± 0.1 5.9 ± 0.3 0.20 ± 0.02
35 H 6.0 ± 0.1 5.1 ± 0.2 0.19 ± 0.02
36
OH
H 5.7 ± 0.1 - d 0.07 ± 0.01
37
OMe
H 6.8 ± 0.0 4.9 ± 0.1 0.36 ± 0.02
38
Br
H 7.2 ± 0.1 6.1 ± 0.1 0.95 ± 0.03
39
I
H 7.2 ± 0.0 6.0 ± 0.1 0.99 ± 0.02
40
Br
H 6.7 ± 0.0 - d 0.08 ± 0.02
Table 1: General scan of (ortho-)substituents on the outer and inner phenyl rings. a) Measured by [125I]-CXCL10 dis-
placement binding experiments with membranes prepared from HEK293 cells stably expressing the CXCR3 receptor. 
b) Measured by using a [35S]-GTP…γS functional assay with membranes prepared from HEK293 cells stably expressing 
the CXCR3 receptor. c) The … represents the relative efficacy of a ligand compared to the endogenous agonist CXCL11 
(which is set at α… = 1.0). d) Could not be determined due to the too low functional assay window. e) Point of attachment 
has been colored red. All shown values are mean ± SEM of at least three independent experiments.
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7.2.3.2: QM- and NOESY NMR-based studies
The SAR study reveals a link between the size and the location of the halogen substituent and 
the efficacy of the compound (e.g. 5, 6, 31, 38 and 39). As such, it is tempting to (partially) 
attribute this agonist switch to a changing dihedral biaryl angle. To validate this hypothesis, 
QM calculations were performed to derive the optimal dihedral angle for each of the biaryls 
by performing a potential energy scan (key structures in Table 3, Fig. S3). Results from these 
simulations correspond to those from similar studies performed on biaryl systems.22, 23 The 
angle of unsubstituted and meta-substituted compounds remains at ca. 40° (25, 27, 40). Due 
to steric hindrance, ortho,ortho-disubstituted compounds possess a typical dihedral angle of 
90° (30, 33, 35), whereas the ortho-monosubstituted compounds possess a dihedral angle in 
the range of 45°-70° depending on the size of the substituent (5, 6, 34, 36, 38, 39). To correlate 
these QM-derived angles to experimentally determined angles, we resorted to quantitative 
NOESY NMR on selected compounds. Larger dihedral angles between the aromatic rings 
will result in a larger distance between the closest set of ortho-protons on adjacent rings 
(designated H’ and H’’, Table 4 & Figure S2A). An indication for mean inter-atom distances 
can be obtained using quantitative NOESY NMR through a r-6 dependence24, 25 and use of an 
absolute calibration distance elsewhere in the molecule allows reasonable approximation of 
unknown distances. For distance calibration we used the normalized sum of the H
a
-H
c
 and H
b
-
H
c
 NOESY signals (1H-NMR shifts H
a
 and H
b
 overlap), since these are far away from the R group 
and the rigidity of the myrtenyl groups bodes well for using distances extracted from a crystal 
structure of an unrelated myrtenyl-containing compound.26 The NOESY signal between the 
ortho-protons is a sum of the H’-H’’ and H’-H’’’ NOESY effects, but at angles substantially 
smaller than 90° the r-6 dependence predicts that the measured signal can be attributed 
almost exclusively to the NOESY signal between the closest set of ortho-protons H’ and H’’. 
Indeed, our calculations (Table 4) suggest that the deviation in experimentally determined 
H’-H’’ distance as a result of interference of the more distant H’-H’’’ pair does not exceed 3.5 
% for the set of selected compounds, meaning that the NOESY measurements are considered 
a reasonable approach for approximating the mean calculated angles. The distance H
d
-H
e
 was 
measured as control, as we expected R not to have a significant influence on this distance. 
Selected ortho-substituted compounds with varying efficacies were subjected to NOESY 
NMR in CDCl
3
 (5, 6, 25, 29, 34 and 38). Severe overlap of 1H-NMR signals in the aromatic 
region prohibited the inspection of e.g. 39. The results, collected in Table 4, confirm that the 
reference H
d
-H
e
 distance does not change with R, while the H’-H’’ distance is subject to size of 
the R group: the larger R groups induce a larger distance, hence a larger angle. The correlation 
between calculated and experimental data (Figure S2B) is good with minor deviations for the 
larger angles (interference of H’-H’’’, vide supra). This indicative correlation between theory 
and experiment shows that the calculated angles are representative for the actual dihedral 
angles under the measurement conditions and strengthens the confidence in the quantum 
mechanics calculations for the biaryl compounds.
With the confirmed calculated angles at hand it is evident that, on average, ligands with 
a considerable efficacy (…α > 0.5) seem to require a dihedral angle of around 60° (Figure 
3).  However, from the experimental results it is clear that the angle cannot be the sole 
determinant for agonism (e.g. 6 vs. 31). More particularly, the biaryl ortho-switch most likely 
has dual contributions from the spatial arrangement as well as electronic properties of the 
biaryl moiety. The possibility of a halogen bond, known to be especially applicable to the 
bigger halogens, also emerges in these considerations.27, 28 As such, the electrostatic potential 
surfaces were calculated for the biaryl portion of the compounds (key structures in Table 3) as 
well as the electrostatic potential of the ortho-substituent. The electronegativity of the ortho-
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# R R2
Affinity
(pK
i
)a
Potency
(pEC
50
)b Efficacy (α)
b,c
27
Cl
6.6 ± 0.0 - d 0.05 ± 0.01
39
I
7.2 ± 0.0 6.0 ± 0.1 0.99 ± 0.02
41
Cl
H
6.3 ± 0.1 - d 0.07 ± 0.01
42
I
H
7.0 ± 0.0 5.9 ± 0.1 0.83 ± 0.01
43
Cl
6.3 ± 0.0 - d 0.07 ± 0.01
44
I
6.7 ± 0.0 5.8 ± 0.1 1.05 ± 0.03
45
Cl
6.5 ± 0.0 - d 0.05 ± 0.01
46
I
7.3 ± 0.1 6.2 ± 0.1 0.98 ± 0.03
I
R2
N
R
Table 2: In-depth inspection of key compounds. a) Measured by [125I]-CXCL10 displacement binding experiments with 
membranes prepared from HEK293 cells stably expressing the CXCR3 receptor. b) Measured by a [35S]-GTP…γS func-
tional assay with membranes prepared from HEK293 cells stably expressing the CXCR3 receptor. c) The … represents 
the relative efficacy of a ligand compared to the endogenous agonist CXCL11 (which is set at α = 1.0). d) Could not be 
determined due to the too low functional assay window for this low-efficacy compound. All shown values are mean ± 
SEM of at least three independent experiments.
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# R R
1
Top view
ESP -18.8 to 18.8 kcal/
mol
Bottom view
ESP -18.8 to 18.8 
kcal/mol
Optimal
Angle (°)
Efficacy 
(γα)
5
F
H 43 0.20
6
Cl
H 58 0.73
25 H 40 0.11
27
Cl
H 39 0.05
31 Cl 58 0.06
38
Br
H 62 0.95
39
I
H 67 0.99
40
Br
H 40 0.08
Table 3: Electron density surfaces mapped with the electrostatic potential for selected compounds. Also the optimal 
biaryl dihedral angle as well as the relative efficacy (α) is given for these compounds.
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substituent influences the electrostatic potential of the inner aromatic ring (25 vs 27 and 38 
vs 40), yet there is little effect on the outer ring. Furthermore, the ortho-F group possesses 
a full negative hemisphere, whereas the heavier halogens introduce a positive potential (the 
so-called sigma-hole28) at the extension of the C-X axis (Table 3). With the increase of the 
halogen atom, the sigma-hole becomes progressively stronger (compounds 5 < 6 < 38 < 39). 
Interestingly, this trend corresponds to the order of efficacies of these compounds (Table 3), 
suggesting another contributor to the agonism switch. 
 
We compared the efficacy (α) with both dihedral angle (φ, in degrees (º)) of the optimal ligand 
conformation and the electrostatic potential (ESP, in kcal/mol) at the van der Waals radius of 
the ortho-halogen (Figure 4A). A regression analysis, shown in Figure 4B, gave a significant 
correlation with α = 0.024 * ESP - 0.010 * φ + 0.979 (R=0.89, R2=0.79, R
adj
=0.71, SE=0.17). 
The results on the SFR, electrostatic potential surfaces and regression analysis collectively 
demonstrate that the ortho-halogen may be involved in halogen bonding and that this may 
play a role in the switch from antagonism to full agonism, by possibly stabilizing an active 
state of the CXCR3 receptor. The current case arguably illustrates the concept of ‘mechanism 
cliffs’ (recently discussed29) with subtle structural changes inducing switches in functional 
efficacies of small-molecule ligands. While this phenomenon appears to be more common 
for aminergic class A GPCRs,30 mechanism cliffs for chemokine receptors are less frequently 
described.31 Notably, for CCR3 and for CCR5 a few subtle activation triggers have been 
disclosed.32-34 The structural class described in the present study includes a trigger that 
involves e.g. mere size of a single atom (from F to Br and I) and can therefore be considered as 
displaying a very steep mechanism cliff for chemokine receptor CXCR3. 
# R Hd-He in Å(NOESY)
H’-H’’ in Å 
(NOESY)
H’-H’’ in Å
(QM)
H’-H’’’ in Å
(QM)
5 F 2.34 2.37 2.40 4.41
6 Cl 2.32 2.58 2.68 4.16
25 H 2.33 2.40 2.40 4.42
29 2,5-diCl 2.33 2.66 2.69 4.16
34 Me 2.32 2.65 2.72 4.12
38 Br 2.33 2.63 2.76 4.09
Table 4: Experimental and calculated distances of several proton pairs based on QM calculations and on quantitative 
NOESY NMR experiments. The graph depicts the hydrogen atom correlations used.
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7.3 Conclusion
The molecular details of activation of peptide GPCRs by small molecules remains of both 
fundamental and practical relevance. Here, we describe the first non-peptidomimetic 
agonists for the CXCR3 receptor. A total of 26 compounds, all possessing a polycycloaliphatic 
group and biaryl system linked through a quaternary ammonium cation, were prepared by 
versatile synthetic routes. A remarkably subtle trigger for receptor activation is present on the 
outer aryl ring of the biaryl system and this allows for a full spectrum of functional efficacies 
to be achieved. Most notably, mere enlarging of the halogen atom size on the ortho-position 
of the outer ring from F to Br (38) or I (39) furnishes full CXCR3 agonists, whereas moving the 
Br/I group to the meta-position completely abolishes agonism. In contrast, modifications in 
the polycycloaliphatic group only had relatively minor effects on the agonist efficacies. QM 
and NOESY NMR were used to interrogate these phenomena. An important role is suggested 
for an optimal dihedral angle within the biaryl system of around 60° and halogen-bonding 
is hypothesized to be a key player in explaining the intriguing halogen-effect. Collectively, 
we have described how an ensemble of chemical tools can be applied to a relevant chemical 
biology event. Practically, we present 38 (VUF11222) and 39 (VUF11418) as useful tools in 
CXCR3 research. 
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7.4 Materials and Methods
Pharmacological assays
 General. All cell culture materials were purchased from PAA Laboratories GmbH 
(Pasching, Austria). [125I]-CXCL10 radioligand (2200 Ci/mmol) was obtained from Perkin 
Elmer Life and Analytical Sciences (Boston, MA, USA). Unlabeled CXCL11 was from Peprotech 
Figure 4: A) Representation of the dihedral angle … and the ESP at the extension of the C-X bond shown for 39. B) 
Predictive value of the regression analysis of the dihedral angle and the ESP to the experimental efficacy. Compound 
numbers are indicated for each individual data point in the figure.
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(Rocky Hill, NJ, USA). All mentioned chemicals were purchased from Sigma-Aldrich (St. Louis, 
MO, USA).
 Cell culture and transfection. HEK293 cells stably expressing CXCR3 were a kind 
gift from Dr K. Biber, (University Medical Center Groningen, The Netherlands) and were 
cultured as described previously.35 The cells were transfected with plasmid containing the 
reporter gene CRE-Luciferase as described in a previous report from our lab.36 
Membrane preparation and chemokine binding assay. Membrane preparation and competition 
radioligand bindings were performed as described previously35 with the exception that 
membranes from HEK293 cells stably expressing CXCR3 were used. 
 [35S]-GTPγ S functional assay. The used protocol was as described previously.35 
Briefly, 5 μg/well of membranes prepared from HEK293 cells stably expressing CXCR3 were 
incubated with CXCL11, or compounds in assay buffer containing 50 mM HEPES, 10 mM 
MgCl2, 100 mM NaCl, pH 7.2 supplemented with 3 mM GDP and 300 pM of [
35S]-GTPγ…S (Perkin 
Elmer) for 1 hour at room temperature before harvesting of the membranes on Unifilter GF/B 
plates. [35S]-GTPγ…S incorporation was determined using the Microbeta. When the assay was 
run in antagonist mode, the compound was added 30 min prior to addition of [35S]-GTPγ…S. The 
response was normalized to that of the endogenous agonist CXCL11 (set to α… = 1). As such, 
this normalized response represents relative efficacy of a given ligand presented as …α-value.
 CRE-luciferase reporter gene assay. This assay was performed as described 
previously.36 In brief, culture medium was aspirated and replaced with serum-free medium 
supplemented with 0.05% BSA and ligands. After 5 h, stimulation medium was replaced by 
25 μL substrate solution (39 mM Tris-H
3
PO
4
 pH 7.8, 39% glycerol, 2.6% Triton X-100, 860 μM 
dithiothreitol, 18 mM MgCl2, 825 μM ATP, 77 μM disodium pyrophosphate, 230 μg/mL beetle 
luciferin) and luminescence was measured using a Victor3 plate reader (PerkinElmer, Boston, 
MA).
 Data analysis. Non-linear regression analysis of the data and calculation of pK
d 
and pK
i
 values was performed using Prism 5.0d (GraphPad Software Inc., San Diego, CA) as 
described before.35 
Computational methods
 Quantum Mechanical Calculations. Quantum mechanical calculations were 
performed with Gaussian 03W37 using the Becke3LYP functional and the 6-311+G* basis set. 
For iodine, an additional SDD basis set was used. To alleviate computational complexity, only 
the biaryl portion was used: the rest of the molecule was omitted from the calculations as this 
is not expected to influence the electron density distribution of the outer substituted phenyl 
ring. As such, for the remaining biaryl model system, different conformations were generated 
by performing a potential energy scan for the dihedral angle between the two phenyl rings. 
Due to ligand symmetry, calculations were performed for a dihedral angle between 0° and 
180° with an interval of 30° (Figure S3). Potential energy differences were calculated and the 
lowest energy conformation was optimised with Gaussian to obtain the corresponding optimal 
dihedral angle. Subsequently, the electrostatic potential (ESP) of the ortho-substituent was 
determined at the van der Waals radius of the halogen atom in the extension of the C-X bond. 
Distances between the ortho-hydrogen atoms of the phenyl rings for selected compounds 
were experimentally approximated by NOESY for the verification of our calculations (see Main 
Text).
 Data Regression. A 2D quantitative structure activity relationship (QSAR) model was 
constructed using the ESP value and the dihedral angle of the optimized ligand conformations 
for a multiple linear regression to the efficacy. Data regression was performed using SPSS 
(SPSS Inc.; Chicago, IL, 2005; http://spss.com).
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Synthetic methods
 General. 2-Hydroxybenzeneboronic acid was from Alfa Aesar. All other chemicals 
were from Sigma-Aldrich. THF, toluene and CH2Cl2 were distilled freshly from CaH2, all other 
solvents were used as received. Compound 1 was prepared as described by us.35 Unless 
indicated otherwise, all reactions were carried out under an inert atmosphere. TLC analyses 
were performed with Merck F254 Alumina Silica Plates using UV visualization or staining. 
Microwave reactions were carried out on a Biotage® Initiator. Column purifications were 
carried out manually using Silicycle Ultra Pure Silica Gel or automatically using the Biotage® 
equipment. All HRMS spectra were recorded on Bruker micrOTOF MS using ESI in positive 
ion mode. Elemental Analysis was carried out at Mikroanalytisches Labor Pascher (Remagen, 
Germany). The 1H-, 13C- and 2D-NMR spectra were recorded on a Bruker 200, 250, 400 or 500 
MHz spectrometer. Infrared spectra were recorded on a Galaxy Series FT-IR 6030. Systematic 
names for molecules were generated using ChemBioDraw Ultra 11. Melting points were taken 
using the Stanford Research Systems Optimelt apparatus and values given are uncorrected. 
Optical rotations were measured with a sodium lamp and are reported as follows: [α…]
D
23 (c 
= g/100 mL, solvent). Unless reported otherwise, all compounds have a purity ≥95 % as 
measured by LC-MS. Chromatographic analyses were carried out as outlined in detail in the 
Supporting Information.
  General Procedure A1. A microwave vial was charged with the aryl bromide (0.90 
mmol), the boronic acid (ArB(OH)2, 1.80 mmol), toluene (3 mL), i-PrOH (0.8 mL), and a 2.0 
M Na2CO3-solution (0.50 mL). This mixture was degassed for 15 min by bubbling N2 through 
the mixture using a needle. Next, Pd(PPh
3
)
4
 (52 mg, 0.045 mmol) was added to the mixture 
and the vial was immediately capped and again degassed for 5 min. The vial was heated in 
the microwave at 130˚ C for (unless mentioned otherwise) 90 min. After this, the reaction 
mixture was filtered over Celite and most of the organic solvents were evaporated in vacuo. 
The pH of the residue was adjusted to pH>11 with a 1.0 M aq. NaOH solution and the mixture 
was extracted with DCM (3x). The combined DCM layers were washed with brine, dried over 
Na2SO4, filtered and concentrated in vacuo. This afforded the crude product, which was 
purified by column chromatography. 
 General Procedure A2. A microwave vial was charged with the aryl bromide (free base 
or salt, 1.0 mmol), the boronic acid (ArB(OH)2, 1.1 eq), Na2CO3 (3.0 eq in case of arylbromide 
salt, 2.0 eq in case of aryl bromide free base), DME (15 mL) and water (5 mL). This mixture 
was degassed for 15 min by bubbling N2 through the mixture using a needle. Next, Pd(PPh3)4 
(0.05 eq) was added to the mixture and the vial was immediately capped and again degassed 
for 5 min. The vial was heated in the microwave at 120˚ C for (unless mentioned otherwise) 60 
min. After this, the reaction mixture was diluted with DCM and 2.0 M aq. Na2CO3. Extraction 
was performed twice with DCM. The combined organic layers were dried over Na2SO4, filtered 
and concentrated in vacuo. This afforded the crude product, which was purified by column 
chromatography.
 General Procedure B. The amine (given eq) and aldehyde (1.0 eq) were dissolved in 
DCE (given amount). The reaction mixture was stirred at r.t. for 30 minutes. Then, NaBH(OAc)
3
 
(given eq) was added. After stirring overnight (unless mentioned otherwise) at r.t., the reaction 
was quenched with aqueous Na2CO3 (2.0 M). The mixture was stirred for 30 minutes at r.t. The 
layers were separated and the aqueous layer was extracted twice with DCM. The combined 
organic layers were dried over Na2SO4, filtered and concentrated in vacuo to give the crude 
product, which was purified by column chromatography.
 General procedure C. In a round bottom flask, the tertiary amine precursor (0.25 
mmol) was dissolved in DCM (6.4 mL). The flask was placed under a nitrogen atmosphere, 
closed with a septum and covered with aluminum foil. Then, excess MeI (given amount) was 
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added to the solution via a syringe. The reaction mixture was allowed to stir at r.t. in the 
dark. TLC analysis was used to monitor the progress of the reaction. If required, additional 
quantities of MeI were added followed by prolonged stirring. Such cycles were applied until 
completion of the reaction. 
The work-up (unless mentioned otherwise) was as follows. The reaction mixture was cooled in 
an ice bath and 3 volume equivalents of MTBE were added to the reaction mixture slowly via 
a dropping funnel while stirring. This usually caused precipitation of the salt. The precipitate 
was filtered and washed with a precooled solution of DCM/MTBE (1/3). Typically, this delivers 
the product salt in high purity. If required, the salt was either reprecipitated from DCM/MTBE 
as just described, or recrystallised from hot DCM/MTBE. Occasionally (for example, in the 
case of 28 and 33), in the initial precipitation with MTBE the salt does not precipitate as a 
solid but as a sticky oil. In those cases, the following procedure was used. The solution was 
concentrated in vacuo. A small amount of DCM was added, the mixture was gently warmed 
and enough MTBE was added drop wise until slight turbidity appears. Cooling to r.t. and then 
to -30 °C yielded a precipitate. This solid was filtered and washed with a precooled solution 
of DCM/MTBE (1/3).  All final ammonium salts were thoroughly dried under high vacuum and 
stored in the dark. Even then, some salts tend to retain DCM traces as crystal solvates, but 
these are non-interfering.
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Figure S1: Functional responses are specifically mediated via CXCR3. [35S]-GTPγ…S functional assay performed on mem-
branes derived from HEK293/CXCR3 cells with (A) a single 10 μM (EC
80
) concentration of 6 in presence or absence of 
specific CXCR3 antagonist NBI-74330 (10 μM), or (B) a concentration series of 39 and a concentration series of the 
antagonist NBI-74330 with an EC
80
 concentration (3.6 μ…M) of 39. (C) A [35S]-GTPγ…S experiment with compounds 27, 6 
and 39 (10 μM) on membranes derived from empty HEK293 cells. 
Figure S2: (A) Correlation between calculated dihedral angle and calculated H’-H’’ distance (B): NOESY NMR ex-
periments. Correlation between the calculated and experimentally determined H’-H’’ distance. The red reference line 
shows the hypothetical correlation.
A B
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Figure S3: Potential energy diagrams for biaryl compounds. Indicated are the potential energy values for every 30° 
dihedral angle rotation (red dots) relative to the lowest energy conformation (indicated with squares). For each subplot, 
the Y-axis indicates the relative potential energy in kcal/mol and the X-axis indicates the angle in degrees. Numbers 
above the graphs indicate molecule number and corresponding preferred angle.
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8: Abstract
The chemokine receptor CXCR7 binds with high affinity CXCL12 and CXCL11, chemokines that 
were previously thought to bind exclusively to CXCR4 and CXCR3, respectively. Expression 
of CXCR7 has been associated with cardiac development as well as with tumor growth and 
progression. Despite having all the canonical features of G protein-coupled receptors (GPCRs), 
the signalling pathways following CXCR7 activation remain controversial, since unlike typical 
chemokine receptors, CXCR7 fails to activate Gα
i
-proteins. CXCR7 has recently been shown 
to interact with β-arrestins and such interaction has been suggested to be responsible for 
G protein-independent signals through ERK-1/2 phosphorylation. Signal transduction by 
CXCR7 is controlled at the membrane by the process of GPCR trafficking. In the present 
study we investigated the regulatory processes triggered by CXCR7 activation as well as the 
molecular interactions that participate in such processes. We show that, CXCR7 internalizes 
and recycles back to the cell surface after agonist exposure, and that internalization is 
not only β-arrestin-mediated but also dependent on the Serine/Threonine residues at the 
C-terminus of the receptor. Furthermore we describe, for the first time, the constitutive 
ubiquitination of CXCR7. Such ubiquitination is a key modification responsible for the correct 
trafficking of CXCR7 from and to the plasma membrane. Moreover, we found that CXCR7 is 
reversibly deubiquitinated upon treatment with CXCL12. Finally, we have also identified the 
Lysine residues at the C-terminus of CXCR7 to be essential for receptor cell surface delivery. 
Together these data demonstrate the differential regulation of CXCR7 compared to the related 
CXCR3 and CXCR4 receptors, and highlight the importance of understanding the molecular 
determinants responsible for this process.
8.1: Introduction
CXCL12 (SDF-1…)-mediated effects have been classically attributed to its interaction with 
chemokine receptor CXCR4. However, it has recently been appreciated that CXCL12 also 
binds with high affinity to chemokine receptor CXCR7 (earlier also referred to as RDC-1 or 
CXC-CKR2), an evolutionary conserved G protein-coupled receptor (GPCR) (1, 2). In addition, 
the CXCR3-ligand CXCL11 (I-TAC) has also been found to bind to CXCR7 (1, 2). CXCR7 plays a 
Figure 1: …β-arrestin2 recruitment to CXCR7 is dependent on C-terminal Ser/Thr residues. (A) CXCL11 or CXCL12-
mediated …β-arrestin2 recruitment to CXCR7. HEK293T co-expressing RLuc-tagged CXCR7 and YFP-tagged …β-arrestin2 
were stimulated with increasing concentrations of CXCL11 (open circles) or CXCL12 (filled circles) (B) HEK293T co-
expressing RLuc-tagged CXCR7 and YFP-tagged …β-arrestin2 were incubated overnight with 25 ng/ml of PTX or for 30 
min with the CXCR7-specific antibody 8F11 prior to the BRET measurement. (C) CXCL12-induced β…-arrestin2 recruit-
ment to CXCR7 wt (filled circles), a truncated CXCR7 lacking the C-terminus (CXCR7 ∆C, filled triangles) or a mutant 
CXCR7 for which all the Ser and Thr residues were mutated to Ala (CXCR7 ST/A, open squares). Data represent the mean 
± SEM of 4 experiments each performed in triplicate. Results are expressed in Net BRET as described in Materials and 
Methods. ***, p< 0.001 by one-way ANOVA and Bonferroni post test.
Ubiquitination of CXCR7 controls receptor trafficking   137
C8
role in cardiac development (3) as well as in promoting tumor development and progression 
(4, 5). In fact, CXCR7 has been shown to promote the growth of tumors formed from lung, 
breast and liver cancer cells (4, 6) and increased expression of CXCR7 has been correlated 
with the aggressiveness of prostate cancer (7), suggesting an important role for this receptor 
in tumor metastases and progression (8). More recently, it has been shown that CXCR7 is 
also expressed in the nervous system, where it has been described to be involved in both the 
development of the CNS (9, 10) as well as in tumor malignancy (11). Importantly, in cortical 
interneurons, CXCR7 has been postulated to indirectly regulate the expression of CXCR4 
and consequently sustain normal levels of this receptor (12). Similarly, in zebrafish, CXCR7 
is critical for the proper migration of primordial germ cells (13). Such an emerging role for 
CXCR7 in both normal development and cancer are motivating ongoing efforts to target this 
receptor therapeutically. However, molecular interactions and signaling events following 
CXCL11 or CXCL12 binding to CXCR7 remain poorly defined and controversial.
Several reports suggest that CXCR7, despite conserving most of the canonical GPCR features, 
does not activate Gα
i
-mediated pathways that are typical for chemokine receptors and would 
result in GTP hydrolysis, calcium mobilization, and chemotaxis (2, 3, 14). In contrast, other 
studies suggest CXCR7 as a modulator of CXCR4-mediated signaling through CXCR7-CXCR4 
heterodimerization. Indeed, the presence of CXCR7 has a dramatic effect on the signaling 
derived from CXCR4 activation (14-16). Another hypothesis on the physiological function of 
CXCR7 suggests its role as a “decoy” receptor or chemokine scavenger. Internalization upon 
binding of CXCL11 or CXCL12 would generate the gradient of chemokine necessary for a 
correct CXCR4 migratory response (12, 13, 17, 18), without any signaling following chemokine 
binding to CXCR7. Yet, some of these decoy receptors have been shown to be constitutively 
internalized by a β-arrestin-mediated mechanism (19). It has recently been described that 
CXCR7 also interacts with β-arrestin in a ligand-dependent manner (15, 20, 21) and, more 
importantly, that this interaction results in ERK1/2 phosphorylation and translocation via a 
G protein-independent, β-arrestin-mediated signal (22, 23), suggesting different functions 
other than the “decoy” activity of this receptor.
As for all membrane proteins, the magnitude of the cellular response elicited by a ligand 
binding to a GPCR is dictated by the level of receptor expression at the plasma membrane, 
which is the balance of finely tuned endocytic and recycling pathways. Recent data reveal 
that receptor trafficking can have differential effects on the strength of the intracellular 
signaling cascade (24). One of the most common events for receptor desensitization and 
internalization involves the recruitment of the β-arrestin protein, which binds to the activated 
and phosphorylated receptor. This uncouples the receptor from its G protein and scaffolds the 
binding of proteins involved in formation of clathrin-coated pits and receptor endocytosis (25). 
Once internalized in early endosomes, some GPCRs are dephosphorylated and subsequently 
recycled back to the plasma membrane where they can again respond to agonists, a process 
termed resensitization. Alternatively, a subclass of GPCRs enter the degradation pathway, 
where they are targeted to lysosomes for proteolysis, giving rise to long-term attenuation 
of signaling or downregulation (25). Despite recent advances, the mechanisms mediating 
endosomal sorting remain elusive; however, receptor ubiquitination, i.e. the covalent addition 
of the small protein ubiquitin to the lysine side chains of the substrate protein, has recently been 
reported to play an important role for several GPCRs. Recent studies suggest that mammalian 
GPCR ubiquitination is essential for lysosomal sorting but not for receptor internalization 
(26, 27). Direct …β2-adrenergic receptor (…β2AR) ubiquitination is not required for internalization 
but regulates lysosomal sorting and degradation of activated receptors (27). Similar to …β2AR, 
ubiquitination of CXCR4 is essential for agonist-promoted receptor lysosomal degradation but 
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not for internalization (26). In contrast, the protease-activated receptor-1 (PAR-1) has been 
shown to be basally ubiquitinated and de-ubiquitinated after receptor activation, revealing 
a novel function for ubiquitination in the regulation of GPCR internalization (28). Several 
recent reports show that CXCR7 internalizes upon agonist stimulation and, recycles to the cell 
surface (17, 20, 21, 29). However, the mechanisms involved in such regulation have not yet 
been identified. Thus, there is a need to define fundamental mechanisms for the activation 
and regulation of this receptor. In the present study we have investigated the molecular 
determinants responsible for CXCR7/β…-arrestin interaction and CXCR7 regulation. We have 
identified C-terminal CXCR7 residues that are of key importance for its internalization and 
subsequent recycling. Importantly, and in contrast to what has been described for the closely 
related receptor CXCR4, we show that CXCR7 is basally ubiquitinated and investigate the role 
of ubiquitination/de-ubiquitination in CXCR7 regulation. 
8.2: Results
8.2.1: CXCR7 C-terminal Serine/Threonine residues are essential for β-arrestin recruitment 
In order to investigate potential CXCR7-mediated signaling, we evaluated CXCR7 activation 
in several assays that have been traditionally linked to chemokine receptor activation. Unlike 
classical chemokine receptors, and despite being expressed at the cell surface, CXCR7 does 
not show Gα
i
 protein coupling as assessed by [35S]-GTP…γS accumulation assay or inhibition 
of forskolin-induced cAMP levels (Supplemental figure S1 and (14)). Additionally, no 
CXCR7-mediated response was observed in cAMP and inositol phosphates accumulation 
experiments, ruling out the possibility of any detectable Gα
s
 and Gα
q/11
 protein activation 
(data not shown). More recently, the ability of CXCR7 to recruit β-arrestin has emerged as the 
potential initial signaling step after receptor activation (15, 21, 23, 30). In agreement with 
this, we detected β-arrestin recruitment to CXCR7 using a BRET approach. In HEK293T cells 
Figure 2: (A) CXCR7 internalization depends on CCPs and is G protein-independent. HEK293T cells were transfected 
with wt CXCR7 (and …β-arrestin (319-418) were indicated) and cell surface levels of the receptor after CXCL12 stimula-
tion was detected by ELISA using the CXCR7-specific antibody 11G8. Incubation with 0.4M Sucrose was done 30 min 
prior and during stimulation. PTX was incubated overnight at 25 ng/ml final concentration. (B) β…-arrestin1/2 knock-
down prevents CXCR7 internalization. HEK293/CXCR7 cells transfected with control siRNAs (white bars) or pools tar-
geting …β-arrestin1/2 (filled bars), were stimulated with CXCL12 (10-8M) or vehicle for 45 min and receptor surface 
expression was determined. Knockdown of …β-arrestin1 and -2, 48 hrs after transfection, was assessed in western blot 
using an anti β-……arrestin1/2 antibody (inset). Anti-STAT3 (mAb 79D7, Cell Signaling Technologies) was used as loading 
control. (C) CXCR7 C-terminus is essential for receptor internalization. HEK293T cells were transfected with wt CXCR7 
(filled bars), CXCR7 ∆C (grey bars) or CXCR7 ST/A (white bars) and cell surface receptor levels were assessed as above. 
Data represent the mean ± SEM of at least 3 experiments each performed in triplicate. ***, p< 0.001 by one-way ANOVA 
and Bonferroni post test. 
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transiently transfected with CXCR7-RLuc and …β-arrestin2-YFP, a dose-dependent increase in 
energy transfer was observed when stimulating the receptor with CXCL11 or CXCL12 (pEC
50
 = 
8.5 ± 0.1 and 8.6 ± 0.1 respectively) (Fig. 1A). Furthermore, …β-arrestin1 recruitment to CXCR7 
by CXCL11 and CXCL12 was induced with similar potencies as observed for …β-arrestin2 (pEC
50
 
= 8.7 ± 0.1 and 8.6 ± 0.1 for CXCL11 and CXCL12 respectively). The anti-CXCR7 antibody 
8F11 blocked the chemokine-mediated …β-arrestin recruitment in the transfected HEK293T 
cells, indicating that it is a CXCR7-specific effect (Fig. 1B and (21)). In addition, β…-arrestin 
recruitment was shown to be Gα
i/o
 protein-independent, as an overnight treatment of the cells 
with pertussis toxin (PTX) had no effect on the ability of CXCR7 to interact with the scaffolding 
protein (Fig. 1B).
It has been shown for several GPCRs that β-arrestin binds to phosphorylated amino acid 
residues of the C-terminus of the GPCR protein (31). We therefore generated a C-terminally 
truncated CXCR7 mutant, which lacks the 39 C-terminal amino acids after the NPxxY motif 
(CXCR7 ∆C, Supplemental Table 1). Radioligand binding assays showed that the truncated 
receptor retained the same binding affinity for CXCL12 as the wild type (pK
d
 ± SEM, 9.7±0.1 
and 9.3±0.1 for CXCR7 wt and CXCR7 ∆…C respectively, Supplemental Table 2). …β-arrestin 
recruitment experiments using an RLuc-tagged form of CXCR7 …∆C confirmed that this truncated 
receptor was unable to recruit …β-arrestin2 (Fig. 1C). In addition, mutation of all the serine 
(Ser) and threonine (Thr) residues in the C-terminus to alanine (Ala) residues (CXCR7 ST/A, 
Supplemental Table 1) resulted in similar observations. CXCR7 ST/A was not able to recruit …β-
arrestin2 (Fig. 1C). As expected, CXCL12 displayed similar affinity for the CXCR7 ST/A mutant 
compared to the CXCR7 WT (pK
d
 ± SEM, 10.6±0.3, and 9.7±0.1, respectively, Supplemental 
Table 2). Cell surface expression of RLuc-tagged CXCR7 ∆C or ST/A was confirmed by whole 
cell [125I]-CXCL12 binding, ruling out the possibility that the lack of β…-arrestin recruitment is 
caused by the absence of the receptor mutants at the cell surface (Supplemental figure S2). 
8.2.2: CXCR7 internalizes via clathrin-coated pits in a β-arrestin-dependent manner 
…β-arrestins have classically been involved in GPCR signal termination and internalization by 
binding to activated/phosphorylated receptors. We therefore investigated CXCR7 regulation 
after agonist exposure (Fig. 2). After 45 min incubation with 10-8 M CXCL12, a decrease in cell 
surface CXCR7 expression was observed by ELISA using the specific CXCR7 antibody 11G8. 
This effect was mimicked by CXCL11 and was not affected by overnight PTX treatment (Fig. 2A 
and 2C). Internalization was blocked when the incubation was performed at 4°C or in presence 
of 0.4 M sucrose, typical inhibitors of receptor internalization (32) (Fig. 2A). Co-transfection 
of CXCR7 with the β…-arrestin (319-418) dominant negative (DN), effectively inhibited agonist-
induced CXCR7 internalization. …β-arrestin (319-418) encodes for the last 100 aa of the C-tail 
of …β-arrestin1 and effectively binds clathrin, but completely lacks the capacity to bind GPCRs. 
Consequently, overexpression of β…-arrestin (319-418) DN depletes the clathrin-mediated 
endocytic machinery (33). Therefore, these results suggest that CXCR7 rapidly internalizes 
upon CXCL11 and CXCL12 exposure by a mechanism dependent on clathrin-coated pits. This 
result, together with the fact that the endocytic processing of CXCR7 is G protein-independent, 
suggests the involvement of β-arrestins in CXCR7 internalization. This hypothesis was further 
validated by performing ELISA experiments in the presence of siRNAs targeting …β-arrestin1 
and 2 (Fig 2B). Transfection of HEK293/CXCR7 cells with a non-targeting siRNA pool had no 
effect on the previously observed CXCL12-induced internalization. However, transfection 
of siRNA pools targeting …β-arrestin1 and -2, resulted in a significant knock-down of the 
endogenous levels of these proteins (as shown by Western blot analysis in Fig. 2B) and was 
able to completely inhibit CXCL12-mediated internalization of CXCR7 (Fig. 2B). 
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Furthermore, and in agreement with the previous results indicating the lack of β-arrestin 
recruitment, no internalization was observed after CXCL12 or CXCL11-stimulation of the 
CXCR7 ∆C or the CXCR7 ST/A mutant receptors since the cell surface receptor levels detected 
by ELISA were not significantly different in the presence or absence of either CXCL11 or 
CXCL12 (Fig. 2C). Altogether, these results demonstrate that CXCR7 internalization is mainly 
(if not only) β-arrestin-dependent and relies on the presence of the Ser and Thr residues in the 
C-terminus of the receptor. 
Figure 3: CXCR7 recycles to the cell surface after internalization. (A) HEK293 stably expressing CXCR7 were stimu-
lated with 10-8M CXCL11, CXCL12 or vehicle for 45 min or 3 h and fixed immediately. CXCR7 was detected using the 
specific 11G8 antibody and an Alexa-488-conjugated secondary antibody. Scale bar represents 10 …μm. (B) HEK293T 
cells expressing CXCR7 (filled symbols) or CXCR3 (open symbols) were incubated with CXCL11 (10-8M, squares), 
CXCL12 (10-8M, triangles) or vehicle (circles) for the indicated times. Cell surface receptor levels were detected by 
ELISA using CXCR7- or CXCR3-specific antibodies (11G8 and mAB160, respectively). Results were normalized to basal 
surface protein levels, and data represent the mean ± SEM of 4 experiments each performed in triplicate. (C) ELISA 
was performed as in B in cells pre-incubated for 2h with the de novo protein synthesis inhibitor cycloheximide (10 …μg/
ml). (D) ELISA performed as in C on intact HEK293/CXCR7 cells treated with vehicle or 1 …μM of bafilomycin A1 (Baf 
A1), 30 min prior to incubation with CXCL12. (E) C-terminal Ser/Thr clusters determine receptor fate after internaliza-
tion. HEK293T cells were transiently transfected with CXCR7 wt (white bars) or with a chimeric receptor consisting 
of CXCR7 harboring the C-terminal sequence of CXCR3 (CXCR7-X3, filled bars). To assess the cell surface expression 
of the receptor, ELISA experiments were performed after 30 min or 3 hours of incubation with 10-8M CXCL12. Data 
represent the mean ± SEM of 3 experiments each performed in triplicate. ***, p< 0.001, ** and *, p<0.05 by one-way 
ANOVA and Bonferroni post test.
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8.2.3: CXCR7 recycles to the cell surface after internalization
Once internalized, GPCRs are either directed to late endosomes and processed for lysosomal 
degradation, or recycled to the cell surface (25). To investigate the fate of internalized CXCR7 
receptors, we stimulated HEK293 cells, stably expressing CXCR7, with 10-8M of CXCL11 
or CXCL12 and incubated them for 45 min or 3 hours and subsequently stained for CXCR7 
immunoreactivity. In basal conditions, CXCR7 was uniformly distributed at the cell surface (Fig. 
3A). However, after 45 min of chemokine incubation a marked decrease in cell surface staining 
was observed, in agreement with the results from the ELISA experiments and suggesting 
receptor internalization (Fig. 2). In contrast, after 3 hours incubation with chemokine, the level 
of cell surface CXCR7 expression was similar to the expression in basal conditions, indicating 
the reappearance of CXCR7 proteins at the cell surface (Fig. 3A). These results were then 
confirmed by time-course ELISA experiments. In cells transiently transfected with CXCR7, 
we observed receptor internalization after 1 hour of ligand stimulation and recovery of cell 
surface CXCR7 levels at 3 hours of chemokine incubation (Fig. 3B). In contrast, stimulation of 
CXCR3 with its agonist CXCL11, led to significant internalization after 1 hour, but no recycling 
to the cell surface was detected at later time points, indicating the occurrence of receptor 
downregulation (Fig. 3B). In addition, permeabilization of the cells showed a decrease of 
CXCR3 but not CXCR7 total receptor levels (supplemental Fig. S3) further highlighting the 
differences in post-endocytic sorting of both receptors. To rule out the detection of newly 
synthesized receptors after 3 hours of agonist incubation, cells were treated with the de novo 
protein synthesis inhibitor cycloheximide (10 μg/ml). This had no effect on the recovery of 
CXCR7 cell surface levels, suggesting that, after internalization CXCR7 recycles back to the 
cell surface, despite the continuous presence of chemokines (Fig. 3C). Several reports have 
recently suggested that CXCR7 can reside within intracellular pools (13, 17, 29) and therefore, 
mobilization of CXCR7 from such intracellular stores could also account for the reappearance 
of the receptor at the plasma membrane, even in presence of cycloheximide. To exclude this 
possibility we examined the effects of bafilomycin A1, an inhibitor of vacuolar-type H+-ATPases, 
on CXCR7 recycling. It has previously been shown that endosomal acidification promotes 
dissociation of ligand from GPCRs, and that inhibitors of such acidification prevent receptor 
recycling and resensitization (34, 35). As shown in Figure 3D, incubation of CXCR7 expressing 
cells with 1 μM bafilomycin A1 did not affect CXCR7 internalization after 45 min of CXCL12 
stimulation. In contrast, bafilomycin A1 treatment did severely affect the reappearance of 
CXCR7 at the cell surface after 3 hours (Fig. 3D). These results therefore indicate that CXCR7 
proteins are able to recycle to the plasma membrane after CXCL12 stimulation. 
The presence of Ser and Thr clusters within the C-terminus of GPCRs is indicative of a stable 
interaction with …β-arrestin and a slow or no recycling to the cell surface. Conversely, absence 
of such clusters induces a more transient interaction with …β-arrestin and allows rapid recycling 
of the receptor to the cell surface (36). Indeed, the sequence of the C-terminal tails of CXCR3 
and CXCR7 differs substantially (Supplemental Table 1). Whereas the C-terminus of CXCR3 
contains Ser/Thr clusters, such a motif is not present in the CXCR7 C-terminus. To test the role 
of the C-terminus in receptor recycling, we generated a chimeric CXCR7 receptor harboring 
the C-terminal sequence of CXCR3 (CXCR7-X3). This chimeric receptor showed the same 
affinity for CXCL12 as the wild type receptor (9.7±0.1 vs 9.5±0.1, pK
d
 ± SEM, Supplemental 
Table 2). ELISA experiments with transiently transfected HEK293T cells showed no recycling 
of this chimeric receptor after long-term agonist exposure, indicating that the presence of 
Ser/Thr clusters on the CXCR3 C-terminus determines its downregulation, whereas the 
absence of these clusters on the CXCR7 C-terminus, allows its re-routing to the cell surface 
(Fig. 3E). Unfortunately, generation of a chimeric receptor of CXCR3 with the C-terminus of 
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CXCR7 (CXCR3-X7) resulted in a receptor with very limited cell surface expression whilst the 
total expression level was similar to that of the wild type CXCR3. These observations suggest 
the presence of molecular determinants on the CXCR3 C-tail sequence that are absent in 
CXCR7 and that are important for proper cell surface delivery of CXCR3. This observation is in 
line with previous results on the CXCR3 receptor where several C-terminal truncations result 
in poorly expressed receptors (Scholten et al., unpublished observations). 
8.2.4: CXCR7 is constitutively ubiquitinated and CXCL12 stimulation induces receptor de-
ubiquitination
Recently, it has been proposed that ubiquitination plays an important role in GPCR regulation 
(37). Receptors such as the β…2-adrenergic receptor, the vasopressin receptor, PAR1 receptor 
and CXCR4 are all regulated by the covalent linkage of intracellular lysine residues and the 
small protein/peptide ubiquitin (26-28, 38). Ubiquitination of CXCR4 by the E3 ubiquitin 
ligase AIP4 following activation with CXCL12 results in receptor downregulation (26). 
Sequence comparison of the C-terminus of CXCR4 and CXCR7 revealed that, similar to CXCR4, 
CXCR7 contains several lysine (Lys) residues in its C-terminus. We therefore investigated the 
ubiquitination status of CXCR7 by co-immunoprecipitation experiments using HA-tagged 
ubiquitin (HA-Ub) and CXCR7 wt (Fig. 4). Interestingly, and in contrast to CXCR4, we observed 
that CXCR7 is ubiquitinated in basal conditions. In the lane corresponding to non-stimulated 
cells, a clear band could be detected after immunoprecipitation of HA-Ub and subsequent 
detection of CXCR7 with the 11G8 antibody (Fig. 4). This band was not observed when the co-
immunoprecipitation was performed in samples expressing the CXCR7 ∆C or a CXCR7 mutant 
in which all Lys residues had been replaced by Ala (CXCR7 K/A), confirming ubiquitination 
of CXCR7 at C-terminal Lys residues. Moreover, activation of CXCR7 by CXCL12 induced a 
rapid receptor de-ubiquitination, as the intensity of the band corresponding to ubiquitinated 
receptor decreased significantly after 30 min incubation with CXCL12 (10-8M). Conversely, 
removal of the chemokine by subsequent washout steps resulted in the reappearance of 
Figure 4: The C-terminus of CXCR7 is constitutively ubiquitinated. (A) CXCR7 gets deubiquitinated by CXCL12-stim-
ulation. HEK293T cells were transfected as indicated and processed for immunoprecipitation of the HA-Ub (See Materi-
als and Methods). (A) CXCR7 was stimulated with 10-8M CXCL12 for 30 min, and removal of CXCL12 was performed by 
two washes of the cells and additional 30 min incubation with fresh chemokine-free media. Detection of the immuno-
precipitated CXCR7 was done with the 11G8 antibody. HA-Ub expression was confirmed by blotting lysates using an 
anti-HA antibody and equal loading was controlled by detection of actin. Molecular weight markers (kDa) are indicated 
on the right of the blot. (B) Detection of total CXCR7 expression by ELISA in the same cells. 
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the band corresponding to the ubiquitinated state of CXCR7 (Fig. 4) suggesting that ligand-
induced deubiquitination of CXCR7 is a reversible process.
In contrast to CXCR7, the chemokine receptor CXCR3 has no Lys residues in its C-terminus. 
We therefore performed similar co-immunoprecipitation experiments in cells transfected 
with the chimeric receptor CXCR7-X3 and the reciprocal CXCR3-X7. As shown in Fig. 5, and 
in agreement with the results obtained with the CXCR7 ∆C and CXCR7 K/A mutants, the 
introduction of the CXCR3 sequence on the CXCR7 tail resulted in a receptor unable to undergo 
basal ubiquitination, whereas introducing Lys residues in the CXCR3 receptor resulted in a 
mutant receptor able to be co-immunoprecipitated with HA-Ub. 
To confirm the constitutive ubiquitination of CXCR7 and the subsequent de-ubiquitination 
after CXCL12 activation, we performed BRET2 experiments that allow real-time monitoring of 
receptor ubiquitination (39). In these experiments, cells were co-transfected with RLuc-tagged 
CXCR7 and a GFP2-tagged ubiquitin or, as a negative control, a (G75A, G76A)-Ub-GFP2 mutant 
that is unable to take part in the ubiquitination process (39). In cells transfected with CXCR7-
RLuc as energy donor, a decrease of the BRET response was detected after 30 min incubation 
with 10-8 M CXCL12. These data are in agreement with the suggested CXCR7 de-ubiquitination 
after agonist exposure (Fig. 6). In addition, no change in energy transfer was observed when 
the (G75A, G76A)-Ub-GFP2 mutant was co-expressed with CXCR7-RLuc (Fig. 6A). When the 
same experiment was performed with the CXCR7 ∆C-RLuc (Fig. 6A) or CXCR3-RLuc (Fig. 6C) 
as energy donors, agonist stimulation did not induce any change in BRET2 indicating the 
absence of modulation of the ubiquitination state of these receptors. Interestingly, when the 
phosphorylation-deficient mutant CXCR7 ST/A-RLuc was used, we observed an increase of 
receptor ubiquitination upon CXCL12 stimulation. This result suggests that, in the absence of 
…β-arrestin recruitment, CXCR7 cannot undergo deubiquitination and, most importantly, that 
the ubiquitin-conjugated CXCR7 is the prevalent form at the cell surface. Finally, when CXCR4-
RLuc was used as energy donor, CXCL12 stimulation induced an increase in energy transfer 
(Fig. 6B), which is in agreement with previous reports on increased CXCR4 ubiquitination 
after agonist exposure and therefore suggesting differential regulation of the two CXCL12 
receptors (26).
Figure 5: CXCR7/CXCR3 tail switch alters ubiquitination properties of the receptors. (A) Immunoprecipitation 
experiments were performed in cells expressing chimeric receptors consisting on CXCR7 with CXCR3 C-terminus 
(CXCR7-X3) or the reciprocal CXCR3 with CXCR7 C-terminus (CXCR3-X7). Detection of the immunoprecipitated CXCR7 
and CXCR3 was done with the 11G8 and mAB160 antibodies, respectively. HA-Ub expression was confirmed blotting 
lysates using an anti-HA antibody and equal loading was controlled by detection of actin. Molecular weight markers 
(kDa) are indicated on the side of the blots. (B) Detection of total CXCR7 expression by ELISA in the same cells.
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8.2.5: C-terminal lysine residues are important for correct CXCR7 trafficking to the cell 
surface
Despite normal binding characteristics when assessed by [125I]-CXCL12 membrane binding, 
no cell surface expression could be detected for the CXCR7 K/A mutant when performing 
[125I]-CXCL12 whole cell binding, intact cell ELISA and intact cell immunocytochemistry 
(Fig. 7). However, the CXCR7 K/A mutant could be detected after permeabilization of cells in 
both, ELISA and immunocytochemistry experiments. Under these conditions CXCR7 WT was 
distributed in punctate intracellular vesicles whereas the K/A mutant was uniformly distributed 
in the cytoplasm and displaying a marked colocalization with β…-arrestin (Supplemental Fig. 
S4). Such colocalization is in agreement with the fact that, although being unable to detect 
an CXCL12-dependent β-arrestin recruitment for CXCR7 K/A (due to its absence from the 
cell surface), we could observe an increased receptor-β-arrestin2 BRET signal in the basal 
state of CXCR7 K/A when compared to the wild type receptor (Supplemental Fig. S5). These 
results suggest that although its ability to bind chemokines remains unaltered, the absence of 
C-terminal lysines results in constitutive internalization and intracellular retention of CXCR7, 
demonstrating the importance of the Lys residues of the C-terminus of CXCR7 for the correct 
trafficking of this receptor to the cell surface.  
8.3: Discussion
Due to its potential role in cancer development and progression, the recently deorphanized 
chemokine receptor CXCR7 has become a potential therapeutic target for the treatment of a 
variety of tumors (4, 7, 8). In addition, the fact that CXCR7 binds with high affinity to CXCL12 
requires a revisit of some observed effects thought to be solely mediated by CXCR4 and CXCR3, 
and a detailed understanding of the biochemistry and pharmacology of CXCR7. An initial step 
in the characterization of CXCR7 is to establish the mechanisms that regulate its expression 
at the cell surface. The regulatory processes for CXCR4 have been extensively studied and it 
has been demonstrated that CXCR4 is phosphorylated by several kinases at specific sites that 
result in differential CXCL12-induced signaling (40). β…-arrestin recruitment to phosphorylated 
residues of the CXCR4 C-terminus has been shown to mediate not only receptor internalization 
but also CXCL12-mediated chemotaxis via p38 MAPK (41-43). In addition, it has also been 
demonstrated that the interaction between …β-arrestin and CXCR4 targets the receptor for 
lysosomal degradation (44). In the present report we show that …β-arrestin recruitment is 
also the main component of the endocytic machinery that internalizes CXCR7 after agonist 
exposure. Interestingly, despite the difference in CXCR7 affinities of CXCL11 and CXCL12 in 
radioligand binding studies, they have similar potencies in β…-arrestin recruitment. We have 
identified the Ser/Thr residues of the C-tail of the receptor to be essential for …β-arrestin 
interaction as well as CXCR7 internalization, given the findings that CXCR7 ∆C and CXCR7 
ST/A fail not only to recruit …β-arrestin but also to internalize. As intracellular Ser and Thr 
residues represent the phosphorylation sites of GPCRs that lead to arrestin recruitment and 
subsequent desensitization and internalization, our results suggest the existence of one or 
several kinases responsible of CXCR7 phosphorylation. Further investigation is required to 
determine the nature of this phosphorylation and which kinases (e.g. GRKs) are involved. Both 
…β-arrestin recruitment and receptor internalization are G protein-independent as shown by 
their PTX insensitivity. In addition, a clathrin-coated pit endocytic mechanism could also be 
suggested from the inhibition of CXCR7 internalization by the …β-arrestin (319-418) peptide. 
Finally, the ability of …β-arrestin1/2 siRNAs to completely block receptor internalization 
provided further evidence for the involvement of these proteins in the regulation of CXCR7.
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A sequence comparison of the C-terminal tail of CXCR7 and CXCR3 highlighted the presence 
of Ser/Thr clusters in the latter receptor. Such Ser/Thr clusters have been proposed to be 
responsible for a strong interaction with …β-arrestin thus inducing slow internalization and, 
eventually, receptor downregulation (36). This was in fact observed when assessing the 
internalization of CXCR3, which showed a decrease in the total number of receptors after 
3 hours incubation with CXCL11. Internalization via …β-arrestin recruitment and subsequent 
degradation has also been described for CXCR4, which also contains Ser/Thr clusters in its 
C-terminus (41). On the other hand, we here show that once internalized, CXCR7 recycles 
back to the cell surface, which is in agreement with the absence of Ser/Thr clusters in its 
C-tail, corresponding to a more dynamic interaction with …β-arrestin. By generating a chimera 
of CXCR7 with the C-terminus of CXCR3, we obtained a receptor unable to recycle and, most 
likely, subject to CXCR3-like mechanisms of receptor regulation. Unfortunately, we were 
unable to assess the regulation pattern of the reverse chimeric receptor corresponding to the 
CXCR3 with CXCR7 C-terminus due to the very limited cell surface expression of this mutant. 
However, our results suggest that the presence or absence of such clusters in CXCR7 C-tail 
determines the fate of receptors after endocytosis leading to downregulation or recycling, 
respectively. When monitoring the cell surface levels of CXCR7 after agonist exposure, it was 
observed that receptor internalization occurred in the first 45-60 minutes. Strikingly, recycling 
was observed in both conditions, upon chemokine removal (data not shown) but also when 
the incubation mixture was left for longer time periods. Recent publications by Naumann et 
Figure 6: Real-time monitoring of receptor ubiquitination using BRET2. HEK293T cells were transfected with Ub-
GFP2 (white bars) or (G75A,G76A)-Ub-GFP2 (filled bars) and (A) CXCR7-RLuc, CXCR7 ∆C-RLuc, or CXCR7 ST/A-Rluc, 
(B) CXCR4-RLuc, or (C) CXCR3-RLuc. BRET2 was measured 30 min after stimulation with 10-8M of CXCL12 (CXCL11 
for CXCR3) by addition of coelenterazine 400a and immediate read out. Results are expressed in Net BRET normalized 
to basal as described in materials and methods. Data represent the mean ± SEM of 3 experiments each performed in 
triplicate. **, p<0.01, and ***, p<0.001, by Student t test.
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al. and Luker et al. reconcile these events suggesting that CXCR7 mediates effective ligand 
internalization and targeting of the chemokine cargo for degradation. Such CXCR7-mediated 
depletion of CXCL12 (17, 29) would be sufficient to allow receptor recycling.
Apart from receptor phosphorylation, reversible ubiquitination constitutes a key regulatory 
mechanism for GPCRs (37). This post-translational modification results in the covalent 
addition of the small protein ubiquitin to the intracellular lysine side chains of GPCRs with 
profound consequences for endocytic cycles of GPCRs (37). In particular, CXCR4 has been 
shown to undergo CXCL12-induced ubiquitination resulting in lysosomal degradation of 
the receptor. CXCR4 ubiquitination occurs after receptor internalization and is mediated 
by the E3 ubiquitin ligase AIP4 via its interaction with β…-arrestin (45), highlighting a novel 
Figure 7: CXCR7 C-terminal Lys residues are important for correct trafficking of the receptor to the cell surface. 
(A) [125I]-CXCL12 radioligand binding in total membranes of HEK293T cells transfected with CXCR7 wt (filled circles) 
or CXCR7 K/A (open squares) shows that both receptors display the same affinity for CXCL12 (pK
d
 = 9.7 ± 0.1 and 9.5 ± 
0.1 respectively). (B) [125I]-CXCL12 radioligand binding was performed in whole cells expressing pcDEF
3
 (mock), CXCR7 
wt (WT), or CXCR7 K/A (K/A) (C) CXCR7 wt or CXCR7 K/A expressing cells were fixed (open bars) or fixed and permea-
bilized (filled bars) and CXCR7 was detected by ELISA using CXCR7-specific antibody 11G8. (D) Immunocytochemistry 
of HEK293T cells transfected with CXCR7 wt (upper panels) or CXCR7 K/A (lower panels). Cells were fixed (left panels) 
or fixed and permeabilized (right panels) and detection of CXCR7 was performed with 11G8 antibody. Scale bar rep-
resents 10 …μm.
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function of …β-arrestins in endosomal sorting of GPCRs. Deubiquitination of CXCR4, and 
therefore its escape from degradation, has been shown to be mediated by USP14 (46), while 
the deubiquitinating enzyme (DUB) USP8 has been shown to participate indirectly on CXCR4 
regulation by modulating the dynamics of the signaling endosomes (47). Similar to CXCR4, 
CXCR7 contains several intracellular lysines. Therefore, we hypothesized a potential role for 
ubiquitination in the regulation of CXCR7. By using two complementary techniques, i.e. co-
immunoprecipitation and BRET2 (39), we show that in the basal state, CXCR7 is ubiquitinated 
while this is not the case for mutant receptors lacking the entire C-tail (CXCR7 ∆C) or the 
intracellular lysine residues (CXCR7 K/A). Furthermore, we prove that the Lys residues on the 
C-terminus of CXCR7 are responsible of receptor ubiquitination by showing that the chimeric 
CXCR3 receptor containing the CXCR7 C-terminus is ubiquitinated, while the WT CXCR3 and 
the CXCR7 receptor with the CXCR3 C-terminus are not. Moreover, we observed that receptor 
activation by CXCL12 results in reversible deubiquitination since subsequent removal of the 
chemokine from the media partially restored the ubiquitinated receptor levels detected in the 
basal state. These results are in contrast to what has been described for CXCR4, and highlight 
the differences that could potentially underlie distinct functions and/or patterns of expression 
of the two CXCL12 binding receptors.
So far, the only receptor reported to undergo agonist-mediated deubiquitination is the 
protease-activated receptor-1 (PAR1), for which ubiquitination has been shown to play 
a role in regulation of receptor trafficking and a mutant PAR1 lacking intracellular lysines 
has been shown to be constitutively internalized (28, 48). Our data suggests that we could 
propose a similar scenario for CXCR7 as we have observed that a CXCR7 receptor with 
mutated C-terminal lysines is unable to reach the cell surface, but is retained intracellularly 
and displays an increased basal interaction with β…-arrestin2. Therefore, the observation of 
differential receptor trafficking of the different mutants has led us to propose a preliminary 
model based on ubiquitination as an essential determinant for CXCR7 regulation (Fig. 8). 
According to this model, CXCR7 ubiquitination is necessary for cell surface delivery of the 
receptor and the absence of this ubiquitination would lead to a constitutively internalized 
receptor. Upon CXCL12 stimulation, CXCR7 phosphorylation promotes β…-arrestin recruitment. 
We hypothesize that …β-arrestin would scaffold the interaction with a deubiquitinating 
enzyme (DUB) responsible for CXCR7 deubiquitination. The deubiquitinated receptor would 
subsequently be internalized. Due to the dynamic interaction of β-arrestin and the CXCR7 
C-terminus, uncoupling of …β-arrestin and interacting proteins would render the receptor able 
to undergo ubiquitination and recycle to the cell surface. According to this model, CXCR7 ∆C, 
despite not being ubiquitinated would be delivered at the cell surface due to the absence of 
the motifs responsible for …β-arrestin interaction and endocytosis. Additionally, the absence 
of arrestin recruitment would prevent CXCR7 deubiquitination and therefore stabilize the 
receptor at the cell surface, as is observed for the CXCR7 ST/A mutant. As a consequence, the 
overall ubiquitination status of a cell would influence the regulation of CXCR7 and, therefore, 
its function. It will therefore be of key importance in the future to validate the previous findings 
in cells natively expressing CXCR7 and relate them to the ubiquitination machinery of such 
cells. Future studies will also focus on the identification of the E3 ligase and DUB interacting 
with CXCR7 and/or β…-arrestin. 
Recently, Sanchez-Alcaniz et al. reported that CXCR7 indirectly regulates the expression of 
CXCR4 in cortical interneurons. Such regulation is achieved by the dynamic internalization 
of CXCR7 and prevention of excessive CXCR4 desensitization and endocytosis (12). CXCR7 
would thus “fine-tune” the concentrations of CXCL12, thereby enabling directional migration 
of interneurons. Therefore, the differential ubiquitination patterns of these two receptors 
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upon agonist stimulation could reflect a potential mechanism of achieving such dynamic 
regulation.
It is well established that deregulation of ubiquitin pathways (49) as well as defective 
endocytosis (50) result in the development of diseases, including many types of tumors. In 
this context, recent studies have shown that CXCR7 expression increases tumor formation and 
metastasis for some cancers (4, 7), which suggests that this receptor plays an important role 
in this process. However, the ubiquitination state of CXCR7 under these pathophysiological 
conditions remains to be explored. Recent reports also suggest that one important function of 
CXCR7 is to prevent degradation of CXCR4 (12). Therefore, high expression of CXCR7 in tumor 
cells may contribute to excessive signaling through CXCR4, a landmark of the pathophysiology 
of WHIM syndrome, which is also associated with tumor growth and metastasis formation 
(51). 
Figure 8: Proposed model for regulation of CXCR7 trafficking. CXCR7 requires ubiquitination of the Lys residues of 
its C-tail in order to reach the cell surface. Receptor activation by CXCL12 and subsequent phosphorylation of the C-
terminal Ser/Thr residues results in β…-arrestin recruitment by CXCR7 and receptor internalization in CCPs. In addition, 
…β-arrestin scaffolds the interaction of CXCR7 with an unknown deubiquitnating enzyme (DUB) responsible of receptor 
deubiquitination. After chemokine degradation in early endosomes and due to the transient interaction of CXCR7 with 
…β-arrestin, release of …β-arrestin (and DUB) from the endocytosed receptor results in a CXCR7 able to undergo ubiquiti-
nation by a specific E3 ligase (E3) and subsequent delivery of the recycled receptor to the cell surface.
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In summary, we have identified ubiquitination as a post-translational modification of 
CXCR7 responsible for its regulation and we have, for the first time, shown the constitutive 
ubiquitinated state of a chemokine receptor. Hence, future studies are essential to establish 
not only the role of ubiquitination processes in CXCR7-related cancer progression but also 
the potential of therapies targeting the blockade of CXCR7 in cells in which it is co-expressed 
with CXCR4. 
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8.4: Materials and Methods
 Materials. All material for tissue culture was purchased from PAA Laboratories GmbH (Paschen, Austria). 
Lipofectamine 2000 was purchased from Invitrogen (Paisley, UK). Poly-L-lysine, cycloheximide, bafilomycin A1, 
o-phenylenediamine and monoclonal anti-HA-Agarose conjugate were from Sigma-Aldrich (St. Louis, MO, USA), 
Coelenterazine-h was obtained from Promega (Madison, WI, USA). DeepBlueC (Coelenterazine 400a) was obtained 
from Biotium (Hayward, CA, USA). [125I]-CXCL12 (2200 Ci/mmol) and [35S]GTP……S were obtained from PerkinElmer Life 
and Analytical Sciences (Boston, MA, USA). Unlabeled chemokines were purchased from PeproTech (Rocky Hill, NJ, 
USA). Monoclonal antibody anti-CXCR7 (clone 11G8) and anti-CXCR3 (mAb160) were from R&D Systems. Monoclonal 
antibody anti-β-arrestin1/2 (clone D24H9) was purchased from Cell Signaling Technology (Boston, MA, USA). The 
CAMYEL biosensor was purchased from ATCC (#ATCC-MBA-277). …β-arrestin1-YFP was a kind gift from C. Hoffmann, 
…β-arrestin (319-418) from J. Benovic, HA-Ub from F. Mayor Jr., and Ub-GFP2 constructs were a generous gift from M. 
Bouvier. The CXCR7-RLuc construct was generated using PCR, by substituting the stopcodon of CXCR7 with a SpeI/
NotI linker and fusing it in frame to RLuc, as described previously (52). For siRNA transfection experiments, Dharmacon 
siRNA control pools (#D-001810-10) and siRNA pools targeting …β-arrestin1 (#L-011971) and …β-arrestin2 (#L-007292) 
were purchased from Thermo Scientific (Epsom, UK).
 Cell Culture and Transfection. HEK293T cells and HEK293 cells stably expressing human CXCR7 (HEK293/
CXCR7), were grown at 37°C and 5% CO2 in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% FBS, 
penicillin, and streptomycin. HEK293T cells were transfected using linear polyethyleneimine (PEI) with a molecular 
weight of 25 kDa (Polysciences, Warrington, PA) as described previously (53). In …β-arrestin knockdown experiments, 
HEK293 cells stably expressing CXCR7 were transfected with 250 pmol of siRNAs against both …β-arrestin1 and -2 (1:1), 
using lipofectamine 2000 according to standard protocol. The growth medium is replenished 5 hours after transfection. 
In any case, the day after transfection, cells were trypsinized, resuspended into culture medium, and plated in the 
corresponding poly-L-lysine-coated assay plates. Pertussis Toxin (PTX) treatment was performed overnight at a final 
concentration of 25 ng/ml.
 Membrane preparation and Chemokine Binding. Membrane preparation and competition bindings were 
performed as described previously (53). Briefly, cell membrane fractions from HEK293T cells expressing CXCR7 were 
prepared by washing the cells twice with ice-cold PBS and centrifuging them at 1500g for 10 min. The pellet was 
resuspended in ice-cold membrane buffer (15 mM Tris, pH 7.5, 1 mM EGTA, 0.3 mM EDTA, and 2 mM MgCl2), and 
homogenized using a Teflon-glass homogenizer and rotor. The membranes were subjected to two freeze-thaw cycles 
using liquid N2, and centrifuged at 40,000g for 25 min. The pellet was resuspended in Tris-sucrose buffer (20 mM 
Tris, pH 7.4, and 250 mM Sucrose) and aliquots were frozen in liquid nitrogen. For [125I]-CXCL12 competition binding 
experiments, 1 μg/well of membranes were incubated in 96-well plates in binding buffer (50 mM HEPES, pH 7.4, 
1 mM CaCl2, 5 mM MgCl2, 100 mM NaCl, and 0.5% (w/v) BSA) with approximately 70 pM [
125I]-CXCL12 and various 
concentrations of displacer for two hours at room temperature. Membranes were harvested by filtration through 
Unifilter GF/C plates (Perkin-Elmer) presoaked with 0.5% PEI, using ice-cold wash buffer (50 mM HEPES, pH 7.4, 1 mM 
CaCl2, 5 mM MgCl2, and 500 mM NaCl). Radioactivity was measured using a MicroBeta scintillation counter (Perkin-
Elmer).
 [35S]-GTPγS binding assay. 5 μg/well of cell membranes were incubated with CXCL11 and CXCL12 in 
assay buffer (50 mM Hepes, 10 mM MgCl2, 100 mM NaCl, pH 7.2) supplemented with 3 μM GDP and 500 pM of [
35S]-
GTPγ…S. Incubations were placed at room temperature for 1 hour before harvesting the membranes by filtration through 
Unifilter GF/B plates. [35S]-GTPγ…S binding was determined using a Microbeta scintillation counter.
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 cAMP biosensor BRET assay. The experimental procedure for this assay has been adapted from Masri et 
al., (54) using the CAMYEL BRET-based biosensor for cAMP. Twenty-four hours post-transfection, cells were trypsinized 
and seeded in poly-L-lysine coated white 96-well microplates. The cells were then cultured for an additional 24 h. Cells 
were rinsed once with Hank’s Balanced Salt Solution (HBSS) to remove traces of phenol red and were then incubated in 
fresh HBSS. The Renilla luciferase (RLuc) substrate coelenterazine-h was added to reach a final concentration of 5 μM. 
The non-specific phosphodiesterase inhibitor IBMX was added simultaneously to a final concentration of 40 μM. For 
measuring effects of chemokines on cAMP levels, they were added 5 min after coelenterazine-h. Forskolin was added 5 
min later, yielding a final concentration of 10 μM. After 5 min of incubation with forskolin the YFP emission (535 nm), as 
well as the RLuc emission (480 nm), were sequentially recorded for every assay point using a Victor3 multilabel counter 
(Perkin-Elmer). The BRET signal (BRET ratio) was determined by calculating the ratio of the light emitted at 505 to 555 
nm (YFP) to the light emitted at 465 to 505 nm (RLuc). 
… β-arrestin recruitment BRET. For …β-arrestin recruitment experiments, HEK293T cells were transfected 
with a 1:4 ratio of cDNA coding for CXCR7-RLuc and …β-arrestin1- or -2-YFP (total DNA 2.5 μg per million cells). 24 hours 
post-transfection, cells were trypsinized and seeded in poly-L-lysine coated white 96-well culture plates (Greiner). 
The cells were then cultured for an additional 24h. Cells were rinsed once with HBSS to remove traces of phenol red 
and were then incubated in fresh HBSS. The Renilla luciferase (RLuc) substrate coelenterazine-h was added to reach 
a final concentration of 5 μM. After 5 min of incubation with coelenterazine-h, the corresponding agonist was added, 
and incubated for 10 additional minutes. After 10 min readings were collected using a Victor3 instrument (PerkinElmer) 
and BRET ratios were calculated. The values were corrected by subtracting the background signal detected when the 
Receptor-RLuc construct was expressed alone. In inhibition experiments, cells where incubated with the anti-CXCR7 
antibody 8F11 30 min prior to the addition of coelenterazine-h.
 BRET2 monitoring of receptor ubiquitination. To assess receptor ubiquitination using BRET2, HEK293T 
cells were co-transfected in a 1:4 ratio of RLuc-tagged receptor (CXCR7 wt, CXCR7 ∆C, CXCR7 ST/A, CXCR4 or CXCR3) 
and GFP2-tagged Ubiquitin (wt or G75A, G76A mutant). 24 hours post-transfection, cells were trypsinized and seeded 
in poly-L-lysine coated white 96-well culture plates. The cells were then cultured for an additional 24h. On the day of 
the experiment, cells were rinsed once with Hank’s Balanced Salt Solution (HBSS) to remove traces of phenol red and 
were then incubated in fresh HBSS for additional 30 min. Subsequently, cells were incubated with 10-8M of chemokine 
for 30 min. BRET2 measurements were collected 20s after the addition of the Renilla luciferase (RLuc) substrate 
Coelenterazine 400a (Biotium), at a final concentration of 5 μM. Readings were collected with Victor3 instrument 
(PerkinElmer) detecting the signals in the 370-450 and 500-530 nm ranges. BRET2 ratios were calculated as described 
previously (39).
 Cell surface receptor expression and internalization ELISA. Transiently transfected HEK293T- or HEK293/
CXCR7 cells, were trypsinized and replated in poly-L-Lysine coated 48-well plates. After 24 hours, cells were incubated 
with medium containing CXCL11, CXCL12 at 10-8M or vehicle for several time periods in case of internalization 
experiments, or directly fixed when only receptor expression levels were determined. After ligand treatment, cells were 
subjected to three sequential acid washes (DMEM pH~2), fully removing the chemokines from the receptors, such that 
they did not interfere with antibody binding (data not shown). Subsequently, cells were fixed with 4% formaldehyde in 
Tris-buffered saline (TBS). When stated, cells were permeabilized with TBS/0.5% NP-40. After blocking with 1% skim 
milk in 0.1 M NaHCO
3
 pH 8.6, cells were incubated overnight at 4°C with anti-CXCR7 or anti-CXCR3 antibodies (11G8 
(55) and mAB160 respectively) in TBS (50 mM Tris, 150 mM NaCl, pH 7.5) containing 0.1% BSA. The cells were then 
washed three times with TBS, and incubated with goat anti-mouse HRP-conjugated secondary antibody (Bio-Rad). 
Subsequently, cells were incubated with substrate buffer containing 2 mM o-phenylenediamine, 35 mM citric acid, 66 
mM Na2HPO4, and 0.015% H2O2 at pH 5.6. The coloring reaction was stopped by adding 1M H2SO4, and the absorption 
at 490 nm was determined in a Powerwave X340 absorbance plate reader (BioTek).
 Immunofluorescence. HEK293T cells expressing CXCR7 growing on poly-L-lysine-coated coverslips 
were incubated with DMEM containing CXCL11, CXCL12 or vehicle for different time periods. Next the cells were 
washed three times with acid wash (DMEM pH~2), fixed with 4% formaldehyde in PBS and blocked with 3% skim 
milk in PBS or simultaneously permeabilized using 3% skim milk in 0.15% Triton X-100/PBS. Then the cells were 
incubated consecutively with primary anti-CXCR7 11G8 monoclonal antibody and Alexa488-conjugated anti-mouse 
secondary antibody (Molecular Probes, Invitrogen). An Olympus FSX100 BioImaging Navigator was used for detection 
of fluorescence and the capturing of images. Plasma membrane staining was performed after fixation using Image-iT… 
LIVE Plasma Membrane kit (Invitrogen) and following manufacturer’s instructions.
 Whole cell binding. HEK293 cells expressing wt or mutated CXCR7 were plated 100,000 cells/well into a 
48-well assay plate (Greiner). The next day, the medium was aspirated and the cells were incubated in binding buffer 
(50 mM Hepes pH 7.4, 1 mM CaCl2, 5 mM MgCl2 and 100 mM NaCl) containing ~70 pM of [
125I]-CXCL12 in the presence 
and absence of unlabeled ligands. After 4 hours at 4°C, the cells were washed with ice-cold wash buffer (50 mM 
Hepes pH 7.4, 1 mM CaCl2, 5 mM MgCl2 and 500 mM NaCl), lysed and bound radioactivity was measured in a Wallac 
Compugamma counter (PerkinElmer).
 Detection of receptor ubiquitination by immunoprecipitation. A total of five 10-cm plates of transfected 
HEK293T cells were used for every co-immunoprecipitation condition. 48 hours after transfection cells were rinsed 
twice and collected in a final volume of 5 ml of ice-cold PBS (1 ml per plate). Cells were pelleted by centrifugation for 
3 min at 1000 rpm and subsequently lysed, homogenized and incubated at 4°C for 30 min with 1 ml of lysis buffer (1% 
NP-40, 1 mM EDTA, 150 mM NaCl, 10% Glycerol and 1 mM CaCl2). The lysates were then centrifuged at 14,000 rpm and 
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the supernatant was recovered. 50 μl of these lysates were collected for later analysis and the remaining volume was 
incubated with agarose-conjugated HA-antibody for 90 min at 4°C on a rotating shaker. Immunoprecipitates were then 
washed three times by centrifugation with wash buffer (0.1% Triton X-100, 50 mM Tris pH 7.4, 300 mM NaCl, 5 mM 
EDTA) and an additional final wash with cold PBS. Finally, samples were eluted with sample buffer and processed for 
Western Blot analysis.
 SDS-PAGE and Western Blot. Cell lysates were subjected to SDS-PAGE analysis using 4–12% Bis-Tris 
gels (BioRad). After electrophoresis, proteins were transferred onto nitrocellulose membranes that were incubated 
in 5% non-fat milk and 0.1% Tween-20/TBS solution at room temperature on a rotating shaker for 2 h to block 
nonspecific binding sites. The membrane was incubated overnight with the corresponding antibody and detected 
using a horseradish peroxidase-linked secondary antibody. Immunoblots were developed by application of enhanced 
chemiluminescence solution (Pierce).
 Data Analysis. Nonlinear regression analysis of the data and calculation of affinity values was performed 
using Prism 4.03 (GraphPad Software Inc., San Diego, CA). 
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8.6: Supporting information
Figure S1: CXCR7 does not activate Gγ
i/o
 proteins. (A) [35S]-GTPγ…S binding assay in membranes of HEK293 cells tran-
siently transfected with CXCR7 (triangles) or stably expressing CXCR3 (circles). Membranes were incubated with in-
creasing concentrations of CXCL11 (black symbols) or CXCL12 (open symbols). Results are expressed as fold over 
basal [35S]-GTP…γS binding from three independent experiments and represent mean ± SEM. (B) Inhibition of forskolin-
induced cAMP accumulation in HEK293 cells transiently transfected with CXCR7 or stably expressing CXCR3 and si-
multaneously transfected with the cAMP BRET biosensor CAMYEL. Data is expressed as percentage of forskolin (Fsk) 
response and represent mean ± SEM results from three independent experiments.
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Figure S2: Cell surface expression of RLuc-tagged receptors. Expression of RLuc –tagged CXCR7 constructs was 
assessed by [125I]-CXCL12 whole cell binding. Data represent the mean ± SEM of 3 experiments each performed in 
triplicate.
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Figure S3: CXCR7 recycles after agonist stimulation while CXCR3 downregulates upon prolonged exposure to its 
ligand. Receptor expression was assessed by ELISA in HEK293T cells transiently transfected with wt CXCR7 or wt 
CXCR3. To assess for total receptor expression cells were permeabilized after fixation with 0.5% NP-40. Data represent 
the mean ± SEM of 3 experiments each performed in triplicate.
Figure S4: CXCR7 K/A colocalization with γβ-arrestin2. HEK293T cells were transiently transfected with CXCR7 wt 
or K/A (Red) and β…-arrestin2-YFP (green). Cells were fixed and permeabilized prior to the immunodetection of CXCR7 
with the 11G8 anti-CXCR7 antibody and an anti-mouse Alexa546-conjugated secondary antibody. Scale bar represents 
10 μ…m.
Ubiquitination of CXCR7 controls receptor trafficking   155
C8
Figure S5: CXCR7 K/A shows increased basal interaction with γβ-arrestin2. HEK293T cells coexpressing RLuc-tagged 
CXCR7 wt or K/A mutant and YFP-tagged …β-arrestin2 were stimulated with 10-8M of CXCL12 prior to BRET measure-
ments. Results are expressed as fold of basal Net BRET as described in Materials and Methods. Data represent the 
mean ± SEM of 3 experiments each performed in triplicate.
Construct DNA sequence
CXCR7 WT NPVLYSFINRNYRYELMKAFIFKYSAKTGLTKLIDASRVSETEYSALEQSTK
CXCR7-X3 NPVLYSFINRNYRERMWMLLLRLGCPNQRGLQRQPSSSRRDSSWSETSEASYSGL
CXCR7 DC NPVLYSFINRNYR
CXCR7 ST/A NPVLYSFINRNYRYELMKAFIFKYAAKAGLAKLIDAARVAEAEYAALEQAAK
CXCR7 K/A NPVLYSFINRNYRYELMAAFIFAYSAATGLTALIDASRVSETEYSALEQSTA
Table S1: Amino acid sequence of the mutated C-tails of CXCR7. Bold letters indicate the introduced changes from 
the CXCR7 original sequence. The conserved NPXXY motif is underlined as a reference.
Construct Affinity (pKd ± SEM)
CXCR7 WT 9.7 ± 0.1
CXCR7-X3 9.5 ± 0.1
CXCR7 DC 9.2 ± 0.1
CXCR7 ST/A 10.6 ± 0.2
CXCR7 K/A 9.5 ± 0.1
Table S2: CXCL12 binding affinities for mutant CXCR7 receptors . pK
d
 values were obtained by [125I]-CXCL12 homolo-
gous competition binding on membrane preparations of cells expressing CXCR7 WT or mutant receptors.
APPENDIX 1
Evidence on allosterism of chemokine receptor 
small molecules
Adapted from
DJ Scholten et al., Br. J. Pharmacol. 2012. 165(6):1617-43
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Table A1: Evidence supporting the mechanism of action for small-molecule chemokine ligands. Ligands are shown 
for which evidence exists on the interaction with the receptor. Indicated residues are in Ballesteros-Weinstein nota-
tion (Ballesteros & Weinstein, 1995), and significantly affect ligand affinity or antagonism when mutated. Bold resi-
dues indicate that mutation also influenced chemokine binding or function. The residues are categorised into TMS1 
(left column), “interface” (center column) or TMS2 (right column), based on their location in the binding pockets. “In-
terface” signifies residues that reside on the interface of TMS1 and TMS2. Explanation of used symbols: “-”,there is no 
report on mutations of residues in either TMS1, interface, or TMS2 that affects ligand binding; “é”, enhanced binding 
or function; “ê” inhibited binding or function; “NC”, non-competitive behaviour, “C”, competitive behaviour. The last 
column “C” indicates the progress of a compound in clinical trials; 1, 2, or 3 refer to the clinical phase the compound 
currently resides in. If a ligand is approved or suspended it is indicated with an “A” or “S”, respectively. 
1 This compound is an agonist for the indicated receptor. 
2 Residues important for ligand binding at this receptor are part of an intracellular binding pocket. 
3 The binding site of AMD3100 transferred from CXCR4 to CXCR3 by mutations S7.39E, and K7.35A in CXCR3. 
4 A G1283.29H mutation was introduced to facilitate binding of the metal chelator complex. 
5 Interacting residues (within 4Å from the ligand) in CXCR4 crystal structures (42). 
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